Digital Twin Generators for Disease Modeling
Unlearn.AI
Abstract
Apatient’sdigitaltwinisacomputationalmodelthatdescribestheevolutionof
theirhealthovertime. Digitaltwinshavethepotentialtorevolutionizemedicine
by enabling individual-level computer simulations of human health, which can
be used to conduct more efficient clinical trials or to recommend personalized
treatmentoptions.Duetotheoverwhelmingcomplexityofhumanbiology,machine
learningapproachesthatleveragelargedatasetsofhistoricalpatients’longitudinal
healthrecordstogeneratepatients’digitaltwinsaremoretractablethanpotential
mechanisticmodels. Inthismanuscript,wedescribeaneuralnetworkarchitecture
thatcanlearnconditionalgenerativemodelsofclinicaltrajectories,whichwecall
DigitalTwinGenerators(DTGs),thatcancreatedigitaltwinsofindividualpatients.
We show that the same neural network architecture can be trained to generate
accuratedigitaltwinsforpatientsacross13differentindicationssimplybychanging
the training set and tuning hyperparameters. By introducing a general purpose
architecture,weaimtounlocktheabilitytoscalemachinelearningapproachesto
largerdatasetsandacrossmoreindicationssothatadigitaltwincouldbecreated
foranypatientintheworld.
4202
yaM
2
]GL.sc[
1v88410.5042:viXra1 Introduction
Inthenearfuture,mostimportantproblemsinmedicinewillbesolvedwithcomputationalapproaches.
As computational methods such as artificial intelligence (AI) improve at an astounding pace, so
does our ability to model human health. Computational models of individual patients offer the
opportunity to perform in silico experiments, avoiding unnecessary trial-and-error that places a
substantialburdenonpatientsandslowsdownthepaceofmedicalinnovation. Digitaltwinsarea
typeofspecializedcomputationalmodelcommonlyusedinengineeringthatisincreasinglybeing
appliedtohealthcare. Inthiscontext,adigitaltwinisacomputationalmodelofaspecificindividual’s
healththatiscomprehensive,describingascompleteasetofcharacteristicsaspossible,andwhich
allowsonetoforecastthatindividual’sfuturehealthundervariousscenariosofinterest.
Thecomprehensivenatureofdigitaltwinsmeansthattheyareincrediblypowerfultoolsforsolving
problemsinmedicinethattypicallyrequireexperimentationonhumans. Forexample,whendeciding
whichtreatmentapatientshouldreceive,apatient’sdigitaltwinmightallowacliniciantomodel,
forthatspecificindividual,thelikelyeffectsofdifferentcandidatetreatmentsandselecttheonethat
ispredictedtoproducethebestoutcome. Adigitaltwinthatmodelsthedietandmetabolismofan
individualwouldallowthatpersontounderstandhowdietaryandlifestylechoicescanimpacttheir
health. Adigitaltwinthatmodelstheimpactofdiseaseonanindividual’shealthwouldhelpthem
andtheircaregiversplanforfutureneedsfordiseasemanagement.
Theapplicationofdigitaltwinstodrugdevelopmentisparticularlyimportantgiventheincreasing
timeandcostsofbringingnewdrugstomarket. Drugdevelopmentisaslow, resource-intensive
processthatplacesasubstantialburdenonpatientsinordertodevelopnewtherapies. Theplanning
andexecutionofclinicaltrialsareakeycomponentofthis,andsignificantworkneedstobedoneto
makethemfasterandmorebeneficialfortheirparticipants. Becauseclinicaltrialsarewell-controlled
experimentsinspecificpatientpopulations,theyoffertheopportunitytoapplydigitaltwinstoprovide
concretebenefitsforspeed,statisticalpower,anddecisionmakingwithwell-controlledrisks.
Clinicaltrialsproducebroadassessmentsofthesafetyandefficacyofnewtreatmentsrelativeto
placeboorstandardofcare. Drugsafetyandefficacyareinherentlymultidimensionalconcepts–i.e.,
drugsoftenaffectcomplexsystemsinthebodytoalleviatemultiplesymptomswhilepotentially
causing various side effects–which means that any computational models used to create digital
twins of participants in drug trials need to be multivariate in order to produce forecasts for all
outcomesofpotentialinterest. Inaddition,theeffectofadrugisinherentlytime-dependent,and
participantsintrialsaretypicallyassessedlongitudinallyacrossmultipletimepoints. Takentogether,
theseconsiderationsimplythatmultivariatetime-seriesmodelsareneededtocreatedigitaltwinsof
participantsindrugtrials;wecallthesemodelsDigitalTwinGenerators(DTGs).
TheavailabilityofaccurateDTGswouldallowforthedesignofmoreefficientclinicalstudieswhile
also unlocking new capabilities. For example, a participant’s digital twin can be used to create
somethinglikeanindividualcontrolgroupthataddressesthequestion,“Whatwouldlikelyhappento
thisparticipantiftheyweretoreceiveaplacebooralternativetreatment?”. Withthisknowledge,one
couldderiveprognosticscoresusedtoincreasestatisticalpower,estimatetreatmenteffectsdownto
theleveloftheindividualparticipantsinadditiontopopulationaveragesorsubgroups,addsimulated
controlgroupstosingle-armstudiesorduringopen-labelextensionperiods,orevenrunsimulated
head-to-headcomparisonsofalternativetreatmentstoassesscomparativeeffectiveness.
Although the development of detailed mechanistic models is, at least in principle, one pathway
to creating DTGs, the overwhelming complexity of the human body makes this a daunting task
thatislikelybeyondthereachofcurrenttechnologiesandmolecular-leveldatasets. Analternative
approach is to apply Machine Learning (ML) techniques to train models as DTGs directly from
phenotypic-leveldatasets. ThisrequiresthedevelopmentofMLtechniquesthatcanlearntomodel
stochastic,multivariateclinicaltime-series.
Inthiswork,wedescribeanovelgenerativeneuralnetworkarchitecturethatiscapableofcreating
accurateDTGsin13differentdiseaseindicationsacross3distincttherapeuticareas(neurodegen-
eration, immunology and inflammation, and general medicine) with no modifications other than
hyperparametertuning. ThisarchitecturecombinesaNeuralBoltzmannMachine(NBM),anenergy-
basedmodelwithparameterssetbyneuralnetworks,withdeepneuralnetworksdesignedtomodel
multivariatetime-seriestocreateahighlyflexibleconditionalgenerativemodelofclinicaltrajectories.
Wetraindisease-specificDTGsbasedonthisarchitectureusingindividualparticipant-leveldatasets
2aggregatedfrompreviouslycompletedclinicaltrials,observationalstudies,anddiseaseregistries,
assesstheirperformancecharacteristics,andexploretheirinterpretabilitythroughsensitivityanalyses.
Thisreportmakesthefollowingcontributions:
• Wedescribeanovelgenerativeneuralnetworkarchitectureforclinicaltrajectoriesbasedon
anNBMthatusesprobabilisticmodelingtoaddresstheintrinsicvariabilityofclinicaldata.
• Wediscussmethodologicalinnovationsthatallowthesemodelstoreliablytrainonheteroge-
neousclinicaldatasetswithcommonissueslikemissingobservationsinordertoproduce
well-calibratedprobabilisticforecaststhatcapturecomplextemporaldependencies.
• We demonstrate that this architecture can produce accurate DTGs across many disease
indicationswithnomodificationsotherthanhyperparametertuning.
• We report the generative performance of these models across a large and diverse clini-
cal dataset covering13 differentdisease indications, evaluating performanceand model
interpretabilitytoolsineachindication.
AnoverviewoftheprocessusedtodevelopandevaluatetheDTGsisshowninFigure1.
InSection2wepresenttheNBMarchitecturethatisusedtoproduceaDTGineachdiseaseindication.
InSection3wediscussthedatasetsforeachofthe13diseaseindications,thehyper-parametersof
themodelandtheprocessofselectingthemandtrainingtheDTG.InSection4weshowabroadset
ofmetricsevaluatingDTGperformance. InSection5wediscussfuturedirectionsforDTGs,andin
Section6weconclude.
31. Data Curation
Clinical trial Patient Observational Harmonize
results registries studies file formats
. . .
Unified patient Ensure Convert to Harmonize
trajectories consistent scoring common units variable names
2. Training
Model
Unified patients Transformed & trajectories filtered patients
trajectories
Imputer Imputed
Patient shingles patient shingles
Event network
Update model f P W
Compare predicted TTE
to observed
Compute
gradient
NBM
Compare predicted future
to observed future
3. Inference
Trained . . . . . .
model
Patient trajectory samples Patient trajectory
reduction, e.g. mean, STD
ADAS Cog 13
(New) (New) (New)
Patient Clinical trials Patient registries Observational studies
baseline
Study day
Figure1: OverviewofDTGcreationandevaluation. Therearethreemainphases: curationofdata,
trainingaDTG,andusingtheDTGtomakedigitaltwinsfordataoutsidethetrainingset.
4
erutuf
enilesab
erutuf
tnerruc erutuf enilesab tnerruc erutuf2 NeuralBoltzmannMachinesforGeneratingClinicalTrajectories
Energy-basedmodelsprovideageneralframeworkforprobabilisticmodelingthatcanbeviewed
as an alternative to auto-regressive next token prediction, diffusion-based sample generation, or
generativeadversarialnetworksforefficientlylearninghigh-dimensionaljointdistributions. General
energy-based models can be highly expressive but are difficult to sample from, whereas specific
architectureslikeRestrictedBoltzmannMachines(RBMs)arerelativelyeasytosamplefrombut
havelimitedcapacity. NeuralBoltzmannMachines(NBMs)[4]combinethetwoapproachestocreate
anenergy-basedmodelthatisbothhighlyexpressiveandrelativelyeasytosamplefrom. AnNBMis
aneuralnetworkthatmodelsanobservedstatey,andalatentstatehconditionedonsomecontextx
withajointdistributionoftheform
p(y,h|x)=Z−1e−U(y,h|x), (1)
whereU(y,h|x)isajointenergyfunctionparameterizedbysomeneuralnetwork,whichwewill
describesubsequently,andZ isanintractablenormalizationtermtakenastheintegral(orsum)over
allpossibleyandh.
BycouplingthevisiblestatetoalatentstateasinanRBM,anNBMprovidesaflexibleandexpressive
modelforthemarginaldistributionfortheobservedstatey whileenablingefficientblockGibbs
sampling. WedefinetheNBM’sjointenergyas
1
U(y,h|x)= [y−f(x)]T P(x)[y−f(x)]−[y−f(x)]T W(x)h−bT(x)h, (2)
2
wherethefunctionsf(x),b(x),P(x),W(x)areneuralnetworksthatreturneitheravector(f andb),
oramatrix(P,W)output. Inprinciple,thevariablesinthevisiblestatemaybeeithercontinuousor
discrete,asin[4],butinthisworkwewillfocusonthecaseinwhichtheyarecontinuous. Likewise,
wefocusonthecaseinwhichthemodelhasIsinglatentvariables,i.e. h ∈{−1,+1}andwesetthe
i
biasonthehiddenunitstozeroforsimplicity(i.e.,b(x)=0). Parameterizingtheenergywithneural
networksinthiswayisoneoftheprincipleinnovationsoftheNBM,providingmuchmoreexpressive
powerthantypicalRBMsthatsharethisgeneralform[4]. Parameterizingdistributionalparameters
withneuralnetworksisastrategyemployedinothertypesofmodels,notablyinamortizedvariational
inference[7],ofwhichthevariationalauto-encoder[3]ismostfamous.
Bymarginalizingthejointdistributionoverthelatentstate,wecanderivethemarginalprobability
(cid:80)
distributionoftheobservedstateconditionedonthecontextusingp(y|x)= p(y,h|x). Inturn,
H
thisallowsustoexpressamarginalenergyfunctionfortheobservedstate,whichwewillneedin
ordertotrainthemodel,
1
U(y|x)= [y−f(x)]T P(x)[y−f(x)]−1T [logcosh(W(x)(y−f(x)))], (3)
2
where1issimplytheallonesvector. Foragivenarchitecturalchoiceoff,P,andW,trainingan
NBMproceedsinafashionverysimilartoatraditionalRBM,withtheexceptionthatgradientsmust
bebackpropagatedthroughtheconstituentneuralnetworks. Foradetaileddescriptionofhowthe
NBMupdategradientsarecalculated,wereferthereadertoourearlierworkonthetopic[4].
Uptonow,timedependenceofthestateorcontexthasbeensuppressedforclarity. Toexpressthe
time-dependentobservedstatedistributionrequiredforlongitudinallymodelingclinicaltrajectories,
weallowtheneuralnetworksf(x,t),P(x,t),W(x,t)todependontimet. Furthermore,weallow
thestateofthemodelatsomefuturemeasurementtimetobeconditionedonthestateofthemodelat
thecurrenttime,forminganauto-regressivelinkbetweentimesinthejointdistribution
(cid:12)
p(y(t future),h(t future)(cid:12)x=[y(t current),c]). (4)
Thisconstructionallowsustobeginwithameasurementofapatientataninitialtimepointy(0)
(e.g.,theinitialvisitinaclinicaltrial)andsometime-independentcontextvariablesc,thenpredicta
futurevisitatsomearbitrarytimelater. Inprinciple,theconditioningsetcouldincludeallprevious
timepointsifdesired. Duringtraining,themodelisfedasequenceofnext-stepaheadpairs,however,
unlikediscrete-timesequencemodelingasinlanguagemodels,thevaluesoft andt maytake
current future
anycontinuouspositivevalue. Theneedtomodelvariabletimestepsarisesfromi)theheterogeneous
mixtureofclinicaltrialsandobservationalstudies,whichcollectedassessmentsatvariousintervals,
weaggregatedtocreatethetrainingdataset,andii)becausewedesiretocreatedigitaltwinsthatcan
forecastsymptomsatanytimepointinthefuture–notjustonadiscrete,fixedgrid.
52.1 NBMNetworkArchitectureforDiseaseModeling
An NBM is a generic, flexible, energy-based model that derives most of its behavior from its
constituentneuralnetworks. Therefore,creatingafoundationalarchitecturethatcanbeusedtotrain
DTGsinavarietyofindicationscomesdowntomakingselectionsfortheneuralnetworksf,P,and
W. Goodchoicesforthesenetworksneedtobeexpressiveenoughtoaccuratelymodelmultivariate
clinicaltrajectoriesacrossmanydiseaseswhilealsonotbeingpronetooverfittingtoconfounding
factorswhendataavailabilityislow. Inaddition,weusemodulararchitecturesfortheseconstituent
neuralnetworkstoaidininterpretability.
The neural networks that parameterize the NBM energy at t serve different roles: although
future
the mean of the observed distribution is not available in closed-form, it is heavily influenced by
f(x,t ,t ),thediagonalmatrixP(x,t ,t )issimilartoaprecisionmatrixandheavily
future current future current
influencesthevarianceoftheobserveddistribution,andthematrixW(x,t ,t )projectsthe
future current
hidden state from a dimension M to the size of the observed state N and heavily influences the
correlationsbetweenobservedvariables.
Duetothebipartitenatureofthegraphconnectingthevisibleandhiddenunits,RBMsandNBMs
canbesampledrelativelyefficientlybyblockGibbssampling. However,it’swellknownthatthe
resultingMarkovchainsmaymixslowlyrelativetothevolumeofphasespace,sothatittakesalong
timetoobtainarepresentativesamplefromthedistributiondefinedbyanRBM.SinceNBMsare
conditionalgenerativemodels,it’snotnecessarytosamplethesamevolumeasanunconditional
model,whichmakesrepresentativesamplingwithaMarkovchaineasier. Inaddition,onecanfurther
speedupsamplingbasedontheintuitionthatthemean(i.e.,closetof(x,t ,t ))isahigh
future current
probabilitystateandagoodplacetostarttheMarkovchain[4].
InFigure2,weprovideanoverviewofthearchitectureoftheNeuralBoltzmannMachineandits
applicationtotheDigitalTwinGeneratorsdiscussedinthissection.
ImputationNetwork. Onechallengeintrainingmodelsonclinicaldataisthatthereareoftenmany
missinginputs. Theneuralnetworksinf ,P,andW arenotthemselvesequippedtohandlemissing
dataintheirinputs.Toaddressthisweuseanauto-encodernetworkAEImputer(x)toimputemissing
valuesintothedatabeforetheyarepassedtosubsequentnetworks. Theimputerfirstzero-fillsthe
missingdatabeforetransformingitintoanequal-shapedrepresentationythatiscomparedtothe
non-missingvaluesinaseparatereconstructionloss. Thearchitectureusesaclassicencoder-decoder
designwithencodere(x)anddecoderarchitectured(x)takingtheform:
(cid:32) (cid:32) (cid:33)(cid:33)
LayerNorm(x)
l(x)=ϕ Linear (5)
(cid:112)
dim(x)
e(x)=(l ◦···◦l )(ZeroFill(x)) (6)
n 1
(cid:16) (cid:17)
d(x)= ˜l ◦···◦˜l (x) (7)
m 1
AEImputer(x=[y,c])=where(xispresent,x,d(e(x))) (8)
whereϕ(·)isanon-linearactivationfunctionthatwesettoϕ(·)=ArcSinh(·). Duetotheconditional
replacementattheend,theimputeronlyinsertsvalueswheretherearenoneavailableinthedata.
Notethattheimputernetworkdoesnothaveanydependenceontime;itactsoneachvisityseparately.
Forthemodelswedescribehere,boththeencoderanddecoderemploytwolayerseach. Inaddition,
wedetachthegradientsfromtheimputeddatabeforepassingthemtotherestofthenetwork.
MeanPredictionNetwork. Inmanymedicalapplications,it’scommontoneedtopredictmany
futureobservationsbasedonasetofmeasurementstakenatasingletimepoint(alongwithother
contextualinformation). Forexample,inaclinicaltrial,oneisinterestedinforecastingthefuture
evolutionofaparticipant’sclinicalassessmentsfromasetofbaselinemeasurementstakenduring
their first visit as part of the study. As a result, the problem does not look like a sequence-to-
sequence prediction task but is instead a vector-to-sequence prediction task similar to a neural
ordinarydifferentialequation(NeuralODE).
As a result, we specify f(x,t ,t ) to have a predictor-corrector design inspired by ODE
future current
solvers. Predictions of the future time step are a combination of a prediction from information
availableaboutapatientataninitialtimepoint(e.g.,trialrandomization)andapredictionfromthe
6Digital twins
Weibull NBM weight NBM precision Mode Future prediction
parameters parameters parameters prediction from current prediction
Gate and Add Corrector
ResNet
Future Current Residual
prediction prediction
Events Weights Precision Neural Flow Neural Flow
Network Network Network Predictor Predictor
Current
imputed
Autoencoder
Imputer
Baseline Context
imputed imputed
KEY
Input/output data
Immediate data Autoencoder
Imputer
Neural network
Autoencoder
Parameters
Stop grad
Baseline Context Current
Figure2: OverviewofNeuralBoltzmannMachineArchitectureforDigitalTwinGenerators. Individ-
ualnetworks,parameters,andoutputsaredescribedinthetextinSection2.
7previousavailabletimestep. Thepredictionfromtheinitialtimepointtoagiventimeishandledbya
predictionnetwork,g(·)inspiredbyNeuralFlows[1],whichconsistsofastackofresiduallayers,
(cid:104) (cid:105) (cid:104) (cid:105)
g(y(0),c,t;s)=FlowBlock z(L−1),c,t,s ◦···◦FlowBlock y(0),c,t,s (9)
wherelisalayerindex,sareasetoftrainedtime-scaleparametersofthesamedimensionalityas
y(0),eachFlowBlockoutputsatensorzl ofsizey(0)andtheFlowBlockisdefinedas
LayerNorm(x)
Norm(x)= (10)
(cid:112)
dim(x)
FlowBlock[x,c,t,s]=θ(x+t·Linear[Norm([x,c])]), (11)
whereθ(·)=s⊙ArcSinh(cid:0) s−1⊙·(cid:1)
isanon-linearitywithtrainableparameterss,andN isnumber
ofelementsiny(0). Notethat,unliketheoriginalNeuralFlowsimplementation,wedonotenforce
theinvertibilityoftheseflowblocknetworks.Inourexperiments,wefindL=3tobeagoodselection
forthedepthofthepredictionnetwork. Thepredictionnetworkisusedtoproducepredictionsatboth
t andt ,however,itspredictionsforthesetwotimepointsaremadeindependently–they
future current
botharegeneratedconditionedentirelyoninitialconditionsy(0)andtime-independentcontextc.
In order to introduce auto-correlation through time and permit sensible autoregressive sampling
conditionedonpreviouspredictions,theresidualbetweentheoutputofthepredictionnetworkat
t andthecurrentlyavailableobservedstateatt ispassedthroughthecorrectornetwork.
current current
Thecorrectornetworkmaybeadeepmultilayerperceptron, anditsoutputiscombinedwiththe
outputofthepredictionnetworkatt toformthefinaloutputforf,
future
q(·)=ϕ(Linear[·]) (12)
f(x,t future,t current)=g(x,t future)+e−λ(tfuture−tcurrent)(q
N
◦···◦q 1)(g(x,t current)−y(t current))
(13)
Intheexperimentswepresent,weemployasinglelayerforq(·)withanidentityactivationfunction
ϕ. Althoughthepredictor-correctorarchitecturemayseemmysteriousatfirstglance,theintuitionis
relativelyeasytograsp. Weuseaneuralnetworktomakeapredictionforthestateofthesystemat
timet andmeasuretheresidualerror. Next,weusetheneuralnetworktomakeapredictionfor
current
thestateofthesystematafuturetimet . Ifthedifferencebetweenthetwotimesisshort,thenwe
future
expecttheresidualerrorsforthepredictionsatthetwotimestobesimilar. Ontheotherhand,ifthe
differencebetweenthetwotimesislong,thenknowingtheresidualerroratthefirsttimedoesn’thelp
uspredictwhatitwillbeatthenexttime.
Asanadditionalregularization,asecondarypredictionatt ismade,butusingt asaninitial
future current
conditioninsteadofy(0),
f∗(x,t ,t )=g([g(x,t ),c],t ). (14)
future current current future
Weaimtohavethedifferencebetweenf andf∗minimized,akintotherequirementforanautonomous
ODE. The difference between these two predictions is passed to a consistency loss discussed in
thenextsection. AsimilarstrategyisusedintheoriginalformulationoftheNeuralFlowsandin
ConsistencyModels[9].
WeightPredictionNetwork. AttheheartofW(x,t ,t )isamatrix-valuedfunctionw(x),
future current
meaning it outputs a matrix of size N ×M, in order to produce a linear projection of the latent
state h to the same size as the observed state y. Time dependence of this function is obtained
viamultiplicationbyatime-dependentgate,whichisacommonthemeamongallthecomponent
functionshere:
(cid:32) (cid:34) (cid:35)(cid:33)
LayerNorm(x)
m(x)=ϕ Linear (15)
(cid:112)
dim(x)
1
w(x)= √ (m ◦···◦m )(x) (16)
N 1
outputdim
W(x,t ,t )=e−λ(tfuture−tcurrent)w(x) (17)
future current
Where in our experiments presented here the number of layers in w(x) was 1 and ϕ(x) was the
identityfunction.
8Precision Prediction Network. The precision function P(x,t ,t ) is used to scale the
next current
observedstatewithintheNBM’senergyfunction.Inthiswork,itiscomprisedofanetworkp(x,t )
next
andagatefunction:
p(x)=(m ◦···◦m )(x) (18)
N 1
(cid:104) (cid:16) (cid:17)(cid:105)
P(x,t ,t )=exp β−log 1+(1−e−|λ|(tnext−tcurrent))ep(x,tnext) (19)
next current
WhereboldGreeksymbolsrepresentlearnabletensorsofappropriatesize,m(x)isdefinedinequation
15,andinexperimentspresentedherethenumberoflayerswas1withtheactivationsettotheidentity
function. Thisparticularchoiceforthescalingoftheprecisionmatrixwiththetimedifferencecanbe
derivedbyapproximatingtheresidualswithanOrnstein-Uhlenbeckprocess,butweleavethisasan
exercisefortheadventurousreader.
2.2 Time-to-EventModeling
Sofar,we’veconsideredthetaskofforecastingthetimeevolutionofsomeclinicalvariablesthatwe
mayimagineevolvingaccordingtosomeunknownstochasticdifferentialequation;thatis,theyare
continuouslyevolvingintime. However,therearemanycasesinamedicalcontextforwhichwe
needtoforecastthetimewhenaparticulardiscreteeventwilltakeplace. Althoughonecould,atleast
inprinciple,forecastsuchaneventasthefirstpassagetimeofacontinuouslyevolvingvariable,this
approachdoesn’tworkwellinpractice,andit’seasiertoincorporatededicatednetworkstopredict
specificevents.
Asaresult,ourexperimentsuseabolt-onapproachthatconnectsaTime-to-Event(TTE)component
modeltotheimputermoduleoftheoverallmodel,butthatisdisconnectedfromthelongitudinal
predictions. Usingthisapproach,weprovideadistributionforthetimeittakestoseeaparticular
event, conditionedoninformationavailableattheinitialtimepoint. Thedistributionweuseisa
univariateWeibulldistribution. Weibulldistributionsarecommonlyemployedtomodeltime-to-event
ortime-to-failureanalyses(knownasacceleratedfailuretimemodels)[5]. Inparticular,wemodel
thelogofthetime-to-event,whichtransformstheWeibulltoaGumbeldistributionwhosetwoscalar
parametersareprovidedbyascalar-valuedneuralnetworka(x)andlearnablescalartensorσ:
(cid:32) (cid:34) (cid:35)(cid:33)
LayerNorm(x)
r(x)=x+ϕ Linear (20)
(cid:112)
dim(x)
(cid:34) (cid:35)
LayerNorm(r ◦···◦r )(x)
a(x)=Linear N 1 (21)
(cid:112)
dim(x)
log(T)=a(x)+σ×ε (22)
ε∼Gumbel[0,1] (23)
whereϕ(·)isanonlinearitythatwesettoArcSinh(·)asinpreviousnetworks,a(x)iscomprisedofa
stackofresidualblocksr(x)followedbyaLayerNormandLinearlayertocollapsetheintermediate
(shapedliketheinputx = [y(0),c])toascalar. TheresidualblockiscomprisedofLayerNorm,
scalinglayer,andLinearlayerfollowedbyanArcSinhactivationwithaskipconnectionfromendto
end. Inexperimentspresentedhere,thenumberofresiduallayerswas1. Inprinciple,onecouldadd
additionalresidualblockstothisnetworkifrequired.
2.3 WhySoManyLayerNorms?
Weusearelativelyunusualpatterninwhichtheinputstoalloftheseneuralnetworksarewrapped
insideafunction,
LayerNorm(x)
Norm(x)= (24)
(cid:112)
dim(x)
Applyingthisnormalizationtotheinputsofalinearlayerisasimplewaytoapproximatelycontrol
thevarianceoftheoutputsofthatlayer, whichwillbedeterminedbytheL normofthelayer’s
2
weights. SinceweareusingL weightdecaytoregularizetheparametersinthenetworks,applying
2
thisnormalizationhelpstoputallofthenetwork’sparametersonthesamescale,makingiteasierto
tunetheweightdecay.
92.4 TrainingLossesandRegularizations
Energy-basedmodelslikeNBMsaretypicallytrainedviaapproximatemaximumlikelihood. Inthe
caseofRBMsandNBMs, thisusesanalgorithmknownasContrastiveDivergence. Inourcase,
however,weuseamorecomplexlossfunctionthatalsoincludestermstotraintheautoencoderfor
imputationandthetime-to-eventnetwork,aswellastoregularizetrainingoverall. Allofthenetwork
parametersaretrainedsimultaneouslybydifferentiatingthroughalossfunctionthatisaweighted
sumofthecomponentsoutlinedbelow. Theweightsofthesecomponentsarehyper-parametersof
thetrainingprocedure.
ReconstructionLoss. ThislosstrainstheAEImputertoaccuratelyimputemissingdatapointsby
minimizingthemeansquarederrorbetweentheoriginaldata. Notably,theAEImputeristrained
toimputebothmissingcontextualinformationaswellaslongitudinaldata. Itisalsotime-invariant
andistrainedonavailablepatientvisitswithinthetrainingbatch. Additionally,everyvisitsample
isassignedaweight,w ,tomaketheper-patientlosscontributionuniform. Assumingazero-filled
i
sample,x,theimputerlossisdefinedas
V N
L = 1 (cid:88)(cid:88) w ·m ·|AEImptuer(x ) −x |2 (25)
imputer VN i i,j i j i,j
i=1j=1
where V is the number of visit samples used to update the AEImputer, and m is a masking
i,j
coefficientwithvalue0ifvariablej wasmissingfromx and1otherwise. Lastly,inordertoprevent
i
overfittingNBMlongitudinalpredictionstopotentiallyconfoundingpatternsofmissingnessfrom
multi-sourcetrainingdata,L isoptimizedindependentlyviastop-gradient–inthisway,the
imputer
AEImputerisco-trainedwiththerestoftheNBM,ratherthanhavinggradientsflowfullyend-to-end.
ContrastiveDivergence. AsinanRBM,themaincontributiontothetrainingofanNBMisan
approximategradientofthenegativelog-likelihoodcomputedviacontrastivedivergence. Itincludes
gradientsfromboththeactualdatapoints(positivephase)andthemodel-generateddatasamples
(negativephase). Thegradientscanbecomputedbydifferentiatingthefollowinglossfunction,
L =E [U(y|x)]−E (cid:2)E [U(y|x)](cid:3) . (26)
RBM batch batch y|x
Feature-wiseMSELoss. Thislossassessesthefidelityofthepredictionnetworkuptothepredicted
precisionofeachlongitudinalvariablebycomparingtheoutputofg(·)atatime-pointt toits
next
ground-truth observation. After first performing a zero-filling to account for missing entries in
y(t ),thelossiscalculatedas
next
 
N
L
featurewise_mse
=E batch(cid:88) m
j
·P
j
·|g(y(0),c,t next)
j
−y j(t next)|2 , (27)
j=1
wherem isamaskingcoefficientwithvalue0ifvariablejwasmissingfromy(t )and1otherwise.
j next
ConsistencyLoss. Ensuresthatthemodel’spredictionsareconsistentoverdifferentforecasting
intervals,enhancingthetemporalcoherenceofthemodel’soutputs. Thistermiscomputedasthe
expectationofthesquaredifferencebetweenEq.14andEq.9,
(cid:104) (cid:105)
L =E |g(y(0),c,t ))−g(g(y(0),c,t ),c,t )|2 . (28)
consistency batch next current next
EventLoss. Quantifiestheaccuracyofeventtimepredictions,relevantinmodelsthatfeaturea
time-to-eventprediction. ThelossistheloglikelihoodoftheobservedeventtimeunderaWeibull
distributionparameterizedasshowninEq.20,whichisinspiredby[5].
Inadditiontotheaboveterms,weapplyL weightdecaytothemodelparameters. Wenowturn
2
fromageneraldiscussionofthearchitecturetodetailsabouthowthemodelistrainedandappliedto
individualdiseaseindications.
102.5 TrainingStrategy
Weusek-stepContrastiveDivergence(CD)[2,8]withadditionalpenaltiestotrainNBMmodels.
Thisobjectivepermitsustousestandardbackpropagationtocomputegradientsfortheparameters
of the neural networks involved in f(x), P(x), and W(x). Parameter optimization is done with
AdamW[6]actingonminibatchesofparticipanttrajectories. Samplesoftheobservedstateyfor
eachobservationinthebatcharecomputedusingkMCMCsteps(thelastsampleistaken)without
trackingthegradient. Thesesamplesforyarethenusedtocomputeanempiricalexpectationoverthe
differentiablemarginalenergyU(y|x)inthenegativephaseofthecontrastivedivergenceloss. The
positivephaseofthecontrastivedivergence,whichsamplesyfromthedata,islikewisedifferentiable.
Foreachminibatchofpatienttrajectories,weconvertthetrajectoryofpatientobservationsintoa
sequenceoftripletscomprisedoftheinformationattheinitialtimepoint,thecurrentvisit,anda
future visit. We compute all possible causal triplets. This design enables the model to learn the
progressionofthepatient’sstateoverdifferenttimeintervals.
3 ApplyingNeuralBoltzmannMachinestoClinicalData
3.1 ClinicalTrialDatasetCurationandPreprocessing
TherapeuticArea DiseaseIndication Patients Patient-Visits
Alzheimer’sDisease(AD) 25,212 83,450
Huntington’sDisease(HD) 13,286 33,323
Neurodegeneration AmyotrophicLateralSclerosis(ALS) 10,887 83,581
Parkinson’sDisease(PD) 2,199 9,401
FrontotemproalDementia(FTLD) 1,412 4,182
RheumatoidArthritis(RA) 70,873 150,478
Psoriasis(PSO) 6,202 15,215
Immunology&Inflammation
Crohn’sDisease(CD) 2,944 15,368
AtopicDermatitis(ATD) 1,925 5,614
Hypertension(HTN) 8,955 32,349
Dyslipidemia(DLD) 4,030 21,152
GeneralMedicine
Type2Diabetes(TTD) 3,099 21,105
AcuteIschemicStroke(STR) 2,613 10,087
Total 153,637 485,305
Table1: ThedatasetsusedfortrainingandevaluationofDTGsineachindication,intermsofthe
numberofpatientsandpatient-visits.
WetrainedandevaluatedDTGsin13differentindicationsusingdatasetsaggregatedfromavarietyof
sources,includingpreviouslycompletedclinicaltrials,observationalstudies,andregistries. Across
indications, data came from 156 clinical trials and 33 observational studies and registries, with
study data totaling more than 400,000 patients with more than 3.8 million visits. This data was
wasprocessedandharmonizedintotrainingdatasetsforeachindication,withdatafilteredbasedon
samplequalityandrelevanceforcommonclinicaltrialoutcomes. Theresultingdatasetsusedfor
trainingandevaluationoftheDTGsaredescribedinTable1.
Eachofthesedatasetscontainsmultivariateclinicaltrajectoriestakenfromindividualstudypartici-
pants,whereeachparticipantwasassessedinoneormorefollow-upvisitsatvaryingintervals. The
samplesizes,measuredintermsofthenumberofpatientsorthetotalnumberofpatientvisits(which
ismoreappropriatefortimeseriesmodels),varybyroughlyoneorderofmagnitudeacrossthese
indications. Thesedatasetsgenerallycontaincommonclinicaloutcomeassessmentsusedinclinical
11studiesforthegivenindicationsinadditiontolabtests,dataonbiomarkers,andmedicalhistory. Of
course,theparticularvariablesaredifferentforeachindication.
Clinical datasets are often heterogeneous, multimodal, and have varying data quality standards.
These problems are exacerbated in this case because these datasets do not come from individual
studies,butratherwereconstructedbyaggregatingdatafrommultiplestudiesineachindication.
Thus,heterogeneityofdatasetswithinagivenindicationmaymeanthatstudiesmeasuredifferent
setsofoutcomesassessmentsoradministercustomversionsofassessments;studiesmayalsohave
differentdurationsofdatacollection,withvaryingvisitfrequencies,andmayhaveenrolleddifferent
populations. Multimodal clinical datasets may include variables with different data types (i.e.,
continuous,binary,categorical,andsurvival). Assessmentsandvariablesmayberecordedintheraw
datawithdifferent,nonstandardconventions. Lastly,dataqualitystandardsmayvarysignificantly
acrossclinicaldatasets. Missingdata,dataentryerrors,discrepanciesbetweentherawdataanddata
dictionaries,andanyotherinconsistenciesneedtobeaddressedduringdataharmonizationefforts.
Thesecharacteristicsofclinicaldataposeasignificantchallengewhentryingtoharmonizethem
into single, integrated datasets for each indication. To accomplish this, we use configurable and
standardizeddataprocessingpipelinestoleveragesoftwaretoolsanddomainknowledgetobuild
high-qualitydatasetsfortrainingandvalidation. Therearekeystepstoensuregoodperformanceof
theDTGwhenpreparingdatafromanysingledatasource: standardizationofdatawithdimensions,
standardizedencodingofcategoricalorordinaldata,outlierdetectionfordatawithincorrectencoding,
uninterpretabledata, orunphysicalmeasurements, andentityresolutionfordatasuchasmedical
historiesormedicationinformation. Theseactionsensuredatafromeachsourceishighqualitywhile
also remaining faithful to the original dataset. There are also key steps performed as a result of
harmonizingdataacrossmultiplestudies,whichareimportanttoproducelargerdatasetsthatare
consistentacrossstudiesandmeettheneedforasingle,consistentdatamodelformachinelearning
applications. Thesestepsprimarilyfocusontransformationstodatathatremoveinconsistenciesin
data-takingprocesses,forexample,correctingsupinevitalsignmeasurementsintothemorecommon
sittingversion,ormappingdatabetweenversionsofanassessmenttoensureitcanbeconsistently
interpretedacrossstudies. Incasessuchasthese,harmonizationrequiresmakingchoicesthatwill
make the data less specific and less faithful to individual studies in order to create a consistent,
multi-studydataset.
3.2 Hyper-parameters
We used the same NBM architecture to train DTGs in each of the 13 indications, but we did
optimize model and training hyper-parameters for each indication. We found that the following
hyper-parametersweremostsignificantwhenattemptingtotuneaDTGtobestfitthedatainagiven
indication.
AEImputerEmbeddingDimension. Eachclinicaldatasethasadifferentnumberofobservations
at the initial visit, both for the time-dependent variables as well as time-invariant variables that
makeupthecontext,suchaslabs,vitals,ormedicalhistoryandgeneticmarkers. Furthermore,each
clinical dataset consists of a heterogeneous mix of data sources, each of which records different
combinationsofthesevariablesatfrequencies. Therefore,thelongitudinalpatternofmissingness
ishighlydisease-dependent,makingthetuningoftheautoencoder-imputernetworkanimportant
aspectofmodelperformance. Asaresult,tuningtheembeddingdimensionoftheAEImputerisa
necessarysteptoensureaproperbalancebetweenpredictiveperformanceandgeneralization.
WeightDecay. WeapplyL weightdecaytoalloftheparametersintheNBMtoregularizethe
2
networkandpreventoverfitting.Asmentionedpreviously,weappliedaparticularformofLayerNorm
throughoutthemodelinanefforttomakeallofthemodelparametersthesameorderofmagnitude
sothattuningtheweight-decaypenaltyiseasier. Asaresult,eventhoughweseparatelytunedthe
weight-decaypenaltiesforeachsub-network,wefoundthatthetunedpenaltieswereallwithinthe
rangefrom[0.1,0.5].
BlockGibbsSamplingSteps. SamplesaregeneratedfromanNBMbyblockGibbssampling.
Thatis,oneiteratesbetweensamplingfromy∼p(y|h,x)andh∼p(h|y,x). Wefoundthat16or
feweriterationswasgenerallyappropriateforourdisease-specificDTGs.Although,onecangenerally
improvetheperformancebyaddingmoreiterationsattheexpenseofincreasedcomputationalcost.
12NBMHiddenDimensionSize. ThenumberoflatentvariablesintheNBM(i.e.,thedimension
ofh)setsthecapacityforthemodeltocapturecorrelationsbetweenobservedvariables. Choosing
too large of a hidden dimension balloons the size of the weights network, which increases the
computationalcostsandmayincreasethelikelihoodforthenetworktooverfittothetrainingset.
EventLossWeighting. Onlysomeoftheindicationsweconsideredinourexperimentsincluded
specifictime-to-eventvariables. However,itwasnecessarytotunetheweightappliedtothetime-to-
eventlosswhensuchvariableswerepresent. Technically,thetwonetworksaredecoupled,butthe
relativeweightsofthelossfunctionscouldrequiretuningduetointeractionswiththelearningrateof
weightdecayparameters.
Themodelandtraininghyper-parametersweretunedtooptimizetheDTG’sperformanceineach
indication using 5-fold cross-validation. However, this tuning was largely performed by human
evaluationbecauseit’sdifficulttoderiveasinglemetricthatcapturestheperformanceofamultivariate
DTG.Weconsideredvariousmetricssuchasmean-squaredpredictionerrorsforeachvariableat
multiple time intervals, calibration of predicted quantiles at various time intervals, the ability to
accuratelymodelcorrelationsandautocorrelationsbetweenvariables,andothers.Therefore,selection
of“thebest”hyperparametersforagivenindicationwasadmittedlysubjective.
Inaddition,eachindicationhadadifferentnumberoftime-dependentandtime-independentcontext
variables, which affects the number of parameters in the resulting model. The input and output
dimensionsaswellasthenumberofmodelparametersforeachindicationareshowninTab.2.
Indication Inputs Outputs Parameters
PD 112 91 221K
STR 110 58 204K
HD 80 57 144K
AD 76 54 130K
ALS 71 50 115K
RA 69 37 87K
CD 66 22 42K
TTD 42 14 21K
DLD 45 11 18K
FTLD 34 20 11K
HTN 38 9 7K
PSO 42 4 7K
ATD 24 6 6K
Table2: Per-diseasebreakdownofthenumberofinputbaselinevariables(Inputs)usedtocondition
the generation of the disease-specific NBM, the number of time-varying longitudinal variables
predictedbytheNBM(Outputs),andthefinaltrainableparametercountoftheresultingNBMmodel,
includingallsub-networksoftheNBM(Parameters).
4 EvaluationandValidation
Gooddigitaltwinsshouldbestatisticallyindistinguishablefromrealobservationsofpatients. Evalu-
atingwhetherornotourdigitaltwingeneratorsareaccuratelymodelingagivenpopulationofpatients
isacomplexproblem,becausetherearemanywaystoevaluatethegoodness-of-fitforagenerative
model. Forexample,forapopulation,onecancomparethemomentsofthedatadistributiontothe
distributionthattheDTGreturns(givensomeper-patientcontextinformationforthepopulation).
Ofcourse,weareinterestedinmodelingmanypotentialpopulations,notjustoneinparticular. We
wanttheDTGtogeneralizeandaccuratelymodelthedistributionofanyrealisticpopulationthatwe
supplytoit.
13WewillemployacoupleoftoolstoestimategeneralizationoftheDTG.First,topreventthemodel
fromoverfittingonandpotentiallymemorizingitstrainingdata,weusefive-foldcross-validationto
evaluatethemodels. Thismeansthatforeachindication,thetrainingdatasetissplitintofivefolds
ofapproximatelyequalsize. Foreachfold,predictionsaregeneratedfromamodeltrainedonthe
remainingfourfolds. Predictionsfromthefiveseparatemodelsevaluatedontheirheld-outfoldsare
mergedandusedtocomputeevaluationmetricsreportedinthissection. Basedonthisvalidation
method,wefindthatforallindicationsthesamemodelarchitecturewithminimalhyper-parameter
tuningcanlearntomakeaccuratepredictionsacrossindications.
Another way to probe generalization is to examine the performance of the model for different,
clinicallyrelevantsub-populationsor"cohorts". Thesecohortsaredefinedwithsomeinclusionor
exclusioncriteriaonthebaselinefeaturesofthepatientsandsoweexpectthecohortstohavedifferent
clinicalbehaviorovertime. Likewise,onecanalsostratifyapopulationonasinglevariable,which
alsocreatescohortsofadifferentkind. Ideally,wewillseethatforeachsub-populationorpatient
stratification,thedistributionoverthatsub-populationmatchesthedistributionthattheDTGreturns
giventhatsub-population’sbaselineinformation.
EvaluationoftheDTGataper-patientlevel,ratherthanatthepopulationlevel,ismoredifficult.Since
onehasonlyasingleobservationofagivenpatientthroughtime,onecannotcompareaggregates,
expectations,ormomentsofthetwindistributiontothesamequantitiesofthedata. Akeymetric
weexaminethatcontainssomeper-patientlevelinformationisthecorrelationbetweenapatient’s
trajectoryandtheexpectedvaluederivedfromtheirtwin. Whenameasurementofagivenpatient
risesorfalls,andthetwinalsorisesandfallsinconcert,thecorrelationishigh. Tomakeiteasierto
visualizewhatdigitaltwinpredictionslooklike,inFigures22–34weshowtablesofexampledigital
twinsforindividualpatientsineachindicationusingsyntheticbaselinedata,showingthepredicted
meanandstandarddeviationthroughtimeforallvariables.
Finally,weexaminemodelexplainabilitymetricsasawaytoassessrobustnessofourDTGs. We
compute feature importance metrics with SHAP to confirm they meet general expectations from
disease-specificdomainknowledge. Similarly,weassessensitivityofDTGperformancetomissing
inputfeatures,whichisacommonscenariowhentryingtousetheDTGwithclinicaldata.
4.1 MeanPredictionsforKeyCohortsandOutcomes
For each indication, we make a DTG conditioned on the multivariate baseline characteristics of
eachpatient. Baselinetimerefersheretothestartofaclinicaltrialorobservationalstudy. Many
trajectoriesofeachpatientaregeneratedinordertocomputeexpectationsorothersummarystatistics
fromtheirdigitaltwins.
Apatient’sdigitaltwinproducesamultivariateprobabilitydistributionforalloutcomesatallfuture
times,conditionedondatacollectedfromthatpatientatprevioustimes. Onesetofusefulstatistics
forsummarizingthisdistributionistheexpectedvaluesofimportantclinicaloutcomesatkeyfuture
timepoints. Theseexpectedvaluesareessentiallypointpredictionsforthosefutureoutcomesinthe
sensethattheyminimizethemean-squarederrorunderthemodeldistribution. Fromthelawoftotal
expectation,thepredictedmeanforagivenvariableytakenoverapopulationofpatients,atagiven
timet,canbewrittenas
µ [y(t)]=E[E[y (t)|x]], (29)
pred pred
wherexindicatesthebaselinecharacteristicsofagivenpatientandy (t)|xaisasamplefory(t)
pred
obtainedfromapatient’sdigitaltwin. Thus,theinnerexpectationE[y (t)|x]isthepredictedmean
pred
forthevariableobtainedfromapatient’sdigitaltwin,andtheouterexpectationtakestheaverageof
thepopulation.
In Figure3,Figure4,andFigure5,weconsiderakeyoutcomeforeachindicationandreportmean
progressionovertime,comparingdataandDTGpredictionsatthepopulationlevel. Whenavailable,
wereportprogressionfortwoclinicallyrelevantcohorts. Forbinaryoutcomes,wecomparepredicted
andobservedresponseratesovertime. WealsoreportPearsoncorrelationbetweenobservationsand
DTGpredictionsforcontinuousoutcomesandAUCforbinaryoutcomes. Correlationsprovidean
importantmeasureofgoodness-of-fitbeyondthepopulation-levelmeantrajectoriesthatmeasurethe
strengthofthelinearrelationshipbetweenobservedandpredictedchangesinclinicalvariablesatthe
patientlevel. Similarly,AUCmeasuresdiscriminativeperformanceforbinaryoutcomes.
14ThesefiguresdemonstratethattheDTGsareeffectiveatgeneratingdigitaltwinswithlowbiasand
gooddiscrimination. Thepredictedprogressionfromthedigitaltwinstrackstheobservedoutcomes
well,anddistinctcohortsshowdistinctpredictedprogressionsthatmatchobservationswell. The
degreetowhichthedigitaltwinscapturechangesinprogressionacrosspopulationsisquitestarkand
suggeststhatthemodelisdoingagoodjobatutilizingprognosticinformationcontainedinthedataas
wellasmodelingthetimedynamicsofthediseaseacrossallindications. Thedigitaltwinshavegood
correlationwiththeobservations,rangingbetween0.3and0.5acrossnearlyallNeurodegeneration
indications,andbetween0.5and0.7forImmunology&InflammationaswellasGeneralMedicine.
Notethat,tosimplifypresentation,thesefiguresonlyshowasingleoutcomeforeachindication;the
DTGspredictmultipleoutcomesthatarecommonclinicaltrialendpointsforeachindication.
In Figure7, Figure8,Figure9wefocusonhowwelltheDTGsineachindicationareabletomodela
conditionaldistribution. Ratherthanusingclinicalcohorts,westratifytheoveralltrainingpopulation
into quartiles, select the top and bottom quartiles, and examine how well the model can capture
the mean and standard deviation of these different sub-populations. The difference between the
populationdensitiesofthedifferentsub-populationsofboththedigitaltwinsanddataarecompared
intherightcolumnofthesefigures. Thedatadensitiesofthetopandbottomquartilesareshown
intheleftcolumn. Generally,weseethattheDTGisabletonotonlywellapproximatethedensity
ofthedata,butalsothechangeindensityofthedatafromonesub-populationtothenext. There
aretimeswhenthetwindensitydifferencedisagreeswiththedata,mostoftenwhenthedifference
betweenquartilesissmall.
4.2 ComprehensiveEvaluation
Metricsandfiguresdiscussedabovefocusedonafewkeyclinicaloutcomesineachindication,but
eachofthesediseasesismultifaceted,anddigitaltwinsofpatientsineachindicationneedtomodel
manyotherlongitudinalvariablesincludinglaboratorytests,biomarkers,vitals,andadditionalclinical
assessments. IntheleftpanelofFigure10,Figure11,andFigure12,foreachindication,wecompare
predictedandobservedpopulationmeansforallvariablesandtimes. Awell-calibratedmodelshould
correctlyreproducethemeans,sothatdatapointsaccumulatealongthediagonal. Markeropacityis
scaledaccordingtothenumberofobservationsavailableforthatparticularoutcomeandtime,and
colorindicatestimesincebaseline. Aperfectlycalibratedmodelwouldhaveallpredictedmeansfall
alongalineofunitslopeandzerointercept.
Sofar,wehavefocusedonevaluatingthemeantwinpredictions. DTGs,however,characterizeafull
multivariatedistributionovertimeconditionedonapatient’sbaselinecharacteristics. Therightpanel
ofFigure10,Figure11,andFigure12comparesstandarddeviations. Foreachvariableandtime,the
x-axisreportstheobservedpopulationstandarddeviationandy-axisthecorrespondingprediction.
Marker opacity and colors represent size of the population and time, as for plots comparing the
means. Notethatfromthelawoftotalvariance,thepredictedpopulationstandarddeviationfora
givenvariabley,atagiventimet,canbewrittenas
σ [y(t)]=(Var[E[y (t)|x]]+E[Var[y (t)|x]])1/2, (30)
pred pred pred
wherexindicatesthebaselinecharacteristicsofagivenpatientandy (t)|xaisasamplefory(t)
pred
obtainedfromapatient’sdigitaltwin. Thepredictedvariancehastwocontributions: thefirstisthe
populationvarianceoftheper-patientmeantwinsE[y (t)|x], andthesecondisthepopulation
pred
meanoftheper-patientvariancesVar[y (t)|x].
pred
Weseegoodagreementbetweenthepredictedandobservedvaluesforthesefirstandsecondmoments
acrosstherapeuticareasandindications. Outliersarerare,andtendtocoincidewithsmallersample
sizesforevaluation. ThisgivesconfidencethattheDTGsarecorrectlycapturingbehaviorofhte
distributionsacrosstimeforeachindividualvariable.
Next,inFigure13,Figure14,andFigure15wecompareobservedandpredictedequal-timecross-
correlationsacrossvariablesandtimes. Thisallowsustoevaluatethefullcovariancestructureof
thedigitaltwinsandevaluatetherelationshipsbetweenvariables. Asinthepreviousfigure,foreach
pairofvariablesandforagiventime,thex-axisreportstheobservedcross-correlationandy-axis
thecorrespondingpredictedcross-correlation. Markeropacityandcolorsrepresentthesizeofthe
populationandtime,asfortheotherplots. Asforthevariances,thepredictedcorrelationsreceive
contributionsbothfromthecorrelationacrossthepopulationofthemeantwinpredictions,aswellas
fromthecorrelationsofthetwinsforeachpatient. Fromthelawoftotalcovariance,thepredicted
15correlationbetweenvariablesyandzattimetcanbewrittenas
Cov[E[y (t)|x],E[z (t)|x]]+E[Cov[y (t),z (t)|x]]
ρ [y(t),z(t)]= pred pred pred pred , (31)
pred σ [y(t)]σ [z(t)]
pred pred
wherexindicatesthebaselinecharacteristicsofagivenpatient,y (t)|xandz (t)|xaresamples
pred pred
fory(t)andz(t)obtainedfromapatient’sdigitaltwin. Thestandarddeviationsinthedenominator
aredefinedinEquation30. Asforthevariances,predictedcorrelationsalsoreceivetwocontributions.
Thefirstterminthenumeratoristhepopulationcovarianceofthemeantwinsandthesecondtermis
thepopulationmeanofthecovarianceforeachpatient.
Wecanseethatthecorrelationsaregenerallywellmodeled,withtheareasoflargestdeviationat
smallvaluesofcorrelations. Interestingly,onecanlookatthesizeofcorrelationsacrossindications
andtherapeuticareastogaugetherelationshipsinvariablesperindication.
4.3 ModelExplainability
Whenusingmachinelearningmodelstomakeimportantdecisions, itisusefultodevelopanun-
derstandingabouthowthemodelsworkandhowsensitivetheiroutputsmaybetochangesintheir
inputs. Weuseacoupledifferentmethodstoprobeourmodels. Thefirstwecallinputsensitivity
(seeFigure16,Figure17,andFigure18),whichmeasureshowmuchagivenperformancemetric,
forinstancePearsoncorrelationbetweendataandmeantwinsoveracertaincohort,changeswhen
agivenfeatureismaskedfromthepatient’sbaselinedata. Missingdataisacommonproblemin
manyhealthcareapplications–thatis,someassessmentsmaynotbeavailableasmodelinputsbecause
theyaretooexpensive,time-consuming,orinvasivetocollectoneverypatient–sohowrobustmodel
performanceistomissinginputsisanimportantcharacteristic. IncertainindicationslikePD,wesee
thatinputsensitivityislowrelativetootherindicationsintheNeurodegenerationtherapeuticarea.
Thiscanarisewhenthefeaturebeingprobedisnotstronglycorrelatedtootherfeaturesandinstead
dependsprimarilyonitsownbaselinevalue. FortheImmunology&Inflammationtherapeuticarea,
weseethatgenerallyalltheprobedoutcomeshavedominantdependenceontheirbaselinevalueand
thusthechangeincorrelationtomaskingothervariablesissmall. TheGeneralMedicinetherapeutic
areafallsinbetweenNeurodegenerationandImmunology&Inflammationinthisregard.
Inadditiontoinputsensitivity,weuseSHAP(SHapleyAdditiveexPlanations)togaindeeperinsights
into our models decisions. SHAP provides a detailed view of how each feature contributes to
individualpredictions,regardlessofhowwellthatpredictionmatchestothedata. Thisdistinction
iscrucialasSHAPrevealstheinfluenceofeachfeaturewithinthecontextofaspecificprediction,
allowingustounderstandthe"why"behindamodel’soutputinawaythatinputsensitivitydoes
not. SHAPthusoffersacomplementaryperspective,focusingonpredictioncontributionratherthan
performancesensitivity. SHAPisalsoabletoprobetheeffectofthebaselinevalueontheprediction,
whereas Input Sensitivity can only look at the effect of other outcomes on a given outcome. In
Figure19,Figure20,andFigure21wereportSHAPvaluesforkeyoutcomesacrossindicationsfor
eachofourDTGs. WegenerallyfindthatSHAPvaluesagreewithdomainknowledgeofagiven
indication.
4.4 TTE
DTGscanalsomodelsurvivaloutcomes,andinFigure6,wereportacomparisonoftheobservedand
predictedsurvivalcurvesforthetime-to-deathoutcomeinALSfortwoclinicallyrelevantcohorts.
Wealsoreportconcordanceindexasameasureofgoodness-of-fitbeyondpopulation-levelsurvival
curves.
5 FutureDirections
Inthistechnicalreport,wehaveshownhowDigitalTwinGenerators(DTGs)in13separateindications
canbetrainedtoforecastpatientoutcomesinaspecifieddiseasearea,allwithacommonneural
networkarchitecturecalledtheNeuralBoltzmannMachine(NBM).Therearemanypotentialavenues
fortheimprovementofthesemethodologies,suchasincreasingthesizeofthedatasets,incorporating
syntheticdataordataaugmentationtechniquesduringtraining,orexploringalternativeneuralnetwork
architectureswithintheNBM.
16Althoughwe’veshownthatit’spossibletotraintheseDTGsusingthesamegeneralarchitectureand
minimalhyperparametertuning,thereissubstantialeffortrequiredperindicationtodevelopeach
disease-specificDTG,particularlyinthecurationofthetrainingdatasets. Inprinciple,thereisagreat
dealofinformationthatissharedacrossindicationsthatmaybeusefultoinformmodelsofdisease
progressionwithineachindicationthroughtransferlearning. Tofullycapturethatsharedinformation,
asignificantadvancementinAIapplicationsforhealthcarewouldbethedevelopmentofauniversal
DTG.Thisisasinglemodelabletoserveasageneralpredictorofdiseaseprogressionforawide
rangeofindications. Weregardsuchamodelasafoundationalmodelfordigitaltwins,asmanyother
applicationscanbebuiltusingitasacomputationalsubstrate. Likethedevelopmentoffoundational
modelsinotherapplications,modelsofthistypefordigitaltwinsmayevolveovertimetoaccept
andmakeuseofabroadersetofinputdatasuchaselectronichealthrecords(EHR),genomicdata,
wearables,imaging,andmore.
WhiletheDTGsdescribedinthisreportaretrainedtogenerateclinicalrecordsinasingleindication,
theyallrequireandonlymakeuseofthesametypeoftabularlongitudinaldata,andeachistrained
only with the data from that indication. This is limiting in terms of the scope of any individual
DTGsince,forexample,theFrontotemporalDementiaDTGcannotlearnfromthemoreabundant
data from other neurodegenerative diseases. Furthermore, the architecture used here, at least as
implemented,doesnotdirectlypermitmodelstobetrainedwithotherdatasources,suchassummary
data from populations, text-based domain knowledge, or even differently formatted tabular data,
all of which are useful sources of information for modeling disease. We note, however, that the
probabilisticcontinuoustimemodelingcorethattheNBMrepresentscangeneralizeovermultiple
inputmodalities–oneneedonlychangetheneuralnetworksthatparameterizetheNBMtoaccept
newdataformats. WeexpectthatthepathtocreatingauniversalDTGfollowsthesamerecipeas
usedinthedevelopmentofotherfoundationmodels: mappingallpotentialinputsintoasharedlatent
representation,modelingthestochasticdynamicswithinthatlatentrepresentation,andthenmapping
backtothevisiblespace.
ThebroadergoalofusingAItoolstoimproveoutcomesinmedicinerequiresmodelsthatcanserve
manyapplications,suchascomparativedrugeffectiveness,healthoutcomesresearch,andclinical
decisionsupport. Severalchallengesemergeforbuildinguniversalmodelsthatcanforecastpatient
outcomesacrossmultipleindications. Totrulyachieveauniversaldiseaseprogressionmodel,AI
systemsmustbescalableandeasilyadaptabletodifferenthealthcareinfrastructuresandpopulation
demographics. Thisincludestheabilitytoupdatemodelswithnewdatacontinuouslyandadaptto
emergingdiseasesandchangingepidemiologicalpatterns. Intherealmofclinicaltrials,changesto
thestandard-of-careornovelclinicalassessmentsmustbeabletobeseamlesslyintegratedintothese
modelstoensurethatnewtreatmentsareassessedwithup-to-dateinformation. Perhapssomewhat
paradoxically,thesekindsofupdatesaremuchsimplerwithfoundationmodels,astheyareableto
intakeandusedatamoreflexiblyfortraining,canbefine-tunedfornewapplicationswithrelatively
smalldatasets,andrequiresignificantlylessmaintenance.
Toaddressthesechallenges,we’reworkingtowardsdevelopinguniversalDTGswithcapabilitiesfor
zero-shotconditioningandpredictionbyleveragingbroad,multi-indicationdatasetsthatincludeas
wideofavarietyofdatasourcesaspossiblewhilestillmaintaining,orimprovingon,thequalityof
theresultingmodel.
6 Conclusion
Inthisreport,wehavedescribedaneuralnetworkarchitectureusedtocreateDigitalTwinGenerators
(DTGs)in13differentdiseaseindicationsacross3therapeuticareas,aswellaspropertiesofthe
methodsanddatausedtobuildandevaluatetheDTGs. Thisworkshowcasestheabilityofmodern
machine learning architectures for learning to create digital twins of individual patients that can
forecasttheirfuturehealthindetail,pavingthewayforapplicationsinclinicalresearch,comparative
effectivestudies,andpersonalizedmedicine.Inaddition,thisworkcontributestothebroadermachine
learningliteratureby(i)presentinganewapplicationofarecentlyintroducedclassenergy-based
models called Neural Boltzmann Machines and (ii) describing a new approach to probabilistic
modelingofmultivariatecontinuous-timedynamicalsystems.
Pursuingfollow-upworkinmulti-indicationmodelsbringsusclosertorealizinganAI-powered
universalmodelthatnotonlypredictsdiseasesacrossmultipleindications,butalsoenhancesthe
17accessibilityandqualityofhealthcareworldwide. ByusingAItoimproveuponthestatusquo,we
caninnovateanew"goldstandard"forassessingthesafetyandefficacyofnewtreatments,paving
thewayforAI-enabledpersonalizedmedicinetobecomeaglobalreality.
7 Contributors
Nameyeh Alam, Jake Basilico, Daniele Bertolini, Satish Casie Chetty, Heather D’Angelo, Ryan
Douglas, Charles K. Fisher, Franklin Fuller, Melissa Gomes, Rishabh Gupta, Alex Lang, Anton
Loukianov,RachelMak-McCully,CaryMurray,HanaleiPham,SusannaQiao,ElenaRyapolova-
Webb, AaronSmith, DimitriTheoharatos, AnilTolwani, EricW.Tramel, AnnaVidovszky, Judy
Viduya,andJonathanR.Walsh.
8 DataAcknowledgements
Thedatasourcesusedtotrainandtestthemodelsdescribedinthisreportareacknowledgedhere:
https://www.unlearn.ai/data-acknowledgements
18References
[1] MarinBiloš,JohannaSommer,SyamaSundarRangapuram,TimJanuschowski,andStephan
Günnemann. Neuralflows: Efficientalternativetoneuralodes. Advancesinneuralinformation
processingsystems,34:21325–21337,2021.
[2] GeoffreyEHinton. Trainingproductsofexpertsbyminimizingcontrastivedivergence. Neural
computation,14(8):1771–1800,2002.
[3] Diederik P Kingma and Max Welling. Auto-encoding variational bayes. arXiv preprint
arXiv:1312.6114,2013.
[4] AlexH.Lang,AntonD.Loukianov,andCharlesK.Fisher. Neuralboltzmannmachines. arXiv
[cs.LG]:2305.08337,May2023.
[5] EnwuLiu,RyanYanLiu,andKarenLim. Usingtheweibullacceleratedfailuretimeregression
modeltopredicttimetohealthevents. AppliedSciences,13(24):13041,2023.
[6] Ilya Loshchilov and Frank Hutter. Decoupled weight decay regularization. arXiv preprint
arXiv:1711.05101,2017.
[7] DaniloRezendeandShakirMohamed. Variationalinferencewithnormalizingflows. InInterna-
tionalconferenceonmachinelearning,pages1530–1538.PMLR,2015.
[8] EricWTramel,MarylouGabrié,AndreManoel,FrancescoCaltagirone,andFlorentKrzakala.
Deterministicandgeneralizedframeworkforunsupervisedlearningwithrestrictedboltzmann
machines. PhysicalReviewX,8(4):041006,2018.
[9] MarkChenYangSong,PrafullaDhariwalandIlyaSutskever.Consistencymodels.arXivpreprint
arXiv:2303.01469,2023.
19ALSFRS Revised
CDR-SB Change from Baseline (AD) Change from Baseline (ALS)
MCI-mild (Observations) Min FVC (Observations)
4 MCI-mild (Mean Twins) 0 Min FVC (Mean Twins)
Mild-moderate (Observations) Recent onset (Observations)
Mild-moderate (Mean Twins) Recent onset (Mean Twins)
3
5
2
10
1
15
0
1.0 MCI-mild 1.0 Min FVC
Mild-moderate Recent onset
0.5 0.5
0.0 0.0
91 181 271 361 451 541 631 721 811 57 113169225281337393449505561617673
Time from Baseline (Days) Time from Baseline (Days)
FTLD CDR-SB MDSUPDRS Subscore
Change from Baseline (FTLD) Change from Baseline (PD)
12 Behavioral (Observations) Early PD (Observations)
Behavioral (Mean Twins) 12 Early PD (Mean Twins)
10 10
8 8
6
6
4
4
2
2 0
1.0 Behavioral 1.0 Early PD
0.5 0.5
0.0 0.0
361 541 721 901 1081 1261 91 181 271 361 451 541
Time from Baseline (Days) Time from Baseline (Days)
cUHDRS Change from Baseline (HD)
0.5 Manifest (Observations)
Manifest (Mean Twins)
0.0 All (Observations)
All (Mean Twins)
0.5
1.0
1.5
2.0
2.5
1.0 Manifest
All
0.5
0.0
183 365 547 729 911
Time from Baseline (Days)
Figure3: ObservedandpredictedprogressionofkeyoutcomesforindicationsintheNeurodegenera-
tivetherapeuticarea. Ineachplot,weselectedakeyoutcomeanduptotwocohorts(seeTables3
and6fordescriptionsofoutcomesandcohorts,respectively). Thetoppanelcomparestheobserved
andpredictedmeanprogression. ThebottompanelreportsPearsoncorrelationbetweenobservations
and mean twins over time as a measure of discriminative performance of the model. Error bars
represent95%confidenceintervals. DTGsfitwellmeanprogressionacrossindicationsandclinically
relevantcohorts.
20
egnahC
naeM
noitalerroC
egnahC
naeM
noitalerroC
egnahC
naeM
noitalerroC
egnahC
naeM
noitalerroC
egnahC
naeM
noitalerroCChange from Baseline sCDAI (IBD) Binary ACR-20 Response (RA)
50 M Mo od de er ra at te e- -s se ev ve er re e ( (O Mb es ae nr v Ta wti io nn s)s) 0.35 M Mo od de er ra at te e- -s se ev ve er re e ( (O Mb es ae nr v Ta wti io nn s)s)
Crohn's diagnosis (Observations) 0.30 Moderate-severe DMARD-res (Observations)
Crohn's diagnosis (Mean Twins) Moderate-severe DMARD-res (Mean Twins)
0
0.25
0.20
50
0.15
100 0.10
0.05
150
1.0
1.0 Moderate-severe Moderate-severe
Crohn's diagnosis Moderate-severe DMARD-res
0.8
0.5
0.6
0.0
0.4
57113169225281337393449505561617673729 91 181 271 361
Time from Baseline (Days) Time from Baseline (Days)
Binary EASI-75 (ATD) Binary PASI-75 (PSO)
1.4 1.4
Moderate-severe (Observations) All (Observations)
1.2 Moderate-severe (Mean Twins) 1.2 All (Mean Twins)
Mild-moderate (Observations) Moderate-severe (Observations)
1.0 Mild-moderate (Mean Twins) 1.0 Moderate-severe (Mean Twins)
0.8 0.8
0.6 0.6
0.4 0.4
0.2 0.2
0.0 0.0
1.0 1.0
Moderate-severe All
Mild-moderate Moderate-severe
0.8 0.8
0.6 0.6
0.4 0.4
91 181 271 361 451 541 631 721 169 197 225 253 281 309 337 365
Time from Baseline (Days) Time from Baseline (Days)
Figure 4: Observed and predicted mean progression of key outcomes for indications in the Im-
munology&Inflammationtherapeuticarea. Ineachplot,weselectedakeyoutcomeanduptotwo
cohorts(seeTables4and7fordescriptionsofoutcomesandcohorts,respectively). Thetoppanel
comparestheobservedandpredictedmeanprogression.Forbinaryoutcomes,wereportresponserate.
ThebottompanelreportsPearsoncorrelationbetweenobservationsandmeantwinsovertimefor
continuousoutcomesandAUCforbinaryoutcomes,bothasameasureofdiscriminativeperformance
ofthemodel. Errorbarsrepresent95%confidenceintervals. DTGsfitwellmeanprogressionacross
indicationsandclinicallyrelevantcohorts.
21
egnahC
naeM
noitalerroC
etaR
esnopseR
CUA
etaR
esnopseR
CUA
etaR
esnopseR
CUASystolic Blood Pressure
Binary Modified Rankin (STROKE) Change from Baseline (HTN)
All (Observations) 2.5 On HTN meds (Observations)
0.55 All (Mean Twins) On HTN meds (Mean Twins)
0.0 Hypertension (Observations)
Hypertension (Mean Twins) 0.50 2.5
5.0 0.45
7.5
0.40 10.0
12.5
0.35
15.0
0.30 17.5
1.0
All 1.0 On HTN meds
Hypertension
0.8
0.5
0.6
0.0
0.4
31 91 183 274 366 15 29 43 57 71 85 99
Time from Baseline (Days) Time from Baseline (Days)
Cholesterol LDL Hemoglobin A1C
Change from Baseline (DLD) Percent Change from Baseline (TTD)
40 Hyperlipidemia (Observations) 5.0 Comorbid HLD or HTN (Observations)
Hyperlipidemia (Mean Twins) Comorbid HLD or HTN (Mean Twins)
Atherogenic DLD (Observations) 2.5 Comorbid CAD (Observations)
20 Atherogenic DLD (Mean Twins) 0.0 Comorbid CAD (Mean Twins)
0 2.5
5.0
20
7.5
40 10.0
12.5
60
15.0
1.0 Hyperlipidemia 1.0 Comorbid HLD or HTN
Atherogenic DLD Comorbid CAD
0.5 0.5
0.0 0.0
57 169 225 281 393 449 505 91 181 271 361 451 541 631 721
Time from Baseline (Days) Time from Baseline (Days)
Figure5: ObservedandpredictedmeanprogressionofkeyoutcomesforindicationsintheGeneral
Medicine therapeutic area. In each plot, we selected a key outcome and up to two cohorts (see
Tables5and8fordescriptionsofoutcomesandcohorts,respectively). Thetoppanelcomparesthe
observedandpredictedmeanprogression. Forbinaryoutcomes,wereportresponserate. Thebottom
panelreportsPearsoncorrelationbetweenobservationsandmeantwinsovertimeforcontinuous
outcomesandAUCforbinaryoutcomes,bothasameasureofdiscriminativeperformanceofthe
model. Error bars represent 95% confidence intervals. DTGs fit well mean progression across
indicationsandclinicallyrelevantcohorts.
22
etaR
esnopseR
CUA
egnahC
naeM
noitalerroC
egnahC
naeM
noitalerroC
egnahC
naeM
noitalerroCTime to Death (ALS)
1.0 Min FVC (Observations)
Min FVC (Mean Twins)
Recent onset (Observations)
0.9 Recent onset (Mean Twins)
0.8
0.7
0.6
0.5
Min FVC
0.9 Recent onset
0.8
0.7
0.6
57 113 169 225 281 337 393 449 505 561 617 673
Time from Baseline (Days)
Figure6: EvaluationoftheTTEmodelforALStimetodeathoutcome. Inthetoppanelwecompare
theobservedandpredictedsurvivalcurvesforthetwotopcohortsdefinedinTable6. Thebottom
panelreportsconcordanceindexasafunctionoftime. Concordanceindexatagiventimeassumes
thatallobservedeventsafterthattimearecensored. Errorbarsindicate95%confidenceintervals.
23
ytilibaborP
lavivruS
xedni-cDensity Difference between
Data Density Top and Bottom Quartiles Figure7:Weexaminetheabilityofeach
DTGperindicationintheNeurodegener-
631
x1.5 ationtherapeuticareatoaccuratelycap-
turedistributionchangesofthedatafor
451
x1.5
different strata of the overall training
271 x1.5 population. Eachplotstratifiestheheld-
outdataintoquartilesaccordingtothe
91 T Bo op t tQ omua Qrt uile artile x1.5 d twa it na s baselinescoreindicatedinthex-axisla-
-1.0 3.0 7.0 11.0 -1.0 3.0 7.0 11.0 bel. In the left column, the density of
Change in CDR-SB Change in CDR-SB
thetopandbottomquartilesofthedata
aredepictedasaGaussiandensitywith
Density Difference between
Data Density Top and Bottom Quartiles mean and standard deviation obtained
fromthedata. Thedifferencebetween
533
x3.3
thethesedensitiesisdepictedintheright
365 columnasasolidhasheddifferenceden- x3.3
sity. Forsmalldifferenceswemagnify
197 x3.3 thedensitydifferencebyafactornoted
in text on the plot. The difference be-
29 Top Quartile data
Bottom Quartile x3.3 twins tweenthetwindistributionconditioned
-22.0 -14.0 -6.0 2.0 -22.0 -14.0 -6.0 2.0 onthetopquartileandthetwindistribu-
Change in ALSFRS-R Change in ALSFRS-R
tionconditionedonthebottomquartiles
Density Difference between isoverlaidintherightcolumn.
Data Density Top and Bottom Quartiles
991
x3.4
721 x3.4
451
x3.4
181
Top Quartile x3.4 data
Bottom Quartile twins
-4.0 2.0 8.0 14.0 -4.0 2.0 8.0 14.0
Change in FTLD-CDR-SB Change in FTLD-CDR-SB
Density Difference between
Data Density Top and Bottom Quartiles
911
x1.3
547
x1.3
183 Top Quartile data
Bottom Quartile x1.3 twins
-3.6 -1.2 1.2 3.6 -3.6 -1.2 1.2 3.6
Change in CUHDRS Change in CUHDRS
Density Difference between
Data Density Top and Bottom Quartiles
451
x1.8
271
x1.8
91
Top Quartile x1.8 data
Bottom Quartile twins
-18.0 -6.0 6.0 18.0 -18.0 -6.0 6.0 18.0
Change in MDS-UPDRS Subscore Change in MDS-UPDRS Subscore
24
DA
SLA
DLTF
DH
DP
yaD
ydutS
yaD
ydutS
yaD
ydutS
yaD
ydutS
yaD
ydutSDensity Difference between Figure8:Weexaminetheabilityofeach
Data Density Top and Bottom Quartiles
DTGperindicationintheImmunology
& Inflammation therapeutic area to ac-
533 x1.2 curatelycapturedistributionchangesof
365 x1.2 thedatafordifferentstrataoftheoverall
trainingpopulation. Eachplotstratifies
197 x1.2 the held-out data into quartiles accord-
29 Top Quartile x1.2 data ingtothebaselinescoreindicatedinthe
Bottom Quartile twins x-axislabel. Intheleftcolumn,theden-
-240.0 C- h1 a3 n0 g.0 e in- 2 s0 C. D0 AI90.0 -240.0 C- h1 a3 n0 g.0 e in- 2 s0 C. D0 AI90.0 sity of the top and bottom quartiles of
thedataaredepictedasaGaussianden-
Density Difference between sity with mean and standard deviation
Data Density Top and Bottom Quartiles
obtainedfromthedata. Thedifference
betweenthethesedensitiesisdepictedin
631 x0.9 therightcolumnasasolidhasheddiffer-
451 x0.9 encedensity. Forsmalldifferenceswe
magnifythedensitydifferencebyafac-
271 x0.9 tornotedintextontheplot. Thediffer-
91 Top Quartile x0.9 data encebetweenthetwindistributioncon-
Bottom Quartile twins ditionedonthetopquartileandthetwin
-40.0 -20.0 0.0 20.0 -40.0 -20.0 0.0 20.0
Change in EASI Total Score Change in EASI Total Score distribution conditioned on the bottom
quartilesisoverlaidintherightcolumn.
Density Difference between
Data Density Top and Bottom Quartiles
361
x1.4
271 x1.4
181
x1.4
91 Top Quartile x1.4 data
Bottom Quartile twins
-2.6 -0.2 2.2 4.6 -2.6 -0.2 2.2 4.6
Change in DAS-28 ESR Change in DAS-28 ESR
Density Difference between
Data Density Top and Bottom Quartiles
281 x0.9
197 x0.9
113 x0.9
29 Top Quartile x0.9 data
Bottom Quartile twins
-23.0 -11.0 1.0 13.0 -23.0 -11.0 1.0 13.0
Change in PASI Total Score Change in PASI Total Score
25
DBI
DTA
AR
OSP
yaD ydutS
yaD ydutS
yaD
ydutS
yaD ydutSDensity Difference between Figure9: We examine the ability of
Data Density Top and Bottom Quartiles
eachDTGperindicationintheGeneral
Medicinetherapeuticareatoaccurately
366 capturedistributionchangesofthedata x0.8 for different strata of the overall train-
183 ingpopulation. Eachplotstratifiesthe
x0.8
held-outdataintoquartilesaccordingto
31 Top Quartile data thebaselinescoreindicatedinthex-axis
Bottom Quartile x0.8 twins label. Note that in the case of Stroke,
-2.0 Mo1 d. i0 fied R4 a. n0 kin 7.0 -2.0 Mo1 d. i0 fied R4 a. n0 kin 7.0 ModifiedRankinisconditionedonthe
valueat91days,ratherthanatbaseline,
Density Difference between as this feature is not measured at base-
Data Density Top and Bottom Quartiles
line. In theleft column, the density of
533 thetopandbottomquartilesofthedata
x3.5
aredepictedasaGaussiandensitywith
365 x3.5 mean and standard deviation obtained
fromthedata. Thedifferencebetween
197
x3.5
thethesedensitiesisdepictedintheright
29 Top Quartile x3.5 data columnasasolidhasheddifferenceden-
Bottom Quartile twins sity. Forsmalldifferenceswemagnify
-54.0 -18.0 18.0 54.0 -54.0 -18.0 18.0 54.0
Change in LDL Change in LDL thedensitydifferencebyafactornoted
in text on the plot. The difference be-
Density Difference between tweenthetwindistributionconditioned
Data Density Top and Bottom Quartiles
onthetopquartileandthetwindistribu-
tionconditionedonthebottomquartiles
99
x0.9
isoverlaidintherightcolumn.
71
x0.9
43
x0.9
15 Top Quartile x0.9 data
Bottom Quartile twins
-34.0 -18.0 -2.0 14.0 -34.0 -18.0 -2.0 14.0
Change in Systolic Blood Pressure Change in Systolic Blood Pressure
Density Difference between
Data Density Top and Bottom Quartiles
631
x1.1
451
x1.1
271
x1.1
91 Top Quartile x1.1 data
Bottom Quartile twins
-10.0 -5.0 0.0 5.0 -10.0 -5.0 0.0 5.0
Change in hemoglobin a1c Change in hemoglobin a1c
26
EKORTS
DLD
NTH
DTT
yaD
ydutS
yaD
ydutS
yaD
ydutS
yaD
ydutSGoodness of Fit: mean Goodness of Fit: std Study Day
800
102 700
101 600
101 500
400
100
100 300
200
10 1 100
100 101 102 10 1 100 101
Observed Values Observed Values
Goodness of Fit: mean Goodness of Fit: std Study Day
103 700
102 102 600
500
101 101
400
100 100 300
200
10 1 10 1
100
10 1 100 101 102 100 102
Observed Values Observed Values
Goodness of Fit: mean Goodness of Fit: std Study Day
102 1200
101 1000
101 800
600
100 100 400
200
100 101 102 100 101
Observed Values Observed Values
Goodness of Fit: mean Goodness of Fit: std Study Day
102 900
101 101 800
700
100
600
10 1
100
500
10 2 10 1 400
10 3 300
200
10 2 100 102 10 1 100 101
Observed Values Observed Values
Goodness of Fit: mean Goodness of Fit: std Study Day
102 500
101 101 450
400
100 350
100 300
10 1 250
10 2 10 1 12 50 00
10 3 100
10 2 100 102 10 1 100 101
Observed Values Observed Values
Figure 10: Goodness of fit for mean (left column) and standard deviation (right column) in the
Neurodegenerationtherapeuticarea,withtheindicationforagivenplotindicatedbyabbreviationon
theleftaxis. AllplotsreportontheprinciplecohortidentifiedinTable6. Themeanandstandard
deviation for all change from baseline longitudinal outcomes are evaluated at discrete time bins
indicatedbythecolorbarforboththedataandthedigitaltwins. Asthetwinsshouldrepresentthe
datawell,weideallyexpectthemarkerstoforeithermomenttoalllieonthedotteddiagonalline.
27
DA
SLA
DLTF
DH
DP
seulaV
deledoM
seulaV
deledoM
seulaV
deledoM
seulaV
deledoM
seulaV
deledoM
seulaV
deledoM
seulaV
deledoM
seulaV
deledoM
seulaV
deledoM
seulaV
deledoMGoodness of Fit: mean Goodness of Fit: std Study Day
700
103 103 600
102
500
102
101 400
100
101
300
10 1 100 200
100
10 2 10 1
10 1 101 103 100 102
Observed Values Observed Values
Goodness of Fit: mean Goodness of Fit: std Study Day
700
101 101 600
500
400
100
100 300
200
10 1
100
10 1 100 101 100 101
Observed Values Observed Values
Goodness of Fit: mean Goodness of Fit: std Study Day
102 102 350
101 300
101
100 250
10 1 100 200
10 2 10 1 150
10 3 100
10 2 100 102 10 1 100 101 102
Observed Values Observed Values
Goodness of Fit: mean Goodness of Fit: std Study Day
350
300
250
100 200
150
100
100
50
100 100
Observed Values Observed Values
Figure 11: Goodness of fit for mean (left columns) and standard deviation (right column) in the
ImmunologyandInflammationtherapeuticarea,withtheindicationforagivenplotindicatedby
abbreviationontheleftaxis. AllplotsreportontheprinciplecohortidentifiedinTable7. Themean
andstandarddeviationforallchangefrombaselinelongitudinaloutcomesareevaluatedatdiscrete
time bins indicated by the color bar for both the data and the digital twins. As the twins should
representthedatawell,weideallyexpectthemarkerstoforeithermomenttoalllieonthedotted
diagonalline.
28
DBI
DTA
AR
OSP
seulaV
deledoM
seulaV
deledoM
seulaV
deledoM
seulaV
deledoM
seulaV
deledoM
seulaV
deledoM
seulaV
deledoM
seulaV
deledoMGoodness of Fit: mean Goodness of Fit: std Study Day
350
102 102
300
101 101 250
200
100
100
150
10 1 10 1 100
50
10 1 100 101 102 10 1 100 101 102
Observed Values Observed Values
Goodness of Fit: mean Goodness of Fit: std Study Day
102 700
102 600
500
101 400
300
101 200
100
100
101 102 100 101 102
Observed Values Observed Values
Goodness of Fit: mean Goodness of Fit: std Study Day
102 90
101
80
70
60
101
50
100
40
30
100 20
100 101 102 100 101
Observed Values Observed Values
Goodness of Fit: mean Goodness of Fit: std Study Day
102 700
102
600
500
101
101 400
300
100
200
100 100
100 101 102 100 101 102
Observed Values Observed Values
Figure 12: Goodness of fit for mean (left column) and standard deviation (right column) in the
GeneralMedicinetherapeuticarea,withtheindicationforagivenplotindicatedbyabbreviationon
theleftaxis. AllplotsreportontheprinciplecohortidentifiedinTable8. Themeanandstandard
deviation for all change from baseline longitudinal outcomes are evaluated at discrete time bins
indicatedbythecolorbarforboththedataandthedigitaltwins. Asthetwinsshouldrepresentthe
datawell,weideallyexpectthemarkerstoforeithermomenttoalllieonthedotteddiagonalline.
29
EKORTS
DLD
NTH
DTT
seulaV
deledoM
seulaV
deledoM
seulaV
deledoM
seulaV
deledoM
seulaV
deledoM
seulaV
deledoM
seulaV
deledoM
seulaV
deledoMGoodness of Fit: Correlations Study Day Goodness of Fit: Correlations Study Day
1.00 800 1.00 700
0.75 700 0.75 600
0.50 0.50
600 500
0.25 0.25
500 400
0.00 0.00
0.25 400 0.25 300
0.50 300 0.50 200
0.75 200 0.75 100
1.00 100 1.00
1.0 0.5 0.0 0.5 1.0 1.0 0.5 0.0 0.5 1.0
Observed Values Observed Values
Goodness of Fit: Correlations Study Day Goodness of Fit: Correlations Study Day
1.00 1.00 900
1200
0.75 0.75 800
0.50 1000 0.50
700
0.25 0.25 800 600
0.00 0.00
500
0.25 600 0.25
400
0.50 0.50
400
0.75 0.75 300
1.00 200 1.00 200
1.0 0.5 0.0 0.5 1.0 1.0 0.5 0.0 0.5 1.0
Observed Values Observed Values
Goodness of Fit: Correlations Study Day
1.00
500
0.75
450 0.50
400
0.25
350
0.00
300
0.25 250
0.50 200
0.75 150
1.00 100
1.0 0.5 0.0 0.5 1.0
Observed Values
Figure13: GoodnessoffitforcrosscorrelationsintheNeurodegenerationtherapeuticarea,withthe
indicationforagivenplotindicatedbyabbreviationontheleftaxis. Allplotsreportontheprinciple
cohort identified in Table 6. Cross-correlations between all change from baseline longitudinal
outcomesareevaluatedatdiscretetimebinsindicatedbythecolorbarforboththedataandthedigital
twins. Asthetwinsshouldrepresentthedatawell,weideallyexpectthesecross-correlationstoalllie
onthedotteddiagonalline.
30
DA
DLTF
DP
seulaV
deledoM
seulaV
deledoM
seulaV
deledoM
SLA
DH
seulaV
deledoM
seulaV
deledoMGoodness of Fit: Correlations Study Day Goodness of Fit: Correlations Study Day
1.00 700 1.00 700
0.75 0.75
600 600
0.50 0.50
0.25 500 0.25 500
0.00 400 0.00 400
0.25 300 0.25
300
0.50 200 0.50
200
0.75 0.75
100
1.00 1.00 100
1.0 0.5 0.0 0.5 1.0 1.0 0.5 0.0 0.5 1.0
Observed Values Observed Values
Goodness of Fit: Correlations Study Day Goodness of Fit: Correlations Study Day
1.00 1.00
350 350
0.75 0.75
0.50 300 0.50 300
0.25 0.25 250
250 0.00 0.00 200
0.25 200 0.25 150
0.50 0.50
150 100
0.75 0.75
1.00 100 1.00 50
1.0 0.5 0.0 0.5 1.0 1.0 0.5 0.0 0.5 1.0
Observed Values Observed Values
Figure14: GoodnessoffitforcrosscorrelationsintheImmunologyandInflammationtherapeutic
area,withtheindicationforagivenplotindicatedbyabbreviationontheleftaxis. Allplotsreport
ontheprinciplecohortidentifiedinTable7. Cross-correlationsbetweenallchangefrombaseline
longitudinal outcomes are evaluated at discrete time bins indicated by the color bar for both the
data and the digital twins. As the twins should represent the data well, we ideally expect these
cross-correlationstoalllieonthedotteddiagonalline.
Goodness of Fit: Correlations Study Day Goodness of Fit: Correlations Study Day
1.00 1.00
350 700
0.75 0.75
300 600
0.50 0.50
0.25 250 0.25 500
0.00 200 0.00 400
0.25 150 0.25 300
0.50 0.50 200
100
0.75 0.75
100
50
1.00 1.00
1.0 0.5 0.0 0.5 1.0 1.0 0.5 0.0 0.5 1.0
Observed Values Observed Values
Goodness of Fit: Correlations Study Day Goodness of Fit: Correlations Study Day
1.00 1.00 700
0.75 90 0.75
600
0.50 80 0.50
0.25 70 0.25 500
0.00 60 0.00 400
50
0.25 0.25
300
40
0.50 0.50
30 200
0.75 0.75
20
1.00 1.00 100
1.0 0.5 0.0 0.5 1.0 1.0 0.5 0.0 0.5 1.0
Observed Values Observed Values
Figure15: GoodnessoffitforcrosscorrelationsintheGeneralMedicinetherapeuticarea,withthe
indicationforagivenplotindicatedbyabbreviationontheleftaxis. Allplotsreportontheprinciple
cohort identified in Table 8. Cross-correlations between all change from baseline longitudinal
outcomesareevaluatedatdiscretetimebinsindicatedbythecolorbarforboththedataandthedigital
twins. Asthetwinsshouldrepresentthedatawell,weideallyexpectthesecross-correlationstoalllie
onthedotteddiagonalline.
31
DBI
AR
EKORTS
NTH
seulaV
deledoM
seulaV
deledoM
seulaV
deledoM
seulaV
deledoM
DTA
OSP
DLD
DTT
seulaV
deledoM
seulaV
deledoM
seulaV
deledoM
seulaV
deledoMadas remember instructions alsfrs revised preslope
adas orientation alsfrs speech
adas word recall symptom onset day of study
mmse recall alsfrs cutting
adascog11 alsfrs insufficiency
faq symptom onset day of study
mmse orientation time diagnosis als definite
mmse drawing alsfrs revised preslope
faq symptom onset day of study
-0.18 -0.15 -0.12 -0.10 -0.08 -0.05 -0.02 0.00 -0.18 -0.15 -0.12 -0.10 -0.08 -0.05 -0.02 0.00
correlation correlation
mci attention cap
npi severity age
cdr personal care cag repeats
age tms gait and balance
mmse orientation place symptom onset other
cdr personal care fa
mmse orientation place symptom onset psychiatric
mmse orientation time symptom onset other
mmse symptom onset cognitive
-0.18 -0.15 -0.12 -0.10 -0.08 -0.05 -0.02 0.00 -0.18 -0.15 -0.12 -0.10 -0.08 -0.05 -0.02 0.00
correlation correlation
temperature
moca
sodium
chloride
rigidity at diagnosis
age
albumin
hemoglobin
history psychiatric illness
-0.18 -0.15 -0.12 -0.10 -0.08 -0.05 -0.02 0.00
correlation
Figure16: InputSensitivityfortheNeurodegenerationtherapeuticArea. Foreachindication,three
importantoutcomesareselectedandindicateinthey-axislabel. Barsindicatehowmuchcertain
features indicated in the text on the plot reduce the correlation of the feature’s prediction when
evaluatedontheentirepopulationofheldoutpatients.
32
DA
DLTF
DP
ni
egnahC
ni
egnahC
ni
egnahC
ni
egnahC
ni
egnahC
ni
egnahC
ni
egnahC
ni
egnahC
ni
egnahC
bawhcS
.M
SRDPU-SDM
SRDPU-SDM
ESMM
31goC-SADA
BS-RDC
latoT
SDG
ytireveS
IPN
BS-RDC-DLTF
LDA
dnalgnE
latoT
rotoM
erocsbuS
SLA
DH
ni
egnahC
egnahC
egnahC
egnahC
ni
egnahC
ni
egnahC
CVF
ni
ni
ni
rabluB-SRFSLA
R-SRFSLA
)sretiL(
erocS
SMT
erocS
CFT
SRDHUCses sub rectum age
ses sub right colon days on second line tx
taking targeted small molecules taking 2ln tx recomputed
pro2 history smoking
colon resection cecum days on second line tx
small bowel resection taking 2ln tx recomputed
small bowel resection history smoking
taking targeted small molecules days on second line tx
bmi taking 2ln tx recomputed
-0.02 -0.02 -0.01 -0.01 -0.00 0.00 -0.02 -0.02 -0.01 -0.01 -0.00 0.00
correlation correlation
eq5d3l index value taking immunomodulators
taking ts dmard bmi
haq di taking il23 il39 biologic
eq5d3l index value pasi total
phys global assessment ra dlqi embarassed
haq di taking il23 il39 biologic
taking cs dmard bmi
haq di taking immunomodulators
taking ts dmard taking il23 il39 biologic
-0.02 -0.02 -0.01 -0.01 -0.00 0.00 -0.02 -0.02 -0.01 -0.01 -0.00 0.00
correlation correlation
Figure 17: Input Sensitivity for the Immunology & Inflammation therapeutic Area. For each
indication,threeimportantoutcomesareselectedandindicateinthey-axislabel. Barsindicatehow
muchcertainfeaturesindicatedinthetextontheplotreducethecorrelationofthefeature’sprediction
whenevaluatedontheentirepopulationofheldoutpatients.
33
DBI
AR
ni
egnahC
ni egnahC
ni
egnahC
ni
egnahC
ni
egnahC
ni
egnahC
lanimodbA
MB
yliaD
latoT
IADCS
AR
IADC
RSE
82
SAD
PRC
82
SAD
niaP
tnuoC DTA
OSP
egnahC
ni
egnahC
ni egnahC
ni
egnahC
ni
egnahC
ni
egnahC
ni
AGI
latoT
IQLD
latoT
ISAE
latoT
ISAP
latoT
IQLD
AGIsex f history renal disorders
neutrophils glucose normal
glucose blood pressure normal
glucose systolic blood pressure
white blood cell count height
age glucose diabetes
sodium age
age triglycerides
time index event to randomization cholesterol normal
-0.07 -0.06 -0.05 -0.04 -0.03 -0.02 -0.01 0.00 -0.07 -0.06 -0.05 -0.04 -0.03 -0.02 -0.01 0.00
correlation correlation
taking insulin providing drug bmi obesity class1
age heart rate
hemoglobin a1c diastolic blood pressure
race asian bmi
potassium bmi obesity class1
taking acei age
race black heart rate
taking ccb history hypertension
taking acei age
-0.07 -0.06 -0.05 -0.04 -0.03 -0.02 -0.01 0.00 -0.07 -0.06 -0.05 -0.04 -0.03 -0.02 -0.01 0.00
correlation correlation
Figure18: InputSensitivityfortheGeneralMedicinetherapeuticArea. Foreachindication,three
importantoutcomesareselectedandindicateinthey-axislabel. Barsindicatehowmuchcertain
features indicated in the text on the plot reduce the correlation of the feature’s prediction when
evaluatedontheentirepopulationofheldoutpatients.
34
EKORTS
DTT
egnahC
egnahC
ni egnahC
egnahC
tnecreP
lehtraB
deifidoM
ni
ni
gnitsaF
nibolgomeH
ni
xednI
niknaR
SSHIN
IMB
esoculG
doolB
c1A
DLD
NTH
egnahC
egnahC
egnahC
ni
egnahC
egnahC
egnahC
ni
ni
ni
gnidnatS
ni
ni
sedirecylgirT
LDH
LDL
PB
cilotsyS
PB cilotsaiD
PB
cilotsySDiagnosis Alzheimers Disease ALSFRS Revised
FAQ Score ALSFRS Revised Preslope
Diagnosis MCI ALSFRS Climbing
ADAS Word Recognition ALSFRS Revised
ADASCog 11 Score ALSFRS Revised Preslope
FAQ Score Site Of Onset Limb
MMSE Attention Calculation FVC Liters
Diagnosis Cognitively Normal ALSFRS Revised
MMSE Orientation Time ALSFRS Revised Preslope
0.00 0.05 0.10 0.15 0.20 0.25 0.30 0.00 0.05 0.10 0.15 0.20 0.25 0.30
Normalized Absolute SHAP Feature Importance Normalized Absolute SHAP Feature Importance
MMSE Score MDSUPDRS Motor Total
Systolic Blood Pressure MDSUPDRS Subscore
FAQ Score MDSUPDRS NM EDL Total
FAQ Score MDSUPDRS Motor Total
MMSE Score MDSUPDRS Subscore
CDR Community MDSUPDRS Motor Toe Tapping Right
MMSE Score Modified Schwab England ADL
FAQ Score MDSUPDRS Motor Total
Systolic Blood Pressure History Psychiatric Illness
0.00 0.05 0.10 0.15 0.20 0.25 0.30 0.00 0.05 0.10 0.15 0.20 0.25 0.30
Normalized Absolute SHAP Feature Importance Normalized Absolute SHAP Feature Importance
TFC Score
FA Score
Stroop Word Correct
TFC Score
FA Score
Symptom Onset Motor
TMS Occularmotor
TMS Hand Movements
FA Score
0.00 0.05 0.10 0.15 0.20 0.25 0.30
Normalized Absolute SHAP Feature Importance
Figure19: SHAPvaluesfortheNeurodegenerationtherapeuticArea. Foreachpatient,SHAPvalues
foreachbaselinefeaturearefirsttakenasabsolutevalues,thennormalizedsothattheirsumequals
one. Thisprocessisrepeatedforeachofthreeimportantoutcomesforeachindicationindicatedin
they-axislabel. Finally,thesenormalizedSHAPvaluesareaveragedacrossallpatientstoderivethe
averagecontributionofeachfeatureperoutcome.
35
DA
DLTF
DH
RDC
er
n oi c e Sg
Bn
SahC
3n
1i g ee o rg oCn cSa SAh DC
A
ESMM
e n roi ce SgnahC
D eL rT oF c Sn
i B e Sg
Rn Dah
CC
QAF
en ri oe cg SnahC
ESMM
e n roi ce SgnahC
n Si
Re
Dgn Ha
Uh
CC
CFT
n eri
oe cg SnahC
SMT
en
ri oe cg SnahC
SLA
DP
desn
ivi
ee Rg n Sa
Rh
FC SLA
rabn
li u ee B rg oSn cRa Sh FSC
LA
CVF
n sri ee tg iLnahC
Sn eRi r De oPg
cU sn bSa
uh D SC M
roton
Mi
e S lag R tn D oTa Ph
UC
SDM
bawn
hi
ce Sg n da eh ifC
idoMSCDAI Total Score C Reactive Protein
Pro2 Abdominal Pain Score Swollen Joint 28
SCDAI Daily BM Count Tender Joint 28
SCDAI Daily BM Count Tender Joint 28
Daily BM Count Pt Global Assessment RA
Pro2 Abdominal Pain Score ESR
SCDAI Abdominal Pain Score Tender Joint 28
Pro3 Abdominal Pain Score Swollen Joint 28
Disease Location Unknown Pt Global Assessment RA
0.0 0.1 0.2 0.3 0.4 0.5 0.0 0.1 0.2 0.3 0.4 0.5
Normalized Absolute SHAP Feature Importance Normalized Absolute SHAP Feature Importance
EASI Total Score PASI Total Score
Taking 2ln Tx Recomputed Taking Il23 Il39 Biologic
Days On Second Line Tx Days Taking Il23 Il39 Biologic
IGA PASI Total Score
Taking 2ln Tx Recomputed Taking Il23 Il39 Biologic
Age Days Taking Il23 Il39 Biologic
IGA PASI Total Score
Taking 2ln Tx Recomputed Taking Il23 Il39 Biologic
Age Days Taking Il23 Il39 Biologic
0.0 0.1 0.2 0.3 0.4 0.5 0.0 0.1 0.2 0.3 0.4 0.5
Normalized Absolute SHAP Feature Importance Normalized Absolute SHAP Feature Importance
Figure20: SHAPvaluesfortheImmunology&InflammationtherapeuticArea. Foreachpatient,
SHAPvaluesforeachbaselinefeaturearefirsttakenasabsolutevalues,thennormalizedsothattheir
sumequalsone. Thisprocessisrepeatedforeachofthreeimportantoutcomesforeachindication
indicatedinthey-axislabel. Finally,thesenormalizedSHAPvaluesareaveragedacrossallpatients
toderivetheaveragecontributionofeachfeatureperoutcome.
36
DBI
DTA
IAD
eC
rS o
cn Si
le ag tn oTahC
ylia
tD n un oi Ce
g Mn
BahC
nian
Pi
l ee a rg n on i cma Sh oC
dbA
57
ISAE
yraniB
10
AGI
yraniB
AGI
ni egnahC
AR
OSP
esnopseR
02
RCA
SAD
R n Si E e
8g 2nahC
IADC
n Ai RegnahC
yraniB
57ISAP
yraniB
09ISAP
ISA eP
ro
n ci S e lg an
toa
ThCGlucose Systolic Blood Pressure
NIHSS Score Systolic Blood Pressure Stand
NIHSS Motorarm Left Weight
NIHSS Motorarm Left Diastolic Blood Pressure
NIHSS Motorleg Left Age
NIHSS Motorarm Right Region Other
History Type2 Diabetes Systolic Blood Pressure Stand
Glucose History MI
NIHSS Score Blood Pressure Stage 1 Hypertension
0.00 0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.00 0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40
Normalized Absolute SHAP Feature Importance Normalized Absolute SHAP Feature Importance
Cholesterol LDL Fasting Blood Glucose Cholesterol High Height
Cholesterol Borderline Sex F
Cholesterol HDL Weight
Sex F BMI
Cholesterol High Height
Triglycerides Hemoglobin A1C
Region Other Taking Insulin Providing Drug
Cholesterol HDL Age
0.00 0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.00 0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40
Normalized Absolute SHAP Feature Importance Normalized Absolute SHAP Feature Importance
Figure21: SHAPvaluesfortheGeneralMedicinetherapeuticArea. Foreachpatient,SHAPvalues
foreachbaselinefeaturearefirsttakenasabsolutevalues,thennormalizedsothattheirsumequals
one. Thisprocessisrepeatedforeachofthreeimportantoutcomesforeachindicationindicatedin
they-axislabel. Finally,thesenormalizedSHAPvaluesareaveragedacrossallpatientstoderivethe
averagecontributionofeachfeatureperoutcome.
37
EKORTS
DLD
nikna yR ra
d ne
iBifidoM
yraniB
SSHIN
xed
yn rI a le nh
iBtraB
LDLn i l oe rg en tsa
eh
lC ohC
LDHn
i l oe
rg en ta seh
lC ohC
sen
di
ie rg ecn ya
lh gC
irT
NTH
DTT
ni egnahC
ni
egnahC
ni
egnahC
ni egnahC
egnahC
tnecreP
doolB
cilotsyS
doolB
cilotsaiD
doolB
cilotsyS
doolB gnitsaF
IMB
ni
egnahC
nibolgomeH
ni
erusserP
erusserP
dnatS
erusserP
esoculG
C1A9 Appendix
Some supplemental tables with indication specific definitions of outcomes and cohorts (sub-
populations of a dataset) are provided here, broken down by therapeutic area. We also report
exampledigitaltwinsforindividualpatientsineachindication, showingthepredictedmeanand
standarddeviationthroughtimeforallvariables.
38DiseaseIndication: AD
Outcome Description
CDR-SBchangefrombaseline ClinicalDementiaRatingScaleSumofBoxes.
Itassessesstagesofdementia.
ADASCog-13changefrombaseline Alzheimer’sDiseaseAssessmentScalecogni-
tivesubscale. Itmeasurescognitivefunction.
MMSEchangefrombaseline Mini Mental State Examination. It measures
cognitivefunction.
DiseaseIndication: ALS
Outcome Description
ALSFRSRevisedchangefrombaseline RevisedAmyotrophicLateralSclerosisFunc-
tional Rating Scale. It measures severity of
ALS.
ALSFRSRevisedBulbarSubscorechangefrom BulbarSubscoreofALSFRSRevised. Itmea-
baseline sures impairments to speech, salivation, and
swallowing.
FVCchangefrombaseline Forced Vital Capacity. It measures breathing
function.
DiseaseIndication: FTLD
Outcome Description
FTLDCDR-SBchangefrombaseline FTLDversionoftheClinicalDementiaRating
ScaleSumofBoxes. Itmeasuresstagesofde-
mentia.
FAQchangefrombaseline FunctionalActivitiesQuestionnairewhichmea-
suresfunctionalproblemsinactivitiesofdaily
living.
MMSEchangefrombaseline Mini Mental State Examination. It assesses
cognitivefunction.
DiseaseIndication: PD
Outcome Description
MDSUPDRSSubscorechangefrombaseline MovementDisorderSociety-UnifiedParkin-
son’sDiseaseRatingScale. Itevaluatesmotor
and non-motor symptoms of Parkinson’s dis-
ease.
MDSUPDRS Motor Subscore change from ThemotorcomponentoftheMDSUPDRS.
baseline
Modified Schwab and England change from Itmeasuresabilitiesinavarietyofactivitiesof
baseline dailyliving.
DiseaseIndication: HD
Outcome Description
cUHDRSchangefrombaseline CompositeUnifiedHuntingtonDiseaseRating
Scale. Itmeasuresmotor,cognitive,andfunc-
tionaldecline.
TFCchangefrombaseline Total Functional Capacity. It measures func-
tionaldecline.
TMSchangefrombaseline TotalMotorScore. Itmeasuresmotordecline.
Table3: BriefdescriptionofoutcomesforindicationsintheNeurodegenerativeTherapeuticArea.
39DiseaseIndication: CD
Outcome Description
sCDAIchangefrombaseline Short Crohn’s Disease Activity Index. It
measurescurrentseverityofthedisease.
DailyBMCountchangefrombaseline Countofbowelmovements.
AbdominalPainScorechangefrombase- Itmeasuresintensityofabdominalpain.
line
DiseaseIndication: RA
Outcome Description
BinaryACR20Response Acompositemeasureofwhetherthepar-
ticipantimprovesbyatleast20%inboth
swollenandtenderjointcountsandatleast
threeoffiveadditionaldiseasecriteria.
DAS-28ESRchangefrombaseline DiseaseActivityScore-28forRheumatoid
Arthritis with ESR. It measures severity
ofrheumatoidarthritisusingclinicaland
laboratorydata,includingErythrocyteSed-
imentationRate.
CDAI-RAchangefrombaseline Clinical Disease Activity Index for
RheumatoidArthritis. Itmeasuresseverity
ofrheumatoidarthritisusingclinicaldata
only.
DiseaseIndication: ATD
Outcome Description
BinaryEASI-75 Binarized version of Eczema Area and
Severity Index corresponding to at least
75%reductionfrombaseline. Itmeasures
extentandseverityofatopicdermatitis.
BinaryIGA-01 Binarizedversionofinvestigatorglobalas-
sessment.
IGAchangefrombaseline Investigatorglobalassessment.Itmeasures
severityofatopicdermatitis.
DiseaseIndication: PSO
Outcome Description
BinaryPASI-75 Binarized version of Psoriasis Area and
SeverityIndex. Itrepresentsanimprove-
mentofatleast75%frombaseline.
BinaryPASI-90 Binarized version of Psoriasis Area and
SeverityIndex. Itrepresentsanimprove-
mentofatleast90%frombaseline.
PASIchangefrombaseline PsoriasisAreaandSeverityIndex. Itmea-
suresseverityofpsoriasis.
Table4:BriefdescriptionofoutcomesforindicationsintheImmunology&InflammationTherapeutic
Area.
40DiseaseIndication: STR
BinaryModifiedRankin Binarized version of Modified Rankin
Scale. Itmeasuresdegreeofdisabilityin
theactivitiesofdailylivingasaresultof
stroke.
BinaryNIHSS BinarizedversionoftheNationalInstitutes
ofHealthStrokeScale. Itmeasuresstroke
severity.
BinaryBarthelIndex BinarizedversionofBarthelIndex. Itmea-
suresdegreeofdisabilityintheactivities
ofdailylivingasaresultofstroke.
DiseaseIndication: HTN
Outcome Description
Systolicbloodpressurechangefrombase- Thesystolicbloodpressure.
line
Diastolicbloodpressurechangefrombase- Thediastolicbloodpressure.
line
Standing systolic blood pressure change Thesystolicbloodpressuremeasureswhile
frombaseline standing.
DiseaseIndication: DLD
Outcome Description
CholesterolLDLchangefrombaseline Fasting low-density lipoprotein choles-
terol.
CholesterolHDLchangefrombaseline Fasting high-density lipoprotein choles-
terol.
Triglycerideschangefrombaseline Fastingtriglycerides.
DiseaseIndication: TTD
Outcome Description
Hemoglobin A1c percent change from Itmeasuresaveragebloodsugarlevelsover
baseline thepast3months.
Fasting blood glucose change from base- Itmeasuresbloodglucoseafteratleast8
line hourswithouteating.
BMIchangefrombaseline BodyMassIndex.
Table5: BriefdescriptionofoutcomesforindicationsintheGeneralMedicineTherapeuticArea.
41DiseaseIndication: AD
Cohort Description
⋆ Mild Cognitive Impairment (MCI) and • 50≤age≤90
earlyAlzheimer’sDisease(AD)
• Oneofthefollowing:
◦ 20≤MMSE≤28
◦ OR0<CDR-GS≤1
Mild to moderate Alzheimer’s Disease • 50≤age≤90
(AD)
• 13≤MMSE≤26
FullPopulation Allparticipantsinthedataset
DiseaseIndication: ALS
Cohort Description
⋆RecentOnsetofSymptoms ALS symptoms recently (within 24
months)developedsincebaselinemeasure-
ment
MinimumVitalCapacity CohorthasFVC≥60%ofnormalvalue
FullPopulation Allparticipantsinthedataset
DiseaseIndication: FTD
Cohort Description
⋆HasbehavioralvariantofFrontotemporal Asjudgedinprimarydiagnosisofpatient
Dementia
HasknownFTDMutation patient has a mutation in either MAPT,
PGRN,orC9orf72genes
FullPopulation Allparticipantsinthedataset
DiseaseIndication: HD
Cohort Description
⋆Manifest Has HTT expansion (CAG repeats) and
clinicalsymptomsofHD
FullPopulation Allparticipantsinthedataset
DiseaseIndication: PD
Cohort Description
⋆HasEarlyPD Patientisoffsymptom-modifyingtherapies
andisearlystage(HoehnandYahrscale
<=2)
OffSMT Patientisoffsymptom-modifyingtherapies
atbaseline
OnSMT Patientisoffsymptom-modifyingtherapies
atbaseline
Table6: CohortDefinitionsforNeurodegenerationTherapeuticArea. Thecohortindicatedwitha
⋆ indicatestheprincipalcohortfortheindication. Unlessspecifiedotherwise,allplotsherereport
metricsontheprincipalcohort.
42DiseaseIndication: CD
Cohort Description
⋆ModeratetoSevereCrohn’sDisease sCDAIScore≥225
DiagnosedwithCrohn’sDisease ClinicalDiagnosisofCrohn’sDisease
DiseaseIndication: RA
Cohort Description
⋆ModeratetoSevere patients with moderate to severe disease
activity based on DAS28-CRP (> 2.9) or
DAS28-ESR (> 3.2) or SDAI (> 20) or
CDAI(>10)
ModeratetoSevere: DMARDResistant Moderatetoseverepatientswhohavebeen
treated with a Disease Modifying Anti-
Rheumatic Drug (DMARD) at least 3
monthspriortostudystart
ModeratetoSevere: onStableMethotrex- Moderatetoseverepatientswhohavebeen
ate onMethotrexateforatleast3months
DiseaseIndication: ATD
Cohort Description
⋆ModeratetoSevereAtD Patientswith:
• EASITotalScore≥16
• IGA≥3
• BSA≥10%
MildtoModerateAtD Patientswith:
• 1.1≤EASITotalScore≤21
• 2≤IGA≤3
• 3%≤BSA≤20%
Novel Disease-Modifying Antirheumatic Patientswith:
Drug(DMARD)use
• Initiateasecondlinetreatment(biolog-
ics,DMARDs,orimmunomodulators)on
baselineday.
• Atleast90dayssinceendingpriorsec-
ondlinetreatment
DiseaseIndication: PSO
Cohort Description
⋆FullPopulation Allparticipantsinthedataset
ModeratetoSeverePlaquePsoriasis Patientswith:
• PASITotalScore≥12,
• IGA≥3,
• BSA≥10%,
• nodiagnosisofPsoriaticArthritis.
Table7: CohortDefinitionsforImmunology&InflammationTherapeuticArea. Thecohortindicated
witha⋆indicatestheprincipalcohortfortheindication. Unlessspecifiedotherwise,allplotshere
reportmetricsontheprincipalcohort.
43DiseaseIndication: STR
Cohort Description
⋆FullPopulation Allparticipantsinthedataset
DiseaseIndication: DLD
Cohort Description
⋆Hyperlipidemia(HLD) Participantsonstatinswith
• HistoryofdyslipidemiaOR
• 100mg/dL≤LDL-C<190mg/dL,triglyc-
erides≤400mg/dL,andageover18years
Excludesparticipantswith
• Uncontrolledhypertension(bloodpressure
≥140/90mmHg)OR
• Historyofcoronaryheartdisease,heartfail-
ure,myocardialinfarction,orstroke
AtherogenicDyslipidemia Participantsonstatinswithvasculardisease
andatherogenicdyslipidemiadefinedas
• LDL-C≤160mg/dL
• 150mg/dL≤triglycerides≤400mg/dL
• HDL-C≤40mg/dLformenor≤50mg/dL
forwomen
DiseaseIndication: HTN
Cohort Description
⋆OnHypertensionMedication Patients taking at least one antihypertensive
medication
PopulationwithHypertension Participantswith
• ahistoryofhypertensionorbloodpressure
≥130/80
• areolderthan18
• not had history of: stroke, unstable angia,
myocardialinfarction,orheartfailure
DiseaseIndication: TTD
Cohort Description
⋆ComorbidwithHLDorHTN Participantswith
• History of Type-2 Diabetes Mellitus or
HbA1c≥7.0%andeither
• HistoryofhyperlipidemiaorLDL-C≥130
mg/dL,OR
• History of hypertension or systolic blood
pressure≥130mmHg
ComorbidCoronaryArteryDisease Participantswith
• History of Type-2 Diabetes Mellitus or
HbA1c≥7.0%
• History of coronary artery disease: either
ischemicheartdiseaseoracuteeventssuchas
myocardialinfarction
Table8: CohortDefinitionsfortheGeneralMedicineTherapeuicArea. Thecohortindicatedwitha
⋆ indicatestheprincipalcohortfortheindication. Unlessspecifiedotherwise,allplotsherereport
metricsontheprincipalcohort.
44AD Digital Twin Example
Age (years): 80 ApoE e4 count: 2 Amyloid Status: - History of Hypertension: No
Sex: Male Weight: 60.5 kg CSF Total tau: - History of Type II Diabetes: No
Diagnosis: Alzheimer's Disease Height: 168 cm CSF p-tau181: -
Baseline 3 6 9 12 15 18 21 24
ADAS Cancellation 3 3.7 ± 0.9 3.8 ± 0.9 3.7 ± 0.9 3.9 ± 0.9 3.7 ± 1.0 3.7 ± 0.9 3.8 ± 1.0 3.9 ± 1.0
ADAS Commands 0 0.4 ± 0.5 0.4 ± 0.7 0.6 ± 0.7 0.8 ± 0.8 0.9 ± 0.9 1.0 ± 0.9 1.3 ± 0.9 1.4 ± 1.2
ADAS Comprehension 0 0.1 ± 0.7 0.1 ± 0.9 0.1 ± 0.8 0.1 ± 0.8 0.0 ± 0.8 0.1 ± 0.9 0.1 ± 0.9 0.2 ± 1.1
ADAS Concentration - 0.1 ± 0.9 0.1 ± 0.9 0.0 ± 1.0 0.0 ± 1.0 0.1 ± 1.2 0.1 ± 1.2 0.0 ± 1.3 0.1 ± 1.1
ADAS Construction 1 1.3 ± 0.9 1.5 ± 1.0 1.6 ± 1.0 1.7 ± 0.9 1.8 ± 0.9 2.0 ± 1.0 2.3 ± 1.0 2.4 ± 1.1
ADAS Delayed Word Recall 9 8.6 ± 0.5 8.8 ± 0.5 8.9 ± 0.6 8.8 ± 0.4 8.6 ± 0.4 8.7 ± 0.6 8.9 ± 0.6 8.7 ± 0.5
ADAS Executive 3 3.2 ± 1.5 3.2 ± 1.5 3.4 ± 1.4 3.3 ± 1.6 3.6 ± 1.4 3.7 ± 1.5 3.7 ± 1.6 3.8 ± 1.4
ADAS Ideational 3 3.0 ± 0.9 3.0 ± 1.2 3.4 ± 1.3 3.1 ± 1.3 3.2 ± 1.4 3.3 ± 1.6 3.7 ± 1.6 3.8 ± 1.6
ADAS Naming 0 0.0 ± 0.8 0.0 ± 0.9 0.0 ± 0.9 0.1 ± 0.9 0.1 ± 1.0 0.3 ± 0.9 0.4 ± 1.1 0.6 ± 1.1
ADAS Orientation 4 4.4 ± 1.7 5.0 ± 1.7 5.3 ± 1.7 5.4 ± 1.6 5.9 ± 1.3 5.9 ± 1.4 5.7 ± 1.6 5.9 ± 1.5
ADAS Remember Instructions 1 1.4 ± 0.5 1.6 ± 0.8 1.8 ± 1.1 2.3 ± 1.3 2.3 ± 1.3 2.3 ± 1.5 2.6 ± 1.7 2.7 ± 1.8
ADAS Spoken Language 0 0.1 ± 0.3 0.3 ± 0.4 0.3 ± 0.6 0.5 ± 0.7 0.6 ± 0.7 0.7 ± 0.8 0.9 ± 0.9 1.0 ± 1.1
ADAS Word Finding 1 1.1 ± 0.5 1.5 ± 0.6 1.7 ± 0.8 1.7 ± 0.9 2.1 ± 0.9 2.3 ± 1.0 2.5 ± 1.2 2.7 ± 1.1
ADAS Word Recall 8 8.1 ± 1.1 8.2 ± 1.2 8.4 ± 1.0 8.8 ± 1.0 8.9 ± 0.9 8.9 ± 1.0 9.1 ± 1.0 8.9 ± 1.0
ADAS Word Recognition 9 9.4 ± 2.3 9.5 ± 2.2 9.8 ± 2.1 10.1 ± 2.3 9.9 ± 2.3 10.0 ± 2.2 10.2 ± 2.0 10.4 ± 2.0
Alanine Aminotransferase 12 13.0 ± 4.6 12.8 ± 4.4 13.4 ± 4.9 13.2 ± 5.4 14.6 ± 5.6 14.7 ± 4.5 14.8 ± 5.2 14.4 ± 4.7
Alkaline Phosphatase - 25.1 ± 14.9 25.0 ± 17.4 25.1 ± 19.0 25.1 ± 17.1 25.2 ± 17.3 25.1 ± 18.8 25.0 ± 19.6 25.0 ± 20.1
Aspartate Aminotransferase 15 16.3 ± 3.8 16.6 ± 3.9 16.7 ± 4.4 16.9 ± 3.7 17.4 ± 4.4 17.6 ± 4.6 18.0 ± 4.2 18.5 ± 4.3
CDR Community - 0.1 ± 0.6 0.0 ± 0.6 0.0 ± 0.6 0.0 ± 0.6 0.0 ± 0.7 0.0 ± 0.7 0.1 ± 0.6 0.1 ± 0.6
CDR Home Hobbies - 1.4 ± 0.5 1.7 ± 0.6 1.9 ± 0.6 2.2 ± 0.7 2.3 ± 0.6 2.5 ± 0.6 2.5 ± 0.6 2.7 ± 0.5
CDR Judgement - 0.0 ± 0.6 0.3 ± 0.7 0.1 ± 0.7 0.0 ± 0.7 0.0 ± 0.7 0.0 ± 0.7 0.0 ± 0.7 0.0 ± 0.7
CDR Memory - 1.7 ± 0.6 2.0 ± 0.7 2.2 ± 0.6 2.3 ± 0.6 2.4 ± 0.6 2.4 ± 0.6 2.5 ± 0.6 2.6 ± 0.5
CDR Orientation - 0.2 ± 0.6 0.0 ± 0.6 0.0 ± 0.6 0.0 ± 0.6 0.0 ± 0.6 0.0 ± 0.6 0.0 ± 0.6 0.0 ± 0.6
CDR Personal Care - 0.9 ± 0.4 0.9 ± 0.4 1.1 ± 0.4 1.1 ± 0.6 1.3 ± 0.6 1.7 ± 0.6 1.7 ± 0.7 1.8 ± 0.8
Cholesterol - 2.4 ± 0.8 2.5 ± 0.8 2.5 ± 1.0 2.5 ± 1.0 2.4 ± 1.0 2.5 ± 1.0 2.6 ± 1.0 2.6 ± 0.9
Creatine Kinase 31 41.0 ± 17.4 37.2 ± 16.0 37.5 ± 17.6 35.8 ± 15.8 37.9 ± 16.1 36.5 ± 15.8 40.7 ± 19.3 37.4 ± 18.5
Creatinine - 0.9 ± 0.1 0.9 ± 0.1 0.9 ± 0.1 0.9 ± 0.1 0.9 ± 0.1 0.9 ± 0.1 0.9 ± 0.1 0.9 ± 0.1
Diastolic Blood Pressure 58 62.4 ± 7.9 64.2 ± 8.1 66.6 ± 9.0 67.1 ± 9.5 68.1 ± 8.9 66.9 ± 9.3 68.2 ± 8.8 68.0 ± 8.4
Eosinophils 0.1 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.0 0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.1
FAQ Score - 0.3 ± 5.3 0.3 ± 5.0 0.2 ± 4.5 0.4 ± 3.5 0.0 ± 3.1 0.1 ± 4.0 0.1 ± 3.7 0.0 ± 3.5
Gamma Glutamyl Transferase 16 16.7 ± 7.1 17.1 ± 7.2 16.7 ± 7.9 18.6 ± 6.6 17.2 ± 8.2 15.5 ± 7.2 15.7 ± 6.6 16.5 ± 6.2
Glucose 5.8 5.8 ± 1.1 5.9 ± 1.2 5.8 ± 1.1 5.8 ± 1.1 5.7 ± 1.3 5.6 ± 1.1 5.6 ± 1.2 5.5 ± 1.1
Heart Rate 60 62.2 ± 7.7 63.2 ± 7.7 64.9 ± 8.9 64.9 ± 8.9 66.2 ± 9.0 66.6 ± 9.7 68.2 ± 10.0 68.7 ± 10.2
Hematocrit 45 44.8 ± 3.2 44.7 ± 3.0 44.5 ± 3.2 44.5 ± 3.0 44.3 ± 3.0 44.4 ± 3.0 44.1 ± 2.8 43.8 ± 2.7
Hemoglobin 148 146.9 ± 8.8 146.1 ± 8.2 144.6 ± 10.4 143.9 ± 9.2 143.9 ± 8.7 143.5 ± 9.7 142.9 ± 10.2 142.0 ± 8.8
Hemoglobin A1C - 4.1 ± 0.3 4.0 ± 0.3 4.1 ± 0.3 4.1 ± 0.3 4.1 ± 0.3 4.3 ± 0.3 4.0 ± 0.3 4.0 ± 0.3
Indirect Bilirubin - 0.3 ± 0.2 0.4 ± 0.2 0.3 ± 0.2 0.3 ± 0.2 0.4 ± 0.2 0.3 ± 0.2 0.3 ± 0.2 0.2 ± 0.2
Lymphocytes 1.8 1.8 ± 0.4 1.7 ± 0.5 1.7 ± 0.5 1.7 ± 0.5 1.8 ± 0.6 1.7 ± 0.5 1.7 ± 0.5 1.7 ± 0.6
MMSE Attention Calculation 3 2.8 ± 1.2 2.7 ± 1.4 2.6 ± 1.3 2.7 ± 1.4 2.8 ± 1.5 2.6 ± 1.5 2.6 ± 1.5 2.3 ± 1.5
MMSE Drawing 0 0.1 ± 0.4 0.2 ± 0.4 0.2 ± 0.4 0.2 ± 0.4 0.3 ± 0.4 0.3 ± 0.4 0.3 ± 0.5 0.3 ± 0.5
MMSE Language 8 7.5 ± 0.6 7.4 ± 0.8 7.4 ± 0.8 7.1 ± 1.0 7.1 ± 0.9 7.0 ± 0.9 6.7 ± 1.2 6.5 ± 1.2
MMSE Orientation Place 4 3.7 ± 1.0 3.6 ± 1.2 3.2 ± 1.1 3.2 ± 1.2 3.2 ± 1.2 3.1 ± 1.2 2.9 ± 1.3 2.7 ± 1.3
MMSE Orientation Time 1 1.5 ± 0.8 1.7 ± 0.8 1.8 ± 0.9 1.7 ± 0.9 1.7 ± 0.8 1.8 ± 0.9 1.6 ± 0.9 1.6 ± 0.7
MMSE Recall 1 1.2 ± 0.5 1.2 ± 0.5 1.2 ± 0.5 1.2 ± 0.5 1.2 ± 0.5 1.1 ± 0.4 1.2 ± 0.5 1.3 ± 0.5
MMSE Registration 3 3.0 ± 0.2 2.9 ± 0.2 2.9 ± 0.2 2.8 ± 0.3 2.8 ± 0.4 2.8 ± 0.4 2.8 ± 0.4 2.8 ± 0.4
Monocytes 0.4 0.4 ± 0.1 0.4 ± 0.1 0.4 ± 0.1 0.4 ± 0.1 0.4 ± 0.1 0.4 ± 0.2 0.4 ± 0.2 0.4 ± 0.2
NPI-10 Score - 15.7 ± 14.0 18.2 ± 16.9 17.3 ± 20.9 23.4 ± 27.8 26.3 ± 36.3 34.0 ± 42.0 41.0 ± 49.6 35.0 ± 47.1
NPI-12 Score - 16.1 ± 11.7 17.8 ± 16.0 16.8 ± 15.7 17.6 ± 20.1 18.4 ± 21.8 22.7 ± 25.0 24.1 ± 29.3 19.8 ± 25.5
NPI Severity Score - 0.1 ± 4.8 0.1 ± 4.8 0.0 ± 4.9 0.1 ± 5.1 0.0 ± 6.9 0.0 ± 6.9 0.2 ± 8.4 0.1 ± 9.2
Platelet 268 266.0 ± 35.9 264.8 ± 36.0 257.2 ± 38.9 266.5 ± 47.7 269.5 ± 49.8 267.4 ± 49.4 266.4 ± 51.4 266.7 ± 58.9
Potassium 4.3 4.3 ± 0.4 4.3 ± 0.4 4.2 ± 0.4 4.1 ± 0.4 4.2 ± 0.4 4.2 ± 0.4 4.2 ± 0.4 4.2 ± 0.4
Sodium 145 144.3 ± 2.2 143.7 ± 2.5 143.2 ± 2.5 143.3 ± 2.6 142.8 ± 2.5 143.1 ± 2.5 142.9 ± 2.8 142.5 ± 2.9
Systolic Blood Pressure 100.5 107.6 ± 12.3 114.3 ± 13.5 119.4 ± 14.1 120.5 ± 15.8 122.5 ± 16.9 119.9 ± 15.5 122.3 ± 15.8 123.9 ± 14.1
Triglycerides 1.5 1.7 ± 0.7 1.7 ± 0.6 1.6 ± 0.7 1.5 ± 0.7 1.5 ± 0.6 1.5 ± 0.7 1.5 ± 0.6 1.6 ± 0.7
Figure22: AnexampletwinrecordforasingleADpatientisshown,whichreportsthemeanand
standarddeviationofthetwinsforthatpatient. Asampleofstaticbaselineinformationisgivenatthe
topoftherecord. Asampleoflongitudinaloutcomespredictedbythemodelaresuppliedasrows,
withcolumnsindicatingthetimeinmonthssincebaselinevisit.
45ALS Digital Twin Example
Age (years): 61 Diagnosis: ALS Medications: riluzole
Sex: Female Site of Onset: Limb FVC norm: 2.92 Liters
Race: Caucasian Symtom Onset: 568 days Height: 157.5 cm
Baseline 1 2 3 4 5 6 7 8 9 10 11 12
Alanine Aminotransferase 38 41.5 ± 18.0 42.6 ± 21.4 43.0 ± 25.3 45.3 ± 25.7 47.0 ± 29.3 47.7 ± 29.9 46.9 ± 29.1 46.9 ± 28.2 47.6 ± 33.8 48.7 ± 37.8 47.9 ± 34.4 49.7 ± 39.5
Albumin 47 47.0 ± 2.8 46.4 ± 3.3 46.1 ± 3.5 46.0 ± 3.8 45.4 ± 3.5 45.7 ± 3.2 45.3 ± 3.2 45.5 ± 3.3 44.8 ± 3.2 44.6 ± 3.2 44.7 ± 3.1 44.4 ± 3.2
Alkaline Phosphatase 46 46.4 ± 10.3 48.7 ± 14.2 51.3 ± 15.7 52.8 ± 16.3 53.1 ± 18.3 52.8 ± 18.7 56.0 ± 19.3 57.4 ± 20.4 55.4 ± 21.9 58.9 ± 22.5 58.6 ± 24.2 60.4 ± 23.7
ALSFRS Climbing 2 1.2 ± 1.0 1.1 ± 1.1 1.0 ± 1.1 1.0 ± 1.1 0.9 ± 1.1 1.0 ± 1.1 0.7 ± 1.1 0.7 ± 1.0 0.8 ± 1.1 0.8 ± 1.1 0.6 ± 1.0 0.5 ± 1.0
ALSFRS Cutting 4 3.7 ± 0.4 3.7 ± 0.6 3.7 ± 0.8 3.7 ± 0.7 3.5 ± 0.7 3.4 ± 0.9 3.3 ± 1.0 3.3 ± 1.0 3.1 ± 1.1 3.0 ± 1.2 2.8 ± 1.2 2.8 ± 1.2
ALSFRS Dyspnea 4 3.8 ± 0.4 3.8 ± 0.5 3.7 ± 0.6 3.7 ± 0.8 3.6 ± 0.8 3.5 ± 0.9 3.5 ± 0.9 3.4 ± 0.9 3.4 ± 0.9 3.5 ± 1.0 3.4 ± 1.0 3.2 ± 1.0
ALSFRS Handwriting 3 3.5 ± 0.5 3.5 ± 0.5 3.5 ± 0.6 3.5 ± 0.6 3.6 ± 0.6 3.4 ± 0.8 3.3 ± 0.8 3.3 ± 0.8 3.3 ± 1.0 3.1 ± 0.9 3.0 ± 1.0 2.9 ± 1.1
ALSFRS Hygiene 3 2.3 ± 1.0 2.5 ± 1.1 2.5 ± 1.2 2.6 ± 1.3 2.6 ± 1.3 2.6 ± 1.3 2.7 ± 1.3 2.5 ± 1.4 2.4 ± 1.3 2.3 ± 1.3 2.0 ± 1.2 1.9 ± 1.2
ALSFRS Insufficiency 3 3.8 ± 0.1 3.8 ± 0.2 3.7 ± 0.3 3.7 ± 0.2 3.7 ± 0.3 3.7 ± 0.3 3.7 ± 0.3 3.7 ± 0.3 3.6 ± 0.4 3.6 ± 0.4 3.6 ± 0.5 3.6 ± 0.5
ALSFRS Orthopnea 4 3.9 ± 0.1 4.0 ± 0.2 4.0 ± 0.2 3.9 ± 0.3 3.9 ± 0.3 3.9 ± 0.4 3.8 ± 0.5 3.7 ± 0.6 3.7 ± 0.5 3.6 ± 0.7 3.5 ± 0.7 3.4 ± 0.8
ALSFRS Salivation 3 3.6 ± 0.4 3.6 ± 0.5 3.5 ± 0.6 3.5 ± 0.6 3.5 ± 0.6 3.5 ± 0.6 3.5 ± 0.6 3.4 ± 0.6 3.5 ± 0.6 3.5 ± 0.6 3.3 ± 0.7 3.4 ± 0.7
ALSFRS Speech 3 3.8 ± 0.3 3.7 ± 0.4 3.7 ± 0.4 3.6 ± 0.4 3.6 ± 0.6 3.4 ± 0.7 3.4 ± 0.7 3.3 ± 0.8 3.3 ± 0.8 3.2 ± 0.9 3.2 ± 0.9 3.1 ± 1.0
ALSFRS Swallowing 4 3.2 ± 0.8 3.3 ± 0.8 3.5 ± 0.8 3.5 ± 0.9 3.6 ± 0.8 3.4 ± 0.8 3.5 ± 0.9 3.6 ± 0.9 3.4 ± 0.9 3.4 ± 0.9 3.4 ± 1.0 3.5 ± 0.9
ALSFRS Turning 3 3.6 ± 0.4 3.4 ± 0.7 3.4 ± 0.7 3.2 ± 0.8 3.0 ± 0.9 2.9 ± 1.0 2.9 ± 1.0 2.8 ± 1.0 2.6 ± 1.1 2.4 ± 1.3 2.3 ± 1.3 2.1 ± 1.3
ALSFRS Walking 3 2.9 ± 0.8 2.8 ± 0.9 2.7 ± 1.0 2.6 ± 1.1 2.5 ± 1.2 2.4 ± 1.2 2.4 ± 1.3 2.3 ± 1.2 2.0 ± 1.2 1.9 ± 1.2 1.7 ± 1.2 1.7 ± 1.1
Aspartate Aminotransferase 31 32.8 ± 10.2 33.3 ± 13.3 33.4 ± 14.2 34.6 ± 14.4 34.5 ± 15.6 34.4 ± 15.4 33.1 ± 14.4 33.3 ± 15.8 32.8 ± 17.9 32.6 ± 14.1 32.1 ± 12.8 30.9 ± 12.5
Basophils 0.1 0.1 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
Blood Urea Nitrogen 5.4 5.6 ± 1.5 5.4 ± 1.6 5.3 ± 1.8 5.3 ± 1.8 5.4 ± 1.9 5.4 ± 1.9 5.5 ± 1.9 5.7 ± 2.1 5.6 ± 2.1 5.6 ± 2.0 5.5 ± 1.9 5.5 ± 2.0
Calcium 2.3 2.3 ± 0.1 2.3 ± 0.1 2.3 ± 0.1 2.3 ± 0.1 2.3 ± 0.1 2.3 ± 0.1 2.3 ± 0.1 2.3 ± 0.1 2.3 ± 0.1 2.3 ± 0.1 2.3 ± 0.1 2.3 ± 0.1
Chloride 100 100.8 ± 3.9 100.9 ± 4.3 100.9 ± 4.2 100.5 ± 4.0 100.4 ± 4.0 100.2 ± 4.3 100.0 ± 4.4 100.1 ± 4.5 100.4 ± 4.4 100.2 ± 4.3 101.3 ± 3.9 100.4 ± 4.1
Cholesterol 7.9 7.9 ± 1.1 7.8 ± 1.4 7.7 ± 1.5 7.8 ± 1.5 7.7 ± 1.4 7.7 ± 1.5 7.5 ± 1.5 7.6 ± 1.6 7.5 ± 1.6 7.3 ± 1.6 7.4 ± 1.5 7.3 ± 1.5
Creatine Kinase 545 621.9 ± 477.4 641.8 ± 417.3736.4 ± 615.2729.5 ± 486.4740.2 ± 625.3790.0 ± 592.6876.7 ± 774.7843.6 ± 793.1837.9 ± 874.8799.2 ± 1016.0798.8 ± 895.9729.0 ± 803.0
Creatinine 0.9 0.9 ± 0.2 0.9 ± 0.2 0.9 ± 0.2 0.9 ± 0.2 0.9 ± 0.2 0.9 ± 0.3 0.9 ± 0.2 0.8 ± 0.2 0.8 ± 0.2 0.8 ± 0.2 0.8 ± 0.2 0.8 ± 0.2
Diastolic Blood Pressure 86 87.3 ± 12.5 86.2 ± 14.3 85.9 ± 13.5 87.9 ± 14.9 85.4 ± 14.7 84.6 ± 14.2 84.5 ± 14.1 83.1 ± 13.7 83.3 ± 13.3 85.1 ± 14.5 83.8 ± 14.2 83.0 ± 15.5
Eosinophils 0.1 0.2 ± 0.1 0.3 ± 0.2 0.3 ± 0.2 0.2 ± 0.2 0.2 ± 0.3 0.3 ± 0.3 0.3 ± 0.3 0.3 ± 0.3 0.4 ± 0.4 0.4 ± 0.4 0.2 ± 0.4 0.3 ± 0.4
FVC Liters 4.3 4.3 ± 0.6 4.3 ± 0.7 4.2 ± 0.8 4.2 ± 0.8 4.1 ± 0.8 3.9 ± 0.9 3.8 ± 0.9 3.8 ± 1.0 3.8 ± 1.0 3.6 ± 1.1 3.4 ± 1.0 3.4 ± 1.0
Gamma Glutamyl Transferase - 5.1 ± 12.2 5.1 ± 15.3 5.1 ± 18.0 5.1 ± 22.9 5.2 ± 21.1 5.1 ± 25.0 5.0 ± 23.7 5.3 ± 23.8 5.1 ± 26.8 5.1 ± 31.7 5.1 ± 32.1 5.3 ± 30.2
Glucose 5.1 5.1 ± 0.8 5.2 ± 0.8 5.2 ± 1.0 5.2 ± 1.0 5.4 ± 1.1 5.5 ± 1.3 5.5 ± 1.4 5.5 ± 1.4 5.5 ± 1.3 5.7 ± 1.4 5.6 ± 1.3 5.5 ± 1.5
Heart Rate 95 93.5 ± 10.0 92.8 ± 11.0 89.3 ± 11.5 88.9 ± 13.0 87.6 ± 15.2 86.4 ± 13.7 85.7 ± 12.8 85.4 ± 12.7 85.4 ± 14.0 85.3 ± 14.7 85.8 ± 14.6 84.8 ± 15.5
Hematocrit 41.1 41.4 ± 2.7 41.3 ± 2.7 41.3 ± 2.9 41.7 ± 2.8 41.4 ± 3.1 41.7 ± 3.5 42.2 ± 3.3 42.4 ± 3.7 42.1 ± 3.6 41.7 ± 3.4 41.9 ± 3.3 41.7 ± 3.2
Hemoglobin 136 139.0 ± 7.9 137.7 ± 8.9 137.8 ± 10.4 139.1 ± 10.1 137.5 ± 10.9 138.1 ± 10.4 139.1 ± 11.3 138.9 ± 11.0 138.3 ± 10.5 138.2 ± 10.1 137.0 ± 11.0 137.5 ± 11.4
Hemoglobin A1C - 5.5 ± 0.5 5.5 ± 0.6 5.6 ± 0.6 5.6 ± 0.6 5.7 ± 0.7 5.7 ± 0.7 5.7 ± 0.8 5.7 ± 0.9 5.7 ± 0.8 5.7 ± 0.8 5.8 ± 0.9 5.7 ± 0.9
Lactate Dehydrogenase 210 214.2 ± 43.9 220.7 ± 52.9 207.0 ± 51.4 220.1 ± 52.0 234.4 ± 60.2 233.9 ± 59.9 214.6 ± 64.4 218.8 ± 61.5 228.4 ± 62.0 228.8 ± 67.7 237.9 ± 68.3 235.7 ± 72.0
Lymphocytes 1.2 1.3 ± 0.4 1.3 ± 0.4 1.4 ± 0.5 1.4 ± 0.6 1.4 ± 0.5 1.4 ± 0.6 1.5 ± 0.5 1.4 ± 0.6 1.5 ± 0.6 1.4 ± 0.7 1.3 ± 0.5 1.4 ± 0.6
Monocytes 0.3 0.3 ± 0.1 0.4 ± 0.1 0.3 ± 0.2 0.3 ± 0.2 0.3 ± 0.2 0.4 ± 0.2 0.4 ± 0.2 0.4 ± 0.2 0.4 ± 0.2 0.4 ± 0.2 0.4 ± 0.2 0.4 ± 0.2
Neutrophils 3.8 3.9 ± 1.4 3.8 ± 1.6 3.9 ± 1.7 3.8 ± 1.7 4.0 ± 1.9 4.1 ± 1.9 4.5 ± 2.2 4.5 ± 2.0 4.3 ± 1.8 4.4 ± 1.8 4.2 ± 1.6 4.4 ± 1.9
Phosphorus 3.6 3.7 ± 0.5 3.8 ± 0.6 3.8 ± 0.6 3.8 ± 0.6 3.8 ± 0.6 3.8 ± 0.6 3.8 ± 0.6 3.8 ± 0.6 3.9 ± 0.6 3.8 ± 0.6 3.7 ± 0.6 3.8 ± 0.6
Plasma NfL 89.6 91.9 ± 18.6 93.6 ± 18.2 95.1 ± 19.7 95.2 ± 19.3 93.4 ± 19.8 89.5 ± 17.9 97.7 ± 18.9 102.3 ± 17.1 100.5 ± 19.6 94.1 ± 19.3 95.8 ± 17.8 99.4 ± 20.6
Platelet 247 253.6 ± 51.5 252.8 ± 53.3 252.3 ± 56.3 253.3 ± 57.6 257.2 ± 60.8 251.7 ± 58.0 252.6 ± 65.4 258.2 ± 70.9 251.7 ± 68.4 257.3 ± 69.8 252.1 ± 64.8 257.7 ± 69.4
Potassium 4 4.0 ± 0.2 4.0 ± 0.3 4.0 ± 0.3 4.1 ± 0.3 4.1 ± 0.3 4.1 ± 0.3 4.1 ± 0.3 4.1 ± 0.3 4.2 ± 0.4 4.2 ± 0.4 4.2 ± 0.4 4.2 ± 0.4
Protein 75 74.3 ± 4.5 74.0 ± 4.6 73.8 ± 5.3 73.4 ± 4.8 73.3 ± 5.3 73.5 ± 5.3 73.2 ± 5.2 73.6 ± 5.5 73.3 ± 5.6 73.4 ± 5.6 73.6 ± 5.6 73.5 ± 5.3
Respiratory Rate 11 12.8 ± 4.1 13.2 ± 4.2 14.2 ± 4.4 14.8 ± 4.5 15.3 ± 4.2 16.3 ± 4.3 16.7 ± 4.7 16.7 ± 5.0 16.8 ± 4.9 17.3 ± 5.1 17.5 ± 5.0 18.2 ± 5.1
Sodium 138.7 138.8 ± 2.0 138.6 ± 2.0 138.9 ± 2.3 139.2 ± 2.7 138.9 ± 2.6 138.7 ± 3.0 138.4 ± 2.9 138.6 ± 2.9 138.9 ± 2.9 138.8 ± 3.1 138.8 ± 3.2 138.8 ± 3.5
SVC Liters - 3.7 ± 0.4 3.7 ± 0.5 3.7 ± 0.6 3.5 ± 0.6 3.4 ± 0.6 3.5 ± 0.8 3.3 ± 0.8 3.2 ± 0.9 3.2 ± 0.8 3.3 ± 1.0 3.0 ± 1.1 3.0 ± 1.2
Systolic Blood Pressure 125 126.5 ± 11.0 127.9 ± 12.8 126.5 ± 13.2 125.9 ± 15.0 128.6 ± 15.1 127.0 ± 14.7 126.3 ± 15.3 127.0 ± 16.2 127.9 ± 16.7 129.5 ± 17.6 128.8 ± 19.7 127.7 ± 19.7
Temperature 37.6 37.2 ± 0.4 37.0 ± 0.4 37.0 ± 0.5 36.9 ± 0.5 36.8 ± 0.5 36.8 ± 0.5 36.8 ± 0.5 36.7 ± 0.6 36.7 ± 0.6 36.6 ± 0.6 36.6 ± 0.6 36.7 ± 0.7
Total Bilirubin 0.4 0.4 ± 0.1 0.5 ± 0.2 0.5 ± 0.2 0.5 ± 0.2 0.5 ± 0.2 0.5 ± 0.2 0.5 ± 0.2 0.5 ± 0.2 0.5 ± 0.2 0.5 ± 0.2 0.5 ± 0.3 0.5 ± 0.3
Triglycerides - 1.8 ± 0.9 1.8 ± 0.9 1.8 ± 0.9 1.8 ± 1.1 1.9 ± 1.2 1.9 ± 1.3 2.0 ± 1.5 2.1 ± 1.7 2.2 ± 2.1 2.3 ± 1.9 2.2 ± 1.8 2.2 ± 1.6
Uric Acid 453 451.4 ± 79.3 438.5 ± 86.0 429.9 ± 92.4 435.9 ± 86.1 435.3 ± 90.7 430.9 ± 86.1 409.7 ± 88.6 417.2 ± 89.8 417.1 ± 87.2 412.1 ± 96.3 398.6 ± 99.0 399.0 ± 88.9
Weight 81.3 81.6 ± 5.3 81.0 ± 5.2 82.0 ± 5.5 81.2 ± 5.8 81.9 ± 5.3 81.7 ± 5.4 81.5 ± 5.9 80.2 ± 5.7 80.4 ± 5.7 79.5 ± 6.2 79.0 ± 5.8 79.0 ± 5.9
Potassium 4.3 ± 0.0 4.3 ± 0.4 4.3 ± 0.4 4.3 ± 0.4 4.3 ± 0.4 4.3 ± 0.4 4.3 ± 0.5 4.3 ± 0.5 4.3 ± 0.5 4.2 ± 0.4 4.3 ± 0.5 4.3 ± 0.4 4.3 ± 0.5
Sodium 145.0 ± 0.0 144.5 ± 2.2 144.3 ± 2.5 144.0 ± 2.8 143.8 ± 2.8 143.2 ± 2.4 143.0 ± 2.6 142.5 ± 2.6 142.0 ± 2.9 141.2 ± 2.1 142.0 ± 2.4 141.5 ± 2.7 142.3 ± 2.9
Systolic Blood Pressure 121.0 ± 0.0 121.5 ± 11.3 120.7 ± 15.3 120.7 ± 17.6 121.3 ± 14.7 121.5 ± 17.2 121.6 ± 16.9 119.6 ± 16.9 119.5 ± 16.4 118.2 ± 17.5 120.6 ± 16.4 119.8 ± 17.9 120.2 ± 18.4
Triglycerides - 1.3 ± 0.4 1.4 ± 0.5 1.5 ± 0.6 1.5 ± 0.6 1.6 ± 0.7 1.6 ± 0.7 1.6 ± 0.8 1.7 ± 0.9 1.4 ± 0.6 1.5 ± 0.8 1.7 ± 0.8 1.7 ± 0.9
Figure23: AnexampletwinrecordforasingleALSpatientisshown,whichreportsthemeanand
standarddeviationofthetwinsforthatpatient. Asampleofstaticbaselineinformationisgivenatthe
topoftherecord. Asampleoflongitudinaloutcomespredictedbythemodelaresuppliedasrows,
withcolumnsindicatingthetimeinmonthssincebaselinevisit.
FTD Digital Twin Example
Age (years): 64 Has Known FTD Mutation: No MCI attributes: None
Sex: Female History of Hypertension: - Height: 164 cm
Years of Education: 18 History of Type 2 Diabetes: - Weight: 63 kg
Baseline 3 6 9 12 15 18 21 24 27 30 33 36 39 42
CDR Community 3 2.1 ± 0.7 2.1 ± 0.7 2.4 ± 0.7 2.5 ± 0.6 2.6 ± 0.4 2.6 ± 0.4 2.7 ± 0.5 2.6 ± 0.4 2.5 ± 0.4 2.6 ± 0.4 2.6 ± 0.3 2.6 ± 0.4 2.5 ± 0.5 2.6 ± 0.5
CDR Home Hobbies 2 2.3 ± 0.7 2.6 ± 0.6 2.5 ± 0.6 2.8 ± 0.4 2.8 ± 0.4 2.8 ± 0.4 2.8 ± 0.4 2.9 ± 0.3 2.9 ± 0.3 2.8 ± 0.4 2.8 ± 0.4 2.8 ± 0.4 2.8 ± 0.4 2.8 ± 0.5
CDR Judgement 2 2.6 ± 0.4 2.6 ± 0.4 2.7 ± 0.4 2.8 ± 0.4 2.7 ± 0.4 2.6 ± 0.3 2.6 ± 0.4 2.7 ± 0.3 2.7 ± 0.3 2.7 ± 0.4 2.7 ± 0.3 2.7 ± 0.3 2.6 ± 0.4 2.6 ± 0.4
CDR Memory 2 2.7 ± 0.4 2.5 ± 0.5 2.6 ± 0.5 2.6 ± 0.4 2.6 ± 0.5 2.6 ± 0.4 2.6 ± 0.4 2.6 ± 0.4 2.6 ± 0.5 2.6 ± 0.4 2.6 ± 0.5 2.4 ± 0.6 2.5 ± 0.5 2.5 ± 0.5
CDR Orientation 1 2.0 ± 0.8 2.2 ± 0.7 2.2 ± 0.7 2.4 ± 0.6 2.5 ± 0.6 2.5 ± 0.5 2.5 ± 0.5 2.5 ± 0.6 2.5 ± 0.6 2.5 ± 0.6 2.5 ± 0.6 2.5 ± 0.6 2.6 ± 0.6 2.5 ± 0.6
CDR Personal Care 1 2.0 ± 0.8 2.1 ± 0.7 2.3 ± 0.7 2.5 ± 0.6 2.5 ± 0.6 2.4 ± 0.6 2.5 ± 0.5 2.5 ± 0.6 2.5 ± 0.6 2.5 ± 0.6 2.4 ± 0.6 2.5 ± 0.6 2.4 ± 0.6 2.4 ± 0.6
Diastolic Blood Pressure 82 80.8 ± 10.9 77.8 ± 11.6 77.8 ± 11.3 76.3 ± 10.3 75.6 ± 10.4 75.1 ± 11.1 74.1 ± 9.7 73.3 ± 10.0 73.5 ± 10.3 73.2 ± 10.9 73.5 ± 11.6 72.7 ± 10.6 72.1 ± 11.7 72.1 ± 12.1
FAQ Score 30 29.8 ± 0.3 30.0 ± 0.4 29.9 ± 0.5 29.6 ± 0.5 29.6 ± 0.6 29.4 ± 0.9 29.9 ± 1.0 29.4 ± 1.1 28.9 ± 0.9 30.0 ± 1.0 29.9 ± 1.4 29.6 ± 1.9 28.7 ± 2.5 29.4 ± 2.2
FTLD CDR Behavioral 0.5 1.5 ± 0.9 1.8 ± 0.9 2.2 ± 0.9 2.2 ± 0.8 2.2 ± 0.8 2.3 ± 0.8 2.3 ± 0.8 2.3 ± 0.8 2.3 ± 0.8 2.3 ± 0.8 2.2 ± 0.9 2.2 ± 0.9 2.2 ± 0.8 2.2 ± 0.9
FTLD CDR Language 0.5 0.8 ± 0.6 1.1 ± 0.8 1.4 ± 1.0 1.7 ± 1.1 1.9 ± 1.0 2.1 ± 1.0 2.2 ± 0.9 2.3 ± 0.9 2.3 ± 0.9 2.4 ± 0.8 2.4 ± 0.9 2.3 ± 0.9 2.3 ± 0.9 2.3 ± 0.9
GDS Total Score 1 1.1 ± 0.9 1.0 ± 1.2 1.0 ± 1.3 1.2 ± 1.2 1.4 ± 1.4 1.3 ± 1.6 1.7 ± 2.1 2.0 ± 2.4 1.9 ± 2.4 1.8 ± 2.3 1.8 ± 2.4 1.7 ± 2.5 1.9 ± 2.4 1.7 ± 2.4
Heart Rate 53 55.9 ± 8.1 57.2 ± 9.8 60.7 ± 11.7 62.0 ± 11.9 63.2 ± 12.5 63.8 ± 12.8 65.3 ± 15.5 66.6 ± 15.9 64.9 ± 14.8 65.6 ± 14.0 64.3 ± 13.6 65.7 ± 14.4 69.5 ± 16.3 69.2 ± 16.8
MMSE Drawing 0 0.0 ± 0.2 0.2 ± 0.4 0.2 ± 0.4 0.3 ± 0.4 0.3 ± 0.5 0.3 ± 0.5 0.3 ± 0.5 0.4 ± 0.5 0.3 ± 0.5 0.3 ± 0.5 0.3 ± 0.5 0.3 ± 0.5 0.4 ± 0.5 0.4 ± 0.5
MMSE Orientation Place 3 2.0 ± 0.8 1.7 ± 1.0 1.4 ± 0.9 1.1 ± 1.0 1.1 ± 1.0 0.8 ± 1.0 0.9 ± 1.1 1.0 ± 1.2 1.0 ± 1.2 0.8 ± 1.0 0.7 ± 1.2 1.0 ± 1.2 0.9 ± 1.2 0.9 ± 1.4
MMSE Orientation Time 2 1.7 ± 1.5 1.3 ± 1.4 1.2 ± 1.4 1.1 ± 1.4 1.0 ± 1.3 0.9 ± 1.2 0.9 ± 1.2 0.7 ± 1.1 0.6 ± 1.1 0.6 ± 1.1 0.6 ± 1.0 0.6 ± 1.0 0.6 ± 1.1 0.5 ± 0.9
MMSE Score 14 13.4 ± 6.9 12.9 ± 7.7 11.7 ± 8.0 10.5 ± 8.0 9.3 ± 8.0 9.2 ± 7.3 9.3 ± 7.9 8.3 ± 7.3 7.7 ± 6.8 7.5 ± 6.9 7.0 ± 7.2 7.8 ± 6.9 9.6 ± 6.9 10.0 ± 7.1
NPI-10 Score 17 14.5 ± 3.1 13.4 ± 3.7 12.7 ± 3.5 12.4 ± 3.8 11.7 ± 4.0 11.8 ± 4.0 10.7 ± 4.6 10.7 ± 4.9 10.5 ± 4.6 9.6 ± 4.5 8.9 ± 4.7 7.2 ± 4.0 6.3 ± 4.3 5.8 ± 4.8
NPI-12 Score 17 15.6 ± 2.9 15.1 ± 3.4 14.0 ± 4.4 13.4 ± 5.2 14.0 ± 5.8 13.3 ± 6.2 12.5 ± 7.0 13.2 ± 7.9 13.2 ± 8.1 13.2 ± 8.9 11.4 ± 8.6 9.2 ± 8.5 7.6 ± 7.9 8.3 ± 8.7
NPI Severity Score 17 15.6 ± 6.6 16.4 ± 7.0 16.1 ± 6.7 14.8 ± 6.7 15.8 ± 6.6 16.1 ± 7.3 15.4 ± 7.2 15.2 ± 6.9 13.9 ± 6.9 13.4 ± 6.3 10.9 ± 6.4 9.1 ± 6.0 7.9 ± 5.2 6.7 ± 5.1
Systolic Blood Pressure 128 128.0 ± 15.5 126.9 ± 15.9 127.7 ± 18.1 126.5 ± 17.7 123.2 ± 16.4 123.7 ± 18.0 124.9 ± 18.7 124.7 ± 17.4 122.7 ± 17.9 123.2 ± 17.9 122.6 ± 19.7 122.9 ± 16.6 118.9 ± 16.8 118.2 ± 16.9
Figure24: AnexampletwinrecordforasingleFTDpatientisshown,whichreportsthemeanand
standarddeviationofthetwinsforthatpatient. Asampleofstaticbaselineinformationisgivenatthe
topoftherecord. Asampleoflongitudinaloutcomespredictedbythemodelaresuppliedasrows,
withcolumnsindicatingthetimeinmonthssincebaselinevisit.
46PD Digital Twin Example
Age (years): 74 Bradykinesia at diagnosis: Yes Family history of PD: Yes
Sex: Female Rigidity at diagnosis: Yes History of neurological disease: No
Years since diagnosis: 0 Tremor at diagnosis: Yes History of psychiatric illness: Yes
Baseline 3 6 9 12 15 18 21 24
Alanine Aminotransferase 17 15.9 ± 2.9 16.9 ± 3.8 16.5 ± 3.8 17.3 ± 4.6 17.4 ± 4.6 16.0 ± 4.5 15.5 ± 4.9 16.0 ± 4.5
Albumin 44 44.1 ± 1.5 44.5 ± 1.7 44.4 ± 1.7 44.4 ± 1.6 44.6 ± 2.0 44.7 ± 2.1 44.8 ± 1.9 45.0 ± 2.0
Alkaline Phosphatase 56 56.3 ± 5.1 57.7 ± 6.5 59.1 ± 7.6 59.7 ± 8.5 60.0 ± 10.4 61.9 ± 12.5 63.2 ± 10.5 65.9 ± 12.5
Aspartate Aminotransferase 22 21.6 ± 2.6 21.5 ± 2.4 21.6 ± 3.5 22.7 ± 3.3 22.3 ± 4.0 23.1 ± 3.8 22.8 ± 3.9 23.9 ± 4.5
Blood Urea Nitrogen 3.9 4.4 ± 0.9 4.9 ± 1.0 5.0 ± 1.0 5.4 ± 1.0 5.6 ± 1.3 5.7 ± 1.3 6.0 ± 1.3 6.0 ± 1.3
Calcium 2.2 2.3 ± 0.1 2.3 ± 0.1 2.3 ± 0.1 2.3 ± 0.1 2.3 ± 0.1 2.3 ± 0.1 2.3 ± 0.1 2.3 ± 0.1
Chloride 102 101.3 ± 1.4 101.5 ± 1.8 101.8 ± 1.7 101.6 ± 1.8 102.1 ± 2.2 102.1 ± 1.8 102.2 ± 2.1 101.9 ± 2.3
Creatinine 0.7 0.7 ± 0.1 0.7 ± 0.1 0.7 ± 0.1 0.8 ± 0.1 0.7 ± 0.1 0.8 ± 0.1 0.8 ± 0.1 0.8 ± 0.1
Diastolic Blood Pressure 83 81.0 ± 8.9 79.6 ± 8.2 78.5 ± 8.0 78.3 ± 8.4 77.0 ± 7.8 76.5 ± 8.1 76.1 ± 8.6 76.1 ± 7.7
Glucose 4.6 5.1 ± 0.6 5.4 ± 0.8 5.6 ± 0.8 5.6 ± 0.9 5.7 ± 1.0 5.8 ± 1.2 5.8 ± 1.1 5.7 ± 1.2
Heart Rate 55.5 59.0 ± 6.0 61.5 ± 7.0 60.7 ± 6.6 62.3 ± 7.7 63.1 ± 8.5 64.8 ± 9.2 65.4 ± 9.4 65.2 ± 9.4
Hematocrit 48.8 48.4 ± 2.1 48.5 ± 2.3 48.0 ± 2.2 48.3 ± 2.6 47.7 ± 2.7 47.2 ± 2.7 47.3 ± 2.5 47.5 ± 2.9
Hemoglobin 147 144.8 ± 5.9 147.2 ± 6.1 145.1 ± 6.4 146.7 ± 6.6 145.6 ± 7.6 144.6 ± 7.1 144.8 ± 7.7 144.8 ± 8.3
Lymphocytes 2 2.0 ± 0.5 2.0 ± 0.6 2.0 ± 0.7 2.0 ± 0.9 2.1 ± 1.1 2.1 ± 1.3 2.1 ± 1.2 2.2 ± 1.5
MDS-UPDRS Motor EDL Chewing 0 0.0 ± 0.1 0.1 ± 0.0 0.0 ± 0.1 0.0 ± 0.0 0.1 ± 0.2 0.0 ± 0.2 0.0 ± 0.1 0.0 ± 0.2
MDS-UPDRS Motor EDL Dressing 0 0.1 ± 0.3 0.1 ± 0.3 0.1 ± 0.3 0.2 ± 0.4 0.3 ± 0.4 0.2 ± 0.4 0.2 ± 0.4 0.2 ± 0.4
MDS-UPDRS Motor EDL Drooling 1 0.3 ± 0.3 0.3 ± 0.3 0.3 ± 0.4 0.4 ± 0.4 0.4 ± 0.5 0.5 ± 0.5 0.4 ± 0.5 0.5 ± 0.6
MDS-UPDRS Motor EDL Eating 0 0.1 ± 0.3 0.2 ± 0.4 0.3 ± 0.5 0.2 ± 0.4 0.3 ± 0.4 0.3 ± 0.5 0.3 ± 0.5 0.2 ± 0.4
MDS-UPDRS Motor EDL Freezing 1 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0
MDS-UPDRS Motor EDL Getting Out Bed 0 0.1 ± 0.3 0.2 ± 0.4 0.2 ± 0.4 0.2 ± 0.4 0.2 ± 0.5 0.2 ± 0.4 0.2 ± 0.4 0.1 ± 0.4
MDS-UPDRS Motor EDL Handwriting 2 1.5 ± 0.8 1.6 ± 0.9 1.6 ± 0.8 1.6 ± 0.9 1.6 ± 1.0 1.6 ± 1.0 1.5 ± 0.9 1.3 ± 0.9
MDS-UPDRS Motor EDL Hobbies 1 0.4 ± 0.3 0.4 ± 0.4 0.4 ± 0.4 0.4 ± 0.4 0.5 ± 0.5 0.5 ± 0.5 0.5 ± 0.5 0.5 ± 0.5
MDS-UPDRS Motor EDL Hygiene 0 0.1 ± 0.3 0.1 ± 0.3 0.1 ± 0.3 0.1 ± 0.3 0.2 ± 0.4 0.1 ± 0.3 0.1 ± 0.3 0.0 ± 0.2
MDS-UPDRS Motor EDL Speech 0 0.1 ± 0.3 0.1 ± 0.4 0.0 ± 0.3 0.2 ± 0.3 0.0 ± 0.3 0.1 ± 0.3 0.1 ± 0.3 0.1 ± 0.4
MDS-UPDRS Motor EDL Tremor 2 1.4 ± 0.6 1.4 ± 0.6 1.5 ± 0.7 1.5 ± 0.6 1.4 ± 0.7 1.4 ± 0.6 1.5 ± 0.7 1.3 ± 0.7
MDS-UPDRS Motor EDL Turning Bed 1 0.3 ± 0.3 0.3 ± 0.2 0.3 ± 0.2 0.2 ± 0.2 0.2 ± 0.3 0.2 ± 0.2 0.3 ± 0.2 0.2 ± 0.2
MDS-UPDRS Motor EDL Walking 1 0.4 ± 0.3 0.4 ± 0.4 0.4 ± 0.4 0.4 ± 0.5 0.4 ± 0.4 0.4 ± 0.4 0.4 ± 0.5 0.3 ± 0.4
MDS-UPDRS Motor Arising 0 0.0 ± 0.0 0.0 ± 0.0 0.1 ± 0.0 0.2 ± 0.0 0.0 ± 0.0 0.1 ± 0.0 0.0 ± 0.0 0.1 ± 0.0
MDS-UPDRS Motor Body Bradykinesia 0 0.2 ± 0.4 0.4 ± 0.5 0.5 ± 0.5 0.5 ± 0.6 0.7 ± 0.7 0.8 ± 0.8 0.8 ± 0.9 1.1 ± 0.8
MDS-UPDRS Motor Facial Expression 0 0.1 ± 0.3 0.2 ± 0.5 0.4 ± 0.6 0.5 ± 0.6 0.5 ± 0.6 0.5 ± 0.7 0.7 ± 0.7 0.9 ± 0.8
MDS-UPDRS Motor Finger Tapping Left 0 0.1 ± 0.5 0.3 ± 0.5 0.4 ± 0.6 0.6 ± 0.7 0.7 ± 0.7 0.5 ± 0.6 0.6 ± 0.7 0.7 ± 0.7
MDS-UPDRS Motor Finger Tapping Right 1 1.3 ± 0.8 1.1 ± 0.8 1.2 ± 0.7 1.5 ± 0.8 1.4 ± 0.8 1.6 ± 0.8 1.6 ± 0.8 1.8 ± 0.8
MDS-UPDRS Motor Freezing Gait 1 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0
MDS-UPDRS Motor Gait 0 0.2 ± 0.4 0.2 ± 0.5 0.3 ± 0.4 0.3 ± 0.4 0.2 ± 0.5 0.3 ± 0.5 0.2 ± 0.4 0.2 ± 0.4
MDS-UPDRS Motor Hand Movements Left Hand 1 0.4 ± 0.4 0.4 ± 0.4 0.5 ± 0.5 0.4 ± 0.5 0.5 ± 0.5 0.5 ± 0.5 0.5 ± 0.5 0.6 ± 0.6
MDS-UPDRS Motor Hand Movements Right Hand 2 1.2 ± 0.7 1.0 ± 0.7 1.0 ± 0.8 1.1 ± 0.8 1.0 ± 0.7 1.1 ± 0.7 1.2 ± 0.6 1.2 ± 0.7
MDS-UPDRS Motor HY Stage 3 2.2 ± 0.4 2.2 ± 0.5 2.2 ± 0.5 2.2 ± 0.5 2.3 ± 0.5 2.3 ± 0.5 2.3 ± 0.5 2.3 ± 0.5
MDS-UPDRS Motor Kinetic Tremor Hands Left 0 0.1 ± 0.3 0.2 ± 0.4 0.2 ± 0.4 0.2 ± 0.4 0.3 ± 0.5 0.3 ± 0.5 0.3 ± 0.5 0.3 ± 0.5
MDS-UPDRS Motor Kinetic Tremor Hands Right 1 1.1 ± 0.6 1.1 ± 0.7 1.2 ± 0.7 1.3 ± 0.8 1.1 ± 0.7 1.2 ± 0.8 1.1 ± 0.7 1.1 ± 0.8
MDS-UPDRS Motor Leg Agility Left 1 0.2 ± 0.3 0.4 ± 0.3 0.3 ± 0.3 0.4 ± 0.4 0.4 ± 0.4 0.4 ± 0.4 0.4 ± 0.5 0.4 ± 0.5
MDS-UPDRS Motor Leg Agility Right 0 0.2 ± 0.4 0.3 ± 0.4 0.4 ± 0.5 0.4 ± 0.5 0.4 ± 0.6 0.6 ± 0.6 0.6 ± 0.6 0.7 ± 0.7
MDS-UPDRS Motor Postural Stability 0 0.0 ± 0.0 0.0 ± 0.0 0.1 ± 0.0 0.1 ± 0.1 0.1 ± 0.0 0.0 ± 0.1 0.0 ± 0.1 0.0 ± 0.1
MDS-UPDRS Motor Postural Tremor Hands Left 0 0.7 ± 0.6 0.6 ± 0.6 0.4 ± 0.6 0.3 ± 0.6 0.3 ± 0.6 0.2 ± 0.6 0.2 ± 0.6 0.2 ± 0.6
MDS-UPDRS Motor Postural Tremor Hands Right 2 1.8 ± 0.7 2.0 ± 0.9 1.9 ± 0.9 1.8 ± 1.0 1.8 ± 1.1 1.8 ± 1.2 1.8 ± 1.4 1.8 ± 1.2
MDS-UPDRS Motor Posture 1 0.4 ± 0.4 0.4 ± 0.4 0.5 ± 0.5 0.5 ± 0.5 0.6 ± 0.6 0.6 ± 0.6 0.6 ± 0.7 0.7 ± 0.7
MDS-UPDRS Motor Pronation Supination Hands Left 1 0.4 ± 0.4 0.4 ± 0.4 0.4 ± 0.5 0.5 ± 0.5 0.6 ± 0.6 0.6 ± 0.6 0.5 ± 0.5 0.6 ± 0.6
MDS-UPDRS Motor Pronation Supination Hands Right 1 1.1 ± 0.8 1.3 ± 0.8 1.3 ± 0.8 1.3 ± 0.9 1.4 ± 0.8 1.5 ± 0.9 1.5 ± 0.9 1.5 ± 0.9
MDS-UPDRS Motor Rest Tremor Constancy 2 2.6 ± 0.9 2.7 ± 1.1 3.0 ± 0.9 3.1 ± 0.9 3.2 ± 0.8 3.2 ± 0.8 3.2 ± 0.9 3.2 ± 0.9
MDS-UPDRS Motor Rest Tremor Jaw 0 0.0 ± 0.1 0.1 ± 0.2 0.1 ± 0.3 0.2 ± 0.4 0.2 ± 0.4 0.1 ± 0.4 0.1 ± 0.4 0.2 ± 0.4
MDS-UPDRS Motor Rest Tremor Lle 1 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.2 0.2 ± 0.1 0.2 ± 0.1 0.3 ± 0.2
MDS-UPDRS Motor Rest Tremor Lue 1 0.2 ± 0.3 0.4 ± 0.4 0.4 ± 0.4 0.5 ± 0.5 0.5 ± 0.5 0.5 ± 0.5 0.5 ± 0.5 0.5 ± 0.4
MDS-UPDRS Motor Rest Tremor Rle 0 0.0 ± 0.2 0.1 ± 0.3 0.2 ± 0.4 0.2 ± 0.5 0.3 ± 0.5 0.3 ± 0.5 0.3 ± 0.6 0.3 ± 0.6
MDS-UPDRS Motor Rest Tremor Rue 3 2.9 ± 0.7 2.8 ± 0.8 2.8 ± 0.8 2.8 ± 0.9 2.9 ± 0.9 2.7 ± 0.9 2.9 ± 1.0 2.8 ± 1.0
MDS-UPDRS Motor Rigidity Lle 1 0.8 ± 0.7 0.8 ± 0.7 0.5 ± 0.6 0.4 ± 0.5 0.5 ± 0.6 0.4 ± 0.5 0.2 ± 0.5 0.2 ± 0.4
MDS-UPDRS Motor Rigidity Lue 1 0.8 ± 0.7 0.7 ± 0.7 0.9 ± 0.7 0.8 ± 0.7 0.8 ± 0.7 0.7 ± 0.7 0.6 ± 0.7 0.7 ± 0.7
MDS-UPDRS Motor Rigidity Neck 2 1.8 ± 0.9 1.6 ± 0.9 1.6 ± 0.8 1.7 ± 0.8 1.7 ± 0.8 1.6 ± 0.8 1.5 ± 0.9 1.2 ± 0.8
MDS-UPDRS Motor Rigidity Rle 1 1.6 ± 0.9 1.6 ± 0.8 1.6 ± 0.9 1.4 ± 0.8 1.3 ± 0.9 1.2 ± 0.8 1.1 ± 0.7 0.9 ± 0.7
MDS-UPDRS Motor Rigidity Rue 1 1.8 ± 0.8 1.8 ± 0.8 1.8 ± 0.8 1.8 ± 0.8 1.7 ± 0.8 1.8 ± 0.8 1.9 ± 0.9 1.9 ± 0.9
MDS-UPDRS Motor Speech 1 0.2 ± 0.2 0.3 ± 0.4 0.5 ± 0.5 0.6 ± 0.5 0.6 ± 0.5 0.6 ± 0.6 0.7 ± 0.6 0.8 ± 0.7
MDS-UPDRS Motor Toe Tapping Left 0 0.3 ± 0.5 0.3 ± 0.6 0.4 ± 0.6 0.5 ± 0.7 0.7 ± 0.7 0.6 ± 0.7 0.6 ± 0.7 0.7 ± 0.8
MDS-UPDRS Motor Toe Tapping Right 1 0.5 ± 0.6 0.7 ± 0.7 0.9 ± 0.7 1.0 ± 0.7 1.2 ± 0.8 1.1 ± 0.8 1.1 ± 0.8 1.4 ± 0.8
MDS-UPDRS Non-Motor EDL Anxious 0 0.1 ± 0.4 0.1 ± 0.3 0.1 ± 0.4 0.2 ± 0.5 0.2 ± 0.4 0.2 ± 0.4 0.2 ± 0.5 0.2 ± 0.5
MDS-UPDRS Non-Motor EDL Apathy 1 0.2 ± 0.2 0.2 ± 0.1 0.2 ± 0.0 0.3 ± 0.2 0.3 ± 0.2 0.3 ± 0.2 0.2 ± 0.2 0.3 ± 0.3
MDS-UPDRS Non-Motor EDL Cognitive Impairment 1 0.3 ± 0.2 0.3 ± 0.3 0.3 ± 0.3 0.3 ± 0.3 0.3 ± 0.3 0.3 ± 0.4 0.4 ± 0.4 0.3 ± 0.3
MDS-UPDRS Non-Motor EDL Constipation 1 0.3 ± 0.3 0.3 ± 0.4 0.4 ± 0.4 0.3 ± 0.4 0.4 ± 0.5 0.4 ± 0.4 0.3 ± 0.4 0.3 ± 0.3
MDS-UPDRS Non-Motor EDL Daytime Pain 1 0.4 ± 0.5 0.5 ± 0.6 0.6 ± 0.6 0.6 ± 0.6 0.6 ± 0.6 0.5 ± 0.6 0.4 ± 0.4 0.4 ± 0.5
MDS-UPDRS Non-Motor EDL Daytime Sleepiness 1 0.4 ± 0.5 0.4 ± 0.5 0.5 ± 0.5 0.5 ± 0.5 0.5 ± 0.6 0.6 ± 0.6 0.5 ± 0.5 0.5 ± 0.5
MDS-UPDRS Non-Motor EDL Depressed 1 0.3 ± 0.3 0.2 ± 0.3 0.3 ± 0.3 0.3 ± 0.2 0.3 ± 0.3 0.3 ± 0.3 0.3 ± 0.3 0.3 ± 0.3
MDS-UPDRS Non-Motor EDL Dopamine Dysregulation 0 0.1 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.1 ± 0.0 0.0 ± 0.0 0.1 ± 0.0
Figure25: AnexampletwinrecordforasinglePDpatientisshown,whichreportsthemeanand
standarddeviationofthetwinsforthatpatient. Asampleofstaticbaselineinformationisgivenatthe
topoftherecord. Asampleoflongitudinaloutcomespredictedbythemodelaresuppliedasrows,
withcolumnsindicatingthetimeinmonthssincebaselinevisit. Thenumberoflongitudinalrecords
havebeentruncated.
47HD Digital Twin Example
Age (years): 65 CAG repeats: 39 Cognitive onset: No
Sex: Male Dad had HD: Yes Motor onset: Yes
Stage: Pre-manifest Mom had HD: No Psychiatric onset: No
Baseline 6 12 18 24 30
BMI 30.8 30.6 ± 1.4 31.1 ± 1.9 30.6 ± 2.1 30.8 ± 2.5 30.6 ± 2.5
Category Fluency Correct 28 27.7 ± 3.9 27.7 ± 3.9 26.7 ± 4.3 26.9 ± 4.9 26.5 ± 4.3
Category Fluency Intr Errors 1 0.1 ± 0.3 0.0 ± 0.3 0.0 ± 0.3 0.0 ± 0.4 0.0 ± 0.4
Category Fluency Persev Errors 1 0.1 ± 0.5 0.1 ± 0.5 0.1 ± 0.6 0.1 ± 0.5 0.1 ± 0.5
CGI Severity - 0.9 ± 0.6 0.9 ± 0.7 0.8 ± 0.7 0.8 ± 0.6 0.8 ± 0.7
C-SSRS Aborted Attempt 1 0.0 ± 0.0 0.0 ± 0.0 0.1 ± 0.0 0.0 ± 0.0 0.1 ± 0.0
C-SSRS Actual Attempt 0 0.1 ± 0.0 0.0 ± 0.0 0.1 ± 0.0 0.0 ± 0.0 0.1 ± 0.0
C-SSRS Ideation With Intent 1 0.1 ± 0.4 0.1 ± 0.5 0.1 ± 0.5 0.1 ± 0.5 0.1 ± 0.5
C-SSRS Ideation With Plan 0 0.2 ± 0.4 0.3 ± 0.5 0.3 ± 0.5 0.4 ± 0.5 0.4 ± 0.5
C-SSRS Ideation Without Intent 0 0.9 ± 0.5 0.8 ± 0.5 0.7 ± 0.5 0.7 ± 0.5 0.7 ± 0.5
C-SSRS Interrupted Attempt 1 0.1 ± 0.0 0.2 ± 0.0 0.1 ± 0.0 0.0 ± 0.0 0.1 ± 0.0
C-SSRS Preparatory Behavior 0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
C-SSRS Suicidal Thoughts 1 0.1 ± 0.3 0.1 ± 0.3 0.2 ± 0.4 0.1 ± 0.3 0.1 ± 0.3
C-SSRS Wish To Be Dead 0 0.0 ± 0.1 0.1 ± 0.3 0.1 ± 0.4 0.1 ± 0.4 0.2 ± 0.4
cUHDRS 16.3 15.9 ± 1.4 16.7 ± 1.5 15.8 ± 1.6 15.9 ± 1.5 16.3 ± 1.5
Diagnostic Confidence 1 1.1 ± 0.6 0.9 ± 0.8 1.1 ± 0.9 1.2 ± 1.1 1.4 ± 1.2
FA Score 25 24.2 ± 0.7 24.3 ± 0.8 24.3 ± 0.9 24.3 ± 1.1 23.8 ± 1.2
Ind Score 100 97.6 ± 3.3 93.8 ± 4.0 98.7 ± 4.3 95.4 ± 4.9 94.1 ± 5.6
Letter Fluency Correct 73 68.7 ± 7.9 68.1 ± 8.2 67.3 ± 7.4 65.7 ± 7.5 65.1 ± 9.4
Letter Fluency Intr Errors 0 0.4 ± 0.6 0.4 ± 0.6 0.6 ± 0.8 0.6 ± 0.8 0.7 ± 1.0
Letter Fluency Persev Errors 1 0.3 ± 0.8 0.8 ± 1.1 0.9 ± 1.1 1.0 ± 1.2 1.1 ± 1.3
MMSE 29 29.5 ± 0.8 29.5 ± 1.0 29.5 ± 1.0 29.9 ± 1.0 29.1 ± 1.1
PBA-s Is Accompanied 1 0.8 ± 0.4 0.7 ± 0.4 0.6 ± 0.5 0.6 ± 0.5 0.4 ± 0.5
PBA-s Q10 Hallucinations 0 0.1 ± 0.1 0.0 ± 0.2 0.0 ± 0.2 0.0 ± 0.2 0.0 ± 0.2
PBA-s Q11 Disorientation 1 0.0 ± 0.2 0.0 ± 0.3 0.1 ± 0.4 0.1 ± 0.4 0.0 ± 0.5
PBA-s Q1 Depressed 4 4.7 ± 3.3 3.1 ± 2.6 2.9 ± 2.5 3.1 ± 3.1 3.4 ± 3.7
PBA-s Q2 Suicidal 9 5.1 ± 1.7 3.5 ± 1.7 3.0 ± 1.8 2.6 ± 1.8 2.0 ± 1.9
PBA-s Q3 Anxiety 0 0.7 ± 0.9 0.9 ± 1.3 1.6 ± 1.9 1.6 ± 2.2 2.2 ± 2.4
PBA-s Q4 Irritability 0 0.6 ± 1.1 0.7 ± 0.8 0.9 ± 1.1 1.2 ± 1.6 1.4 ± 2.0
PBA-s Q5 Aggression 1 0.1 ± 0.4 0.1 ± 0.6 0.3 ± 0.7 0.5 ± 0.9 0.5 ± 1.1
PBA-s Q6 Apathy 0 0.4 ± 0.7 0.7 ± 0.9 1.0 ± 1.1 1.4 ± 1.3 1.5 ± 2.0
PBA-s Q7 Perseveration 0 0.4 ± 0.6 0.2 ± 0.7 0.4 ± 0.7 0.5 ± 0.9 0.6 ± 1.0
PBA-s Q8 Obsessive 1 0.0 ± 0.4 0.1 ± 0.5 0.1 ± 0.6 0.2 ± 0.8 0.4 ± 1.0
PBA-s Q9 Paranoid 1 0.2 ± 0.1 0.0 ± 0.3 0.0 ± 0.3 0.2 ± 0.3 0.1 ± 0.4
SDMT Correct 53 52.4 ± 8.3 55.7 ± 9.2 51.4 ± 9.3 53.5 ± 8.7 50.7 ± 9.6
Stroop Color Correct 66 67.4 ± 10.2 70.6 ± 9.8 72.1 ± 11.1 71.0 ± 10.7 72.4 ± 11.5
Stroop Color Corrected Errors 0 0.2 ± 0.6 0.1 ± 0.4 0.1 ± 0.4 0.1 ± 0.3 0.1 ± 0.3
Stroop Color Errors 0 0.2 ± 0.4 0.1 ± 0.1 0.0 ± 0.0 0.2 ± 0.1 0.1 ± 0.2
Stroop Interference Correct 41 40.5 ± 7.0 40.6 ± 8.0 40.2 ± 7.5 42.3 ± 7.3 43.0 ± 7.3
Stroop Interference Corrected Errors 0 0.5 ± 0.6 0.4 ± 0.6 0.5 ± 0.7 0.6 ± 0.7 0.6 ± 0.7
Stroop Interference Errors 1 0.1 ± 0.6 0.3 ± 0.7 0.4 ± 0.8 0.3 ± 0.8 0.2 ± 0.7
Stroop Word Correct 87 88.7 ± 12.1 92.9 ± 12.7 91.8 ± 12.5 93.6 ± 12.6 94.0 ± 13.4
Stroop Word Corrected Errors 1 0.1 ± 0.2 0.1 ± 0.3 0.0 ± 0.3 0.3 ± 0.3 0.1 ± 0.4
Stroop Word Errors 0 0.1 ± 0.2 0.0 ± 0.1 0.0 ± 0.2 0.1 ± 0.3 0.0 ± 0.2
TFC Score 12 12.7 ± 0.9 12.5 ± 0.9 12.5 ± 1.0 12.2 ± 1.1 12.4 ± 1.1
Figure26: AnexampletwinrecordforasingleHDpatientisshown,whichreportsthemeanand
standarddeviationofthetwinsforthatpatient. Asampleofstaticbaselineinformationisgivenatthe
topoftherecord. Asampleoflongitudinaloutcomespredictedbythemodelaresuppliedasrows,
withcolumnsindicatingthetimeinmonthssincebaselinevisit. Thenumberoflongitudinalrecords
havebeentruncated.
48Stroke Digital Twin Example
Age (years): 84 Ischemic type: TACI Location: Left hemisphere History heart disease: No
Sex: Female Took TPA: Yes Prior ASA treatment: Yes History renal disorders: Yes
Time to randomization: 110 min TPA dose: 66 mg Prior statins: No History type 2 diabetes: No
Baseline 1 3 6 9 12
Alanine Aminotransferase - 18.1 ± 14.0 17.2 ± 18.6 15.5 ± 27.5 13.35 ± 23.6 11.8 ± 40.2
Alkaline Phosphatase - 247.8 ± 245.1 252.5 ± 244.8 232.4 ± 246.4 257.8 ± 247.5 268.9 ± 247.1
Aspartate Aminotransferase - 11.0 ± 8.7 11.0 ± 8.4 11.0 ± 7.7 11.1 ± 9.7 11.0 ± 17.9
Barthel Bathing - 2.8 ± 2.5 3.4 ± 2.4 3.5 ± 2.3 3.1 ± 2.4 3.0 ± 2.4
Barthel Bladder - 7.5 ± 3.0 8.0 ± 2.6 8.1 ± 2.5 8.4 ± 2.5 7.7 ± 2.9
Barthel Bowels - 7.2 ± 2.9 8.3 ± 2.5 8.8 ± 2.1 8.9 ± 2.1 8.5 ± 2.5
Barthel Dressing - 7.0 ± 3.7 7.7 ± 3.1 8.2 ± 2.6 8.0 ± 2.5 7.5 ± 2.7
Barthel Feeding - 7.8 ± 2.7 8.5 ± 2.3 9.1 ± 2.1 9.0 ± 2.1 8.7 ± 2.2
Barthel Grooming - 3.4 ± 2.3 3.7 ± 2.2 3.9 ± 2.1 4.3 ± 1.8 4.0 ± 1.9
Barthel Mobility - 10.6 ± 5.0 11.9 ± 4.4 12.8 ± 3.2 12.6 ± 3.4 12.4 ± 3.7
Barthel Stairs - 6.1 ± 3.7 5.9 ± 3.8 6.6 ± 3.2 6.0 ± 3.3 6.3 ± 3.1
Barthel Toiletuse - 6.3 ± 3.5 7.6 ± 3.3 8.3 ± 2.5 9.2 ± 2.2 8.5 ± 2.4
Barthel Transfers - 10.4 ± 4.5 11.5 ± 3.9 12.9 ± 2.9 12.8 ± 2.9 12.9 ± 3.0
Basophils - 0.1 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 0.2 ± 0.2 0.3 ± 0.2
Bicarbonate 28 26.0 ± 2.7 24.1 ± 2.8 23.2 ± 3.5 23.3 ± 3.6 22.6 ± 4.1
Chloride 103 104.8 ± 4.0 106.2 ± 5.1 108.2 ± 7.8 108.8 ± 8.3 107.6 ± 9.7
Creatinine 0.7 0.7 ± 0.1 0.7 ± 0.2 0.7 ± 0.2 0.6 ± 0.2 0.6 ± 0.3
Diastolic Blood Pressure 84 73.7 ± 11.4 68.1 ± 12.9 64.5 ± 17.1 64.6 ± 17.9 65.7 ± 20.1
EQ-5D-3L Activities - 2.0 ± 0.8 1.9 ± 0.8 1.9 ± 0.7 2.0 ± 0.7 1.9 ± 0.7
EQ-5D-3L Anxiety - 1.7 ± 0.7 1.5 ± 0.6 1.5 ± 0.6 1.6 ± 0.6 1.5 ± 0.5
EQ-5D-3L Mobility - 1.7 ± 0.7 1.7 ± 0.6 1.6 ± 0.6 1.6 ± 0.6 1.6 ± 0.6
EQ-5D-3L Pain - 1.7 ± 0.6 1.6 ± 0.6 1.5 ± 0.5 1.5 ± 0.6 1.6 ± 0.6
EQ-5D-3L Selfcare - 1.8 ± 0.7 1.5 ± 0.5 1.4 ± 0.5 1.5 ± 0.6 1.5 ± 0.5
Glucose 6.6 6.7 ± 1.8 6.1 ± 1.8 6.2 ± 2.7 6.3 ± 2.9 5.8 ± 2.9
Heart Rate 60 71.2 ± 11.9 70.0 ± 12.6 65.7 ± 15.2 69.7 ± 18.6 67.5 ± 19.4
Hematocrit 34.9 35.8 ± 5.3 35.2 ± 5.2 34.4 ± 6.4 32.7 ± 8.2 33.0 ± 7.7
Hemoglobin 117 111.8 ± 17.8 102.3 ± 18.4 93.0 ± 21.3 82.6 ± 20.0 78.1 ± 24.1
Hemoglobin A1C - 7.6 ± 2.9 6.7 ± 3.2 6.0 ± 3.3 5.8 ± 3.6 5.0 ± 3.3
International Normalized Ratio 1.1 1.1 ± 0.1 1.2 ± 0.1 1.2 ± 0.2 1.2 ± 0.2 1.2 ± 0.2
Lymphocytes - 0.7 ± 3.3 0.7 ± 4.9 0.7 ± 5.6 0.7 ± 6.6 0.7 ± 6.6
Modified Rankin Score - 2.5 ± 1.5 2.2 ± 1.5 2.2 ± 1.5 2.2 ± 1.4 2.5 ± 1.3
Monocytes - 1.3 ± 1.5 2.1 ± 2.2 2.4 ± 2.4 2.7 ± 2.4 2.5 ± 2.5
Neutrophils - 1.8 ± 4.3 1.7 ± 3.9 1.8 ± 5.5 1.8 ± 4.9 1.8 ± 9.8
NIHSS Commands 1 0.3 ± 0.4 0.2 ± 0.2 0.2 ± 0.2 0.2 ± 0.0 0.2 ± 0.2
NIHSS Consciousness 1 0.4 ± 0.4 0.2 ± 0.2 0.2 ± 0.0 0.2 ± 0.1 0.2 ± 0.0
NIHSS Dysarthria 1 0.5 ± 0.6 0.4 ± 0.5 0.1 ± 0.4 0.2 ± 0.4 0.2 ± 0.4
NIHSS Gaze 1 0.2 ± 0.4 0.0 ± 0.2 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
NIHSS Inattention 0 0.4 ± 0.5 0.2 ± 0.4 0.1 ± 0.2 0.0 ± 0.2 0.1 ± 0.3
NIHSS Language 2 1.2 ± 0.9 0.5 ± 0.6 0.2 ± 0.3 0.0 ± 0.2 0.1 ± 0.2
NIHSS Limbataxia 0 0.0 ± 0.1 0.0 ± 0.2 0.2 ± 0.0 0.0 ± 0.2 0.0 ± 0.2
NIHSS Monthandage 2 1.3 ± 0.7 0.9 ± 0.7 0.5 ± 0.7 0.4 ± 0.6 0.3 ± 0.5
NIHSS Motorarm Left 0 0.6 ± 0.9 0.4 ± 0.6 0.1 ± 0.5 0.1 ± 0.4 0.1 ± 0.3
NIHSS Motorarm Right 0 0.7 ± 0.9 0.2 ± 0.6 0.0 ± 0.5 0.1 ± 0.5 0.1 ± 0.4
NIHSS Motorleg Left 1 0.8 ± 0.8 0.6 ± 0.7 0.4 ± 0.4 0.3 ± 0.4 0.3 ± 0.3
NIHSS Motorleg Right 1 1.0 ± 1.0 0.4 ± 0.7 0.2 ± 0.5 0.0 ± 0.3 0.1 ± 0.3
Figure27: AnexampletwinrecordforasingleStrokepatientisshown,whichreportsthemeanand
standarddeviationofthetwinsforthatpatient. Asampleofstaticbaselineinformationisgivenatthe
topoftherecord. Asampleoflongitudinaloutcomespredictedbythemodelaresuppliedasrows,
withcolumnsindicatingthetimeinmonthssincebaselinevisit. Thenumberoflongitudinalrecords
havebeentruncated.
49HTN Digital Twin Example
Age (years): 57 Blood Pressure: Borderline Height: 187 cm History MI: No
Sex: Male Glucose: Diabetes Weight: 82 kg History Stroke: Yes
Race: White History Hypertension: Yes Cholesterol: High
Baseline 2 4 6 8 10 12 14
BMI 22.6 22.6 ± 1.2 23.0 ± 1.4 22.4 ± 1.6 22.9 ± 1.8 22.2 ± 2.0 22.4 ± 2.2 22.4 ± 2.2
Creatinine 0.9 0.9 ± 0.1 0.9 ± 0.1 0.9 ± 0.1 0.9 ± 0.1 1.0 ± 0.1 1.0 ± 0.1 0.9 ± 0.1
Diastolic Blood Pressure 72.5 73.6 ± 7.5 71.5 ± 8.4 72.5 ± 7.6 71.7 ± 8.2 70.8 ± 8.7 70.8 ± 8.4 69.4 ± 8.8
Diastolic Blood Pressure Standing 72 71.0 ± 7.3 71.8 ± 8.0 72.7 ± 8.7 73.4 ± 8.4 73.9 ± 8.6 73.5 ± 10.2 73.7 ± 10.2
Heart Rate 59 60.2 ± 5.6 61.3 ± 6.8 62.1 ± 8.4 61.9 ± 8.9 62.6 ± 8.7 62.2 ± 9.9 61.7 ± 10.6
Potassium 3.6 3.8 ± 0.3 3.8 ± 0.4 3.9 ± 0.3 3.9 ± 0.4 4.0 ± 0.4 4.0 ± 0.5 4.0 ± 0.6
Systolic Blood Pressure 120 121.1 ± 10.6 120.0 ± 11.7 118.7 ± 13.3 120.5 ± 12.3 122.9 ± 13.0 123.7 ± 14.2 120.9 ± 14.1
Systolic Blood Pressure Standing 128 129.2 ± 12.3 129.9 ± 12.7 131.3 ± 15.4 131.6 ± 13.8 132.6 ± 16.3 135.4 ± 17.7 137.8 ± 17.6
Figure28: AnexampletwinrecordforasingleHTNpatientisshown,whichreportsthemeanand
standarddeviationofthetwinsforthatpatientAsampleofstaticbaselineinformationisgivenatthe
topoftherecord. Asampleoflongitudinaloutcomespredictedbythemodelaresuppliedasrows,
withcolumnsindicatingthetimeinmonthssincebaselinevisit.
Dyslipidemia Digital Twin Example
Age (years): 74 BMI stage: Overweight Cholesterol: Borderline History Hypertension: No History of Smoking: Yes
Sex: Female Height: 145 cm Hypertension: Stage 1 History CV Disease: Yes History MI: No
Race: White Region: Northern America Blood glucose: Diabetes History Type II Diabetes: Yes History Endocrine Disorders: -
Baseline 4 8 12 16 20 24 28 32 36 40 44 48 52
BMI 26.1 25.5 ± 3.1 25.7 ± 3.8 25.8 ± 4.4 25.9 ± 4.7 25.5 ± 4.8 25.7 ± 4.9 25.0 ± 4.9 25.5 ± 5.2 25.6 ± 5.2 25.1 ± 5.3 25.0 ± 5.1 25.1 ± 5.0 24.9 ± 5.2
HDL Cholesterol 47 47.9 ± 4.7 47.2 ± 4.8 47.2 ± 4.8 46.3 ± 4.8 46.3 ± 4.7 46.0 ± 5.6 46.9 ± 5.4 46.5 ± 4.9 46.1 ± 5.8 46.4 ± 5.6 47.2 ± 5.7 46.6 ± 5.9 45.5 ± 6.5
LDL Cholesterol 112 106.8 ± 12.7 102.0 ± 13.2 100.6 ± 13.4 100.5 ± 15.0 98.6 ± 18.4 95.8 ± 16.3 92.8 ± 15.1 93.5 ± 18.1 92.8 ± 20.194.1 ± 20.388.8 ± 18.092.1 ± 17.192.9 ± 20.8
Diastolic Blood Pressure 64 64.6 ± 8.3 64.7 ± 10.4 63.8 ± 11.2 63.9 ± 11.2 64.3 ± 11.9 64.3 ± 11.5 62.7 ± 12.1 62.3 ± 11.7 63.3 ± 11.962.3 ± 11.661.7 ± 12.761.5 ± 12.560.0 ± 12.4
Fasting Blood Glucose - 67.1 ± 15.9 67.1 ± 20.2 67.1 ± 21.9 67.0 ± 25.3 67.1 ± 23.2 67.0 ± 26.6 67.1 ± 31.5 67.1 ± 30.9 67.2 ± 29.967.2 ± 31.767.0 ± 31.067.1 ± 30.667.2 ± 36.4
Heart Rate 51 52.7 ± 5.5 54.3 ± 6.2 55.8 ± 6.6 57.5 ± 7.2 58.2 ± 8.3 59.0 ± 8.5 59.1 ± 8.3 59.0 ± 8.6 57.7 ± 9.559.1 ± 10.658.6 ± 11.258.1 ± 11.258.6 ± 11.3
Potassium 4.1 4.2 ± 0.3 4.2 ± 0.3 4.2 ± 0.3 4.2 ± 0.4 4.2 ± 0.4 4.2 ± 0.4 4.2 ± 0.4 4.3 ± 0.4 4.3 ± 0.4 4.3 ± 0.4 4.3 ± 0.4 4.3 ± 0.4 4.3 ± 0.4
Systolic Blood Pressure 137.5 135.7 ± 7.8 134.5 ± 9.5 132.3 ± 11.5 132.7 ± 13.4 132.8 ± 14.1 132.3 ± 16.2 132.9 ± 19.4 132.2 ± 20.9132.1 ± 23.7132.3 ± 25.2132.8 ± 26.6130.4 ± 26.3129.6 ± 29.8
Triglycerides 187 190.3 ± 38.4 188.3 ± 45.4 181.0 ± 47.3 192.1 ± 46.6 191.1 ± 49.3 185.3 ± 50.2 176.7 ± 42.1 181.9 ± 49.9186.1 ± 58.8178.8 ± 50.5173.7 ± 55.1175.2 ± 53.8182.0 ± 58.4
Waist Circumference 100 99.0 ± 2.5 98.8 ± 3.3 98.7 ± 3.4 97.5 ± 3.6 98.5 ± 4.0 96.9 ± 4.5 96.2 ± 4.6 96.7 ± 5.0 96.7 ± 5.2 96.3 ± 5.0 94.9 ± 5.7 95.0 ± 5.5 94.7 ± 5.6
Figure29: AnexampletwinrecordforasingleDLDpatientisshown,whichreportsthemeanand
standarddeviationofthetwinsforthatpatient. Asampleofstaticbaselineinformationisgivenatthe
topoftherecord. Asampleoflongitudinaloutcomespredictedbythemodelaresuppliedasrows,
withcolumnsindicatingthetimeinmonthssincebaselinevisit.
TTD Digital Twin Example
Age (years): 68 History of Congestive Heart Failure : No Taking ACEI: Yes History Dyslipidemia: No Taking ARB: No
Sex: Female History of Hypertension: Yes Height: 161 cm History MI: Yes Taking BB: No
Race: White History of Stroke: Yes Weight: 85 kg History Smoking: Yes Taking Insulin Providing Drug: Yes
Baseline 4 8 12 16 20 24 28 32
BMI 38.8 38.6 ± 2.0 38.6 ± 2.3 38.7 ± 2.5 39.0 ± 2.5 39.1 ± 2.8 39.1 ± 3.0 39.2 ± 3.0 39.2 ± 3.1
Cholesterol 126 126.9 ± 26.3 130.9 ± 31.0 135.2 ± 30.7 129.9 ± 33.3 130.4 ± 35.9 136.4 ± 33.3 131.6 ± 37.6 132.6 ± 39.9
Cholesterol HDL 25 26.9 ± 3.2 28.4 ± 4.1 27.7 ± 4.0 28.8 ± 4.5 29.7 ± 5.1 29.7 ± 5.5 29.2 ± 5.2 30.2 ± 6.4
Cholesterol LDL 59 66.5 ± 21.5 68.5 ± 23.9 68.3 ± 22.7 67.6 ± 24.8 64.2 ± 24.2 66.3 ± 22.9 67.2 ± 28.4 62.9 ± 28.7
Creatinine 1.3 1.3 ± 0.3 1.4 ± 0.4 1.5 ± 0.5 1.5 ± 0.5 1.5 ± 0.5 1.5 ± 0.5 1.5 ± 0.5 1.6 ± 0.6
Diastolic Blood Pressure 89.5 85.1 ± 8.8 80.0 ± 8.8 77.6 ± 8.1 75.5 ± 8.3 71.0 ± 9.5 70.0 ± 11.2 68.4 ± 11.4 68.2 ± 11.5
Fasting Blood Glucose - 144.9 ± 48.7 143.0 ± 50.9 163.5 ± 66.0 180.9 ± 67.2 178.3 ± 76.2 169.6 ± 89.6 178.0 ± 95.2 184.2 ± 101.4
Heart Rate 69 69.2 ± 7.8 67.7 ± 6.9 67.9 ± 8.5 67.9 ± 8.2 66.2 ± 8.3 66.9 ± 9.6 67.1 ± 9.7 67.2 ± 9.9
Hemoglobin A1C 8.9 8.7 ± 1.3 8.6 ± 1.3 8.2 ± 1.5 8.0 ± 1.4 7.6 ± 1.5 7.7 ± 1.4 7.5 ± 1.4 7.5 ± 1.4
Potassium 3.5 3.7 ± 0.3 3.8 ± 0.4 3.9 ± 0.4 4.0 ± 0.4 4.0 ± 0.4 4.1 ± 0.4 4.1 ± 0.4 4.1 ± 0.5
Systolic Blood Pressure 171.5 155.2 ± 22.9 146.9 ± 21.0 141.3 ± 19.5 136.7 ± 24.1 133.8 ± 23.4 134.5 ± 23.8 133.2 ± 25.5 134.6 ± 23.7
Triglycerides 218 236.5 ± 120.3 214.5 ± 106.6 236.5 ± 133.4 216.0 ± 97.1 214.9 ± 118.3 221.4 ± 125.6 231.5 ± 129.2 208.1 ± 120.1
Waist Circumference 129.5 128.8 ± 5.5 128.3 ± 5.9 127.6 ± 5.7 128.1 ± 5.8 129.1 ± 6.1 128.9 ± 6.3 128.9 ± 5.9 129.6 ± 6.3
Figure30: AnexampletwinrecordforasingleTTDpatientisshown,whichreportsthemeanand
standarddeviationofthetwinsforthatpatient. Asampleofstaticbaselineinformationisgivenatthe
topoftherecord. Asampleoflongitudinaloutcomespredictedbythemodelaresuppliedasrows,
withcolumnsindicatingthetimeinmonthssincebaselinevisit.
50CD Digital Twin Example
Age (years): 54 Diagnosis: Crohn's Disease Taking biologics: Yes
Sex: Male Disease Location: Ileocolonic Taking corticosteroids: Yes
Race: White BMI: 19.4 kg/sq m Taking immunomodulators: Yes
Baseline 4 8 12 16 20 24 28 32 36 40 44 48 52
C Reactive Protein 22.4 20.3 ± 5.1 19.9 ± 7.2 18.4 ± 7.8 17.5 ± 8.8 18.2 ± 9.1 16.6 ± 10.1 14.7 ± 9.4 14.8 ± 10.6 14.8 ± 12.113.6 ± 12.714.3 ± 12.115.7 ± 10.715.3 ± 14.3
Calprotectin - 2010.1 ± 2125.31925.9 ± 2502.71987.4 ± 2665.12671.7 ± 3362.12977.1 ± 3416.83623.0 ± 4400.13220.8 ± 4425.13630.5 ± 47223.4718.7 ± 452325.718.4 ± 527338.943.9 ± 535349.523.0 ± 596449.124.3 ± 6139.6
Fecal Calprotectin High Range - 439.1 ± 279.5 468.8 ± 329.3446.8 ± 352.7451.1 ± 396.2470.1 ± 394.6495.2 ± 469.1442.9 ± 457.3490.9 ± 457.8478.0 ± 525.8503.9 ± 539.6515.6 ± 578.4535.5 ± 603.1563.5 ± 595.7
Fecal Calprotectin Low Range - 252.0 ± 288.5 286.8 ± 300.7290.4 ± 306.6239.1 ± 301.6332.8 ± 312.9309.7 ± 315.8292.6 ± 313.5370.3 ± 307.2271.0 ± 312.5250.8 ± 309.4260.7 ± 311.3295.1 ± 315.4314.8 ± 316.0
PGA Score 2 1.9 ± 0.8 1.7 ± 0.9 1.6 ± 0.9 1.6 ± 0.9 1.6 ± 0.9 1.5 ± 1.0 1.6 ± 1.0 1.4 ± 0.9 1.5 ± 0.8 1.6 ± 0.9 1.6 ± 1.0 1.6 ± 0.8 1.6 ± 0.9
PRO2 Abdominal Pain Score 1 1.1 ± 0.8 1.1 ± 0.8 1.0 ± 0.7 1.0 ± 0.8 0.9 ± 0.7 0.8 ± 0.7 0.9 ± 0.7 0.9 ± 0.7 0.9 ± 0.7 0.9 ± 0.7 1.0 ± 0.7 1.1 ± 0.6 1.1 ± 0.6
PRO2 Score 20 19.7 ± 8.9 18.3 ± 8.0 16.6 ± 9.1 17.7 ± 8.3 16.5 ± 8.8 16.7 ± 8.4 17.3 ± 8.3 16.4 ± 8.5 17.1 ± 7.2 17.5 ± 6.9 17.4 ± 7.1 17.3 ± 6.5 16.4 ± 6.6
PRO3 Abdominal Pain Score 1 1.1 ± 0.8 1.1 ± 0.7 1.2 ± 0.8 1.4 ± 0.8 1.2 ± 0.8 1.2 ± 0.7 1.3 ± 0.7 1.3 ± 0.7 1.3 ± 0.7 1.3 ± 0.6 1.4 ± 0.6 1.4 ± 0.7 1.3 ± 0.7
PRO3 Score 27 26.6 ± 11.8 25.2 ± 12.0 23.5 ± 12.5 25.4 ± 11.4 22.4 ± 11.6 21.6 ± 10.6 22.3 ± 10.9 20.9 ± 10.1 21.6 ± 8.9 21.5 ± 9.2 22.1 ± 8.3 22.2 ± 8.8 19.3 ± 8.5
sCDAI Abdominal Pain Score 1 1.1 ± 0.8 1.2 ± 0.8 1.1 ± 0.8 1.2 ± 0.7 1.2 ± 0.7 1.2 ± 0.8 1.2 ± 0.7 1.3 ± 0.8 1.3 ± 0.7 1.2 ± 0.7 1.2 ± 0.7 1.3 ± 0.7 1.3 ± 0.7
sCDAI Daily BM Count 8 7.2 ± 2.9 6.8 ± 2.9 6.6 ± 3.5 6.8 ± 3.4 6.5 ± 3.5 6.4 ± 3.3 6.3 ± 3.2 6.5 ± 3.0 6.9 ± 3.0 7.0 ± 3.4 6.8 ± 3.3 6.2 ± 2.9 6.0 ± 2.9
sCDAI General Well Being Score 1 1.1 ± 0.9 1.1 ± 0.8 1.0 ± 0.9 1.1 ± 0.8 1.0 ± 0.8 1.0 ± 0.9 1.1 ± 0.8 1.2 ± 0.8 1.2 ± 0.7 1.2 ± 0.8 1.2 ± 0.8 1.1 ± 0.8 1.0 ± 0.7
sCDAI Mild 0 0.1 ± 0.3 0.2 ± 0.4 0.3 ± 0.4 0.2 ± 0.4 0.4 ± 0.5 0.4 ± 0.5 0.4 ± 0.5 0.5 ± 0.5 0.4 ± 0.5 0.4 ± 0.5 0.4 ± 0.5 0.4 ± 0.5 0.4 ± 0.5
sCDAI Moderate 1 0.7 ± 0.5 0.5 ± 0.5 0.4 ± 0.5 0.5 ± 0.5 0.4 ± 0.5 0.4 ± 0.5 0.4 ± 0.5 0.4 ± 0.5 0.4 ± 0.5 0.4 ± 0.5 0.5 ± 0.5 0.4 ± 0.5 0.3 ± 0.5
sCDAI Remission 0 0.2 ± 0.4 0.3 ± 0.5 0.3 ± 0.4 0.2 ± 0.4 0.2 ± 0.4 0.2 ± 0.4 0.2 ± 0.4 0.2 ± 0.4 0.1 ± 0.3 0.1 ± 0.4 0.1 ± 0.4 0.2 ± 0.4 0.2 ± 0.4
sCDAI Severe 0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
sCDAI Total Score 235 233.1 ± 89.8 231.5 ± 88.3 226.7 ± 84.2 235.4 ± 84.2 214.0 ± 76.8 210.1 ± 74.7 210.1 ± 77.3 207.5 ± 75.2209.4 ± 62.8213.2 ± 68.2213.4 ± 62.2206.7 ± 64.2205.7 ± 59.6
SES Subscore Ileum 11 11.0 ± 0.3 10.9 ± 0.5 10.8 ± 0.5 10.8 ± 0.6 10.8 ± 0.6 10.7 ± 0.7 10.7 ± 0.8 10.6 ± 0.9 10.5 ± 1.0 10.5 ± 1.0 10.5 ± 1.2 10.5 ± 1.3 10.4 ± 1.5
SES Subscore Left Colon 0 0.0 ± 0.0 0.0 ± 0.1 0.0 ± 0.1 0.0 ± 0.1 0.0 ± 0.2 0.0 ± 0.2 0.0 ± 0.2 0.1 ± 0.2 0.1 ± 0.2 0.1 ± 0.3 0.1 ± 0.3 0.1 ± 0.3 0.1 ± 0.2
SES Subscore Rectum 3 3.1 ± 0.7 3.0 ± 0.8 2.7 ± 0.9 2.6 ± 1.0 2.5 ± 1.1 2.5 ± 1.1 2.4 ± 1.1 2.2 ± 1.2 2.1 ± 1.3 2.0 ± 1.3 2.0 ± 1.4 1.9 ± 1.5 1.8 ± 1.6
SES Subscore Right Colon 0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.1 0.1 ± 0.3 0.1 ± 0.3 0.1 ± 0.4 0.1 ± 0.4 0.2 ± 0.4 0.3 ± 0.6 0.4 ± 0.7
SES Subscore Transverse Colon 0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.1 0.0 ± 0.2 0.0 ± 0.1 0.0 ± 0.2 0.1 ± 0.3 0.1 ± 0.3 0.1 ± 0.4 0.2 ± 0.4 0.2 ± 0.4 0.3 ± 0.6
Figure31: AnexampletwinrecordforasingleCDpatientisshown,whichreportsthemeanand
standarddeviationofthetwinsforthatpatient. Asampleofstaticbaselineinformationisgivenatthe
topoftherecord. Asampleoflongitudinaloutcomespredictedbythemodelaresuppliedasrows,
withcolumnsindicatingthetimeinmonthssincebaselinevisit.
51RA Digital Twin Example
Age (years): 65 Hispanic Ethnicity: No Revascularization: No History of Smoking: Yes
Sex: Female Years Since Diagnosis: 3 History of COPD: No History of Type II Diabetes: No
Race: White Hematologic Disorders: No History of PVD: No History Dyslipidemia: Yes
Baseline 3 6 9 12
HAQ-DI 0.7 0.6 ± 0.3 0.6 ± 0.4 0.7 ± 0.4 0.7 ± 0.5
ACR Functional Class 2 2.0 ± 0.6 1.7 ± 0.6 1.6 ± 0.6 1.6 ± 0.6
Body Mass Index 31.8 31.2 ± 1.8 31.7 ± 1.9 32.5 ± 2.0 32.6 ± 2.0
C Reactive Protein 0.3 0.6 ± 0.5 0.7 ± 0.6 0.6 ± 0.7 0.8 ± 0.7
CCP Positive 0 0.8 ± 0.0 0.8 ± 0.0 0.8 ± 0.0 0.8 ± 0.0
Diastolic Blood Pressure 81 80.6 ± 7.5 78.9 ± 7.4 79.2 ± 9.8 79.7 ± 10.5
EQ-5D-3L Activities 1 1.6 ± 0.6 1.5 ± 0.5 1.4 ± 0.6 1.4 ± 0.6
EQ-5D-3L Anxiety 1 1.5 ± 0.5 1.3 ± 0.5 1.2 ± 0.5 1.2 ± 0.5
EQ-5D-3L Index Value 0.6 0.7 ± 0.1 0.7 ± 0.1 0.7 ± 0.1 0.8 ± 0.1
EQ-5D-3L Mobility 2 1.8 ± 0.5 1.7 ± 0.5 1.5 ± 0.5 1.4 ± 0.5
EQ-5D-3L Pain 3 2.0 ± 0.5 2.1 ± 0.6 2.0 ± 0.6 1.9 ± 0.5
EQ-5D-3L Self Care 2 1.5 ± 0.5 1.2 ± 0.4 1.2 ± 0.4 1.3 ± 0.4
Erythrocyte Sedimentation Rate 30 30.8 ± 17.3 30.4 ± 17.4 27.8 ± 20.8 27.4 ± 21.6
Morning Stiffness 1 0.9 ± 0.2 0.9 ± 0.4 0.7 ± 0.4 0.7 ± 0.4
Morning Stiffness Duration 30 49.3 ± 41.3 45.6 ± 42.7 45.7 ± 51.6 34.8 ± 43.5
Morning Stiffness Severity 21 27.0 ± 18.0 29.6 ± 18.6 31.5 ± 17.1 30.3 ± 18.9
Methtrexate Dose 17.5 17.6 ± 3.0 18.0 ± 3.4 17.7 ± 3.4 17.5 ± 3.6
Physician Global Assessment 19 21.2 ± 19.2 16.4 ± 15.2 16.9 ± 17.8 12.6 ± 13.9
Patient Assessment of Pain 21 26.4 ± 22.8 29.1 ± 22.5 22.7 ± 19.9 25.6 ± 21.6
Patient Global Assessment 20 28.2 ± 19.4 27.8 ± 23.1 21.2 ± 22.1 23.7 ± 24.3
RF Positive 0 0.0 ± 0.0 -0.0 ± 0.0 0.0 ± 0.0 -0.0 ± 0.0
Swollen Joint Count 1 0.7 ± 0.9 0.7 ± 0.9 1.0 ± 1.3 1.1 ± 1.5
Symptoms of Joint Deformity 0 0.0 ± 0.2 0.1 ± 0.3 0.2 ± 0.4 0.1 ± 0.3
Symptoms of Joint Space Narrowing 1 0.8 ± 0.4 0.6 ± 0.5 0.7 ± 0.5 0.6 ± 0.5
Symptoms of Secondary Sjogrens 1 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.1 0.2 ± 0.2
Sysolic Blood Pressure 135 136.1 ± 12.9 135.2 ± 12.1 132.9 ± 17.1 132.3 ± 17.9
Taking Biologic DMARD 1 0.2 ± 0.2 0.3 ± 0.3 0.3 ± 0.3 0.3 ± 0.3
Been Taking Biologic DMARD for 3 Months 0 -0.0 ± 0.0 0.0 ± 0.0 -0.0 ± 0.0 -0.0 ± 0.0
Taking Biologicals 0 0.0 ± 0.0 -0.0 ± 0.0 -0.0 ± 0.0 0.0 ± 0.0
Taking Corticosteroids 0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
Taking Conventional Synthetic DMARD 0 -0.0 ± 0.1 -0.0 ± 0.2 0.0 ± 0.2 0.1 ± 0.3
Been Taking Conventional Synthetic DMARD f1or 3 Months0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0
Taking Immunomodulators 0 0.8 ± 0.2 0.7 ± 0.2 0.7 ± 0.3 0.7 ± 0.3
Taking Methotrexate 0 0.7 ± 0.2 0.7 ± 0.2 0.7 ± 0.3 0.7 ± 0.2
Been Taking Methotrexate for 3 Months 1 0.7 ± 0.5 0.7 ± 0.5 0.6 ± 0.5 0.7 ± 0.5
Taking Targeted Synthetic DMARD 0 -0.0 ± 0.0 0.0 ± 0.0 -0.0 ± 0.1 0.0 ± 0.2
Been Taking Targeted Synthetic DMARD for 3 1Months 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0
Tender Joint Count 0 0.7 ± 1.3 0.9 ± 1.1 0.8 ± 1.5 1.2 ± 1.9
Figure32: AnexampletwinrecordforasingleRApatientisshown,whichreportsthemeanand
standarddeviationofthetwinsforthatpatient. Asampleofstaticbaselineinformationisgivenatthe
topoftherecord. Asampleoflongitudinaloutcomespredictedbythemodelaresuppliedasrows,
withcolumnsindicatingthetimeinmonthssincebaselinevisit.
ATD Digital Twin Example
Age (years): 24 BMI: 30 Region Europe: False
Sex: Male Days on 2nd line meds: 174 Region N. America: True
Race: Multiple Years Since Diagnosis: 10
Baseline 3 6 9 12 15 18 21 24
Body Surface Area 0 1.1 ± 1.3 1.8 ± 2.3 2.1 ± 1.9 1.7 ± 2.1 2.2 ± 3.4 2.4 ± 3.1 3.2 ± 3.9 3.6 ± 6.0
DLQI Total Score 0 0.6 ± 1.1 1.0 ± 1.3 1.2 ± 1.6 1.4 ± 2.2 1.7 ± 2.4 2.7 ± 3.2 2.8 ± 3.1 2.7 ± 3.3
EASI Total Score 0.4 1.1 ± 1.2 1.2 ± 1.9 1.3 ± 1.9 1.1 ± 1.7 1.3 ± 1.7 1.5 ± 2.0 1.5 ± 2.8 0.7 ± 1.5
POEM Total Score 0 1.6 ± 2.2 3.0 ± 3.4 3.4 ± 3.4 3.3 ± 3.3 3.8 ± 3.7 4.5 ± 4.3 4.5 ± 5.0 4.3 ± 4.8
SCORAD Total Score 0.4 2.9 ± 5.4 3.6 ± 6.7 5.0 ± 10.1 7.0 ± 13.1 6.8 ± 10.9 10.2 ± 14.2 8.9 ± 14.1 9.9 ± 16.4
Investigator Global Assessment 0 0.9 ± 1.0 1.2 ± 1.2 1.0 ± 1.1 1.1 ± 1.2 1.3 ± 1.3 1.4 ± 1.3 1.4 ± 1.3 1.2 ± 1.3
Figure33: AnexampletwinrecordforasingleATDpatientisshown,whichreportsthemeanand
standarddeviationofthetwinsforthatpatient. Asampleofstaticbaselineinformationisgivenatthe
topoftherecord. Asampleoflongitudinaloutcomespredictedbythemodelaresuppliedasrows,
withcolumnsindicatingthetimeinmonthssincebaselinevisit.
52PSO Digital Twin Example
Age (years): 70 BMI: 35 Region Europe: False Social Life Affected: True
Sex: Female Hematologic Disorders: False Region N. America: True Feeling Embarassed: True
Race: White Age at Diagnosis: 50 Taking Immunomodulators
Baseline 1 3 5 7 9 11 13
PASI Total Score 2.7 2.4 ± 2.1 1.7 ± 1.6 1.2 ± 1.6 1.1 ± 1.6 1.4 ± 2.0 1.5 ± 1.8 1.2 ± 1.7
Investigator Global Assessment 3 2.4 ± 1.1 1.8 ± 1.2 1.3 ± 1.1 1.0 ± 1.1 1.1 ± 1.0 1.0 ± 1.2 1.0 ± 1.1
Body Surface Area 3 2.6 ± 2.4 2.1 ± 2.3 1.7 ± 2.0 0.9 ± 1.5 1.5 ± 1.7 1.8 ± 2.5 1.4 ± 2.1
DLQI Total Score 5 4.1 ± 2.2 3.0 ± 2.3 2.2 ± 2.0 1.9 ± 2.2 2.5 ± 2.7 2.2 ± 2.5 2.4 ± 2.9
Figure34: AnexampletwinrecordforasinglePSOpatientisshown,whichreportsthemeanand
standarddeviationofthetwinsforthatpatient. Asampleofstaticbaselineinformationisgivenatthe
topoftherecord. Asampleoflongitudinaloutcomespredictedbythemodelaresuppliedasrows,
withcolumnsindicatingthetimeinmonthssincebaselinevisit.
53